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Abstract
Amyloid is a term used to describe a set of diseases caused by protein mis-
folding.  There are 36 proteins known to undergo amyloidosis to date. They
each unfold from their unique native states and refold into a specific cross β-
sheet  motif  to  which  various  macromolecules  can  bind.  These  protein
deposits invade tissues and organs disrupting tissue structure and function. 
The protein serum amyloid P (SAP) is a universal component to all amyloid
deposits regardless of the protein involved. It is a disc shaped protein which is
known to protect amyloid fibres against degradation. The role of SAP in amyl-
oidosis has been a subject of discussion for many years. Some have found
SAP to enhance fibre formation whereas others have found SAP to prevent it.
This  thesis  can  be  divided  into  two  parts.  The  first  half  focuses  on  the
molecular analysis of  SAP in relation to amyloid fibre growth whereas the
second half focuses solely on the structural aspects of SAP. 
Chapters  2  and  3  demonstrate  that  SAP  actually  exhibits  a  dual  role  in
relation to fibrillogenesis. It is capable of acting as both a chaperone and a
fibrillogenic  enhancer  depending  on  its  conformation  at  the  time.  As  a
monomer SAP is responsible for the enhancement and stabilisation of fibres
whereas in its dimerised form it demonstrates characteristics similar to that of
a molecular chaperone. 
Recent developments in amyloid treatment involve the removal of SAP from
deposits  using  anti-SAP antibodies.  As of  yet,  structural  analysis  has not
been carried out on the SAP:antibody complex. Chapters 4 and 5 conclude
this thesis by using crystallographic techniques to demonstrate that a single
antibody binds to an SAP molecule during dissociation from amyloid deposits.
Impact Statement
Although amyloid diseases are considered rare, they are likely more common
than  previously  thought.  The  wide  range  of  symptoms  associated  with
amyloid  disease  often  leads  to  misdiagnosis  and  thus  there  is  a  lack  of
literature  regarding  this  category  of  diseases.  The  field  has  been  grossly
under researched as a result of this. So far 36 proteins have been associated
with  amyloid  diseases  and  this  number  is  continually  increasing.  Each  of
these  diseases  requires  unique  treatment  to  combat  its  unique  set  of
symptoms  and  any  delay  can  easily  result  in  irreversible  if  not  fatal
consequences. Not enough is known about amyloid in general let alone each
specific type to allow for effective, individual treatment plans. Because of this,
the idea of having a general SAP treatment plan is extremely appealing.
This thesis shows that the serum protein, SAP, has the ability to reduce  or
enhance amyloid fibre mass depending on its conformation. 
By showing its ability to reduce amyloid fibre mass, the possibility of using
SAP  decamers  as  a  general  treatment  for  amyloid  can  be  taken  into
consideration. This removes the need for individual treatment of each of the
36 established diseases. Not only is SAP universal to all forms of amyloid, it
is  also a component  already present  in  the human body so is  unlikely  to
impose further damage to the host.
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Chapter 1
An Introduction to Proteins, Amyloid and
SAP
An Introduction to Proteins
Proteins are the building blocks of life. They perform a vast array of duties
within organisms and are responsible for the structure, function and regulation
of the body’s tissue and organs. In fact, proteins are responsible for nearly
every task of cellular life. They receive signals from outside the cell, organise
intracellular  responses  and  are  accountable  for  cell  shape,  product
manufacture and waste clean-up.
They are  the  work-force  molecules  of  the  cell  and are  as  diverse  as  the
functions they serve. For instance, some proteins act as catalytic enzymes for
biochemical reactions in the body whereas others have more of a structural or
mechanical role. Take for an example DNA polymerases and keratin. DNA
polymerases  are  enzymes  responsible  for  synthesising  DNA  molecules
during replication. In contrast, keratin is a protein in your hair, skin and nails
which is responsible for maintaining cell shape and forming a protective layer
around the body. 
Proteins can be big, small, single or multi-unit complexes. They can exist as
mostly hydrophobic or mostly hydrophilic structures and also have the ability
to change their shape if needed. All of these differences arise from the unique
amino acid sequences that make up each protein (Lesk, 2010).
Amino Acids 
Every protein is a macromolecular chain made up of hundreds or thousands
of amino acids -  a simple organic compound containing both a carboxyl (—
COOH)  and  an  amino  (—NH2)  group.  The  chain  is synthesised  by  the
ribosome complex in a process referred  to as DNA translation.  Here, each
amino acid is covalently bound to its neighbour via a condensation reaction
between the carboxyl group of one and the amine group of another.  Water is
released and a CO-NH bond –  a.k.a. a peptide bond – is produced. Once
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linked  in  the  protein  chain,  an  individual  amino  acid  is  referred  to  as  a
residue and the linked series is often referred to as the backbone primary
sequence (Berg, Tymoczko, and Stryer 2002).
There are 20 different amino acids present in nature, all of which share three
common structural features: The first being that they each have a central α-
carbon  to  which  a  hydrogen  atom,  amino  group,  carboxyl  group  and  a
variable side chain are bound. It is these 20 variable side chains which give
the amino acids unique properties and characteristics (more detail to follow).
The amino acid ‘proline’  is the only example which differs from this  basic
format as its variable side chain links back to the nitrogen of the main chain
removing its  ability  to  acts  as  a hydrogen bond donor  (Lodish,  Berk,  and
Kaiser 2007). The second structural feature is that all amino acids are chiral
i.e. their mirror image cannot be superimposed; glycine, due to its variable
side chain consisting of another lone hydrogen atom, is the only exception to
this  rule.  Finally,  the α-carbon is  asymmetric,  meaning that  there are  two
different ways in which groups can be arranged around it. This allows for two
isomers to form, each of which interacts differently with polarised light. The
predominant isomer is the L-form although the D-form is present in bacterial
cell walls and some antibiotics such as valinomycin and gramicidin A. Only
the L-amino acids exist in natural proteins with a few exceptions following
post-translational modifications(Lesk, 2010) (Figure 1) (Figure 2).
Protein Structure 
Proteins are dynamic molecules whose functions almost  invariably  rely  on
interactions with other molecules. Those molecules specific to proteins are
referred to as ligands. Ligands have a variety of roles and structures in terms
of protein binding. They can be small molecules, ions or even other protein
complexes.  Some  act  as  substrates,  were  as  others  behave  as
inhibitors, activators,  and  even neurotransmitters.  Protein-ligand  binding  is
typically a reversible interaction, often results in a change of conformation of 
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Figure 1: (Above) Comparison of the two amino acid isomers. Each isomer interacts differently with polarised light. The
predominant form is the L form although the D form is present in bacterial cell  walls and some antibiotics such as
valinomycin and gramicidin. Only L-form amino acids exist in natural proteins with a few exceptions post-translational
modifications. (Below) The formation of a peptide bond between two amino acids.  A peptide bond takes place between
two adjacent amino acids in a polypeptide chain. It is a condensation reaction which occurs when the carboxyl group of
one molecule reacts with the amino group of the other molecule, releasing a molecule of water (H2O) (Berg, Tymoczko,
and Stryer 2012).
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Figure 2: The structure, full names, single letter code and 3 letter codes
of the 20 amino acids at a physiological pH of 7.4. The variable side
chains of each are highlighted. The amino acids have been categorised
into non polar, polar neutral, polar acidic and polar basic subgroups.
The non polar amino acids are composed purely of hydrocarbon alkyl
groups or benzene rings. The more alkyl groups present, the more non-
polar the amino acid is i.e. valine is more non-polar than alanine and
leucine is more non-polar than valine. Those which are polar but neutral
behave as such due  to the acid and amine groups on the  α-carbon
neutralising  each  other  creating  a  “zwitterion”.  However,  the  polar
acidic and basic side chains each have an additional acid/amine group
producing a net effect of either positive or negative charge respectively
(Lodish, Berk, and Kaiser 2007).
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the target protein and usually involves some form of ligand mediated signal
transmission.  
Ligand‐mediated  signal  transmission  is  essential  to  all  life  processes,
however,  in order for interactions to actually occur,  the binding site of  the
protein  must  be  complimentary  to  the  specific  shape  and  charge  of  its
corresponding ligand;  i.e. binding is successful when the protrusions, clefts
and grooves of the protein binding site match those of the ligand in a fashion
similar to a lock and key. Binding occurs through a variety of intermolecular
forces including ionic binding, hydrogen bonds and Van der Waals forces.
The rate of binding is called affinity, and this measurement typifies a tendency
or  strength  of  the  effect.  Binding  affinity  is  actualized  not  only  by host-
guest interactions,  but  also  by  solvent  effects  that  can  play  a
dominant, steric role  which  drives non-covalent  binding in  solution. The
solvent provides a chemical environment for the ligand and receptor to adapt,
and thus accept or reject each other as partners.
Ligands by nature are three dimensional structures. Therefore protein-ligand
binding can only occur if proteins themselves also have a three dimensional
shape. Every protein has a unique polypeptide sequence and thus folds into a
unique globular shape. This does not occur spontaneously. Instead, a series
of  steps are followed in order  to achieve optimum folding  (Bolsover  et  al.
2003).
Protein  folding  can  be  categorised  into  four  groups:  primary,  secondary,
tertiary  and  quaternary  structures.  The  primary  structure  refers  to  the
sequential  order  of  the amino acid  residues in  the polypeptide chain.  The
secondary structure refers to the folding of the chain into regularly repeating
local formations and the tertiary form is the folding of those formations into a
three dimensional globular shape. The final  quaternary shape occurs when
several  protein  molecules  form  a  combined  structure  to  function  as  a
single protein complex (Figure 3).
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Figure  3:  A  diagram of  the  four  protein  folding  categories:  primary,
secondary, tertiary and quaternary. The primary structure refers to the
sequential order of the amino acid residues in the polypeptide chain.
The secondary structure is the folding of the backbone into regularly
repeating  local  formations  (α-helices  and  β-pleated  sheets)  and  the
tertiary  structure  is  the  folding  of  those  formations  into  a  three
dimensional  globular  shape.  The  quaternary  structure  occurs  when
several protein molecules form a combined structure to function as a
single protein complex. 
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Primary Structure 
The primary structure acts as the backbone of a protein. It spans from an un-
bonded primary amine group (N-terminus) to an un-bonded carboxyl group (C
-terminus) and has the variable side chains of each residue protruding in a
perpendicular manner along its length. The actual folding of this backbone is
influenced  by  steric  constraints  posed by  the  covalent  peptide  bond.  The
peptide bond is planar and is often described as having partial double bond
characteristics.  This  is  due to  the fact  that  it  has a bond length of  1.32Å
instead of the expected 1.49Å or 1.27Å of a single (C-N) or double (C=N)
carbon-nitrogen  bond  respectively.  As  a  result  of  this,  the  peptide  bond
experiences restricted rotation around the axis of  the carbon and nitrogen
atoms which in turn restricts folding options for the backbone (Sipe, 2006). 
Secondary Structure
Folding of the polypeptide backbone is not a case of random trial and error. In
fact, secondary structure folding is influenced by two things. The first of these
is the steric constraints presented by the peptide bond and the second is the
charge and size of the variable side chains which surround it. With regards to
the latter, it is important to know that there are a variety of chemical structures
and properties which make up the side chains. These can be divided into two
categories: polar and non polar. Within these two groups each amino acid can
also be described as being acidic, basic or neutral.  
The amino acids whose variable side chains include various functional groups
such as acids, amides, alcohols, and amines are classified as polar. The level
of  polarity  depends  on  the  functional  group  itself  and  on  the  number  of
carbon-hydrogens present in any alkane or aromatic portion of the side chain.
The greater the difference of electronegativity in a bond the more polar the
bond is.  For  example,  aspartic  acid  is  more polar  than serine as an acid
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functional group is more polar than an alcohol one. However, serine is more
polar than threonine since threonine has one more methyl group than serine.
The methyl group gives more non-polar character to threonine.
Non polar amino acids are composed purely of hydrocarbon alkyl groups or
benzene rings. The more alkyl groups present, the more non-polar the amino
acid  is.  Examples  include  valine,  alanine  and leucine.   As  with  the  polar
group,  the number  of  alkyl  groups  influences  the  polarity.  The  more  alkyl
groups present,  the  more non-polar  the  amino acid  will  be.  This  in  effect
makes valine more non-polar than alanine and leucine more non-polar than
valine.
There are two amino acids which have acidic functional groups: aspartic acid
and glutamic acid. Normally, an amino acid produces a nearly neutral solution
since the acid group and the basic amine group on the  α-carbon neutralize
each other creating a “zwitterion”. However, the above examples each have
an additional acid group producing a net acid effect. In order to create a net
basic effect the contrary must occur. The amino acid must contain an extra
amine functional group such as in the cases of lysine, arginine, and histidine.
There is an exception to this rule in the case of tryptophan.  Even though
tryptophan has an amine group as part of a five member ring, the electron
withdrawing effects of the two ring systems do not allow nitrogen to act as a
base. Also, it should be noted that. Amino acids with an amide on the side
chain do not produce basic solutions i.e. asparagine and glutamine. Although
similar to an amine group, an amide has the carbon double bond oxygen
which changes the property. Amides are neutral.
It  is  the combined effect  of  all  the side chains which help to  determine a
proteins secondary shape and chemical reactivity. Those residues with acidic
side chains will  be more attracted to  those with  basic  side chains so are
expected to be in close proximity. It is likely that the charged residues will be
present more frequently on the surface of the protein as charge (alongside
shape  and  size)  is  another  way  in  which  a  protein  interacts  with  its
corresponding ligand. 
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The Ramachandran Plot
With regards to the steric constraints of the peptide bond, Ramachandran et
al demonstrated that there are 2 angles the polypeptide chain can rotate on
either side of rigid peptide bond: Ø (phi) and Ψ (psi). Ø (phi) is the degree of
rotation at the bond between the nitrogen and carbon atoms of the main chain
whereas Ψ (psi)  is  the  degree of  rotation  between the  alpha carbon and
carbonyl carbon atoms (Ramachandran et al. 1963). He developed a plot in
order to visualize the dihedral angle ψ against φ of amino acid residues in a
protein structure. The plot shows - in theory - which values or conformations
of ψ and φ are possible for a residue in a protein. It also shows the empirical
distribution of data points observed in a single structure. The shading on the
plot represents the different regions described by Morris  et al. (1992). The
darkest  areas  correspond  to  the  "core"  regions  and  indicate  the  most
favourable combinations of phi-psi values. Ideally, one would hope to have
over 90% of the residues in these "core" regions as percentage of residues in
the "core" regions is one of the better guides to stereo-chemical quality.
The  different  regions  of  the  plot  were  taken  from  the  observed  phi-psi
distribution for 121,870 residues from 463 known X-ray protein structures.
The two most favoured regions are the "core" and "allowed" regions which
correspond to 10° x 10° pixels having more than 100 and 8 residues in them,
respectively. The "generous" regions were defined by Morris et al. (1992) by
extending out by 20° (two pixels) all round the "allowed" regions. In fact, the
authors found very few residues in these "generous" regions. Therefore they
can probably be treated much like a "disallowed" region and any residues
found in them should be investigated more closely. Excluding the amino acids
proline and glycine, Ramachandrans plot shows that there is a limited amount
of allowed confirmations that the peptide backbone can take. The planar and
asymmetric nature of the backbone cause steric hindrance and limit the value
that  each residue can assume. It  is  the  combined phi-psi  values of  each
residue in the sequence which dictate the secondary confirmation of the back
bone (Figure 4).
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Figure  4: (Above)  Image of a peptide chain showing the  2 angles that
the chain can rotate on either side of the rigid peptide bond. The phi and
psi angles are labelled. The green lines show the plane that does not
rotate due to the double bond qualities of the peptide bond. (Below) An
example of a Ramachandran plot of a peptide. Unlike a topographical
map,  energy  instead  of  altitude  is  shown  within  the  contours.
Surrounding phi=0, psi=0 there is a high energy "plateau" which drops
into valleys of stability with minima for alpha helices and beta sheet. In
large proteins, the large majority of non-glycine residue possesses phi,
psi  combinations  that  reside  in  these  valleys  (Berg,  Tymoczko,  and
Stryer 2012).
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In reality there are only two major folding types possible in protein secondary
structure. The first of these is called an alpha helix (α-helix) and the second a
beta pleated sheet (β-sheet). Although a third formation - β-turn – is regularly
seen,  60%  of  protein  exists  predominantly  as  helices  and  sheets.  The
remaining 40% experiences little if any periodicity and so acts as supportive
elements (Lodish, Berk, and Kaiser 2007). 
The α-HelixHelix
Nuclear magnetic resonance (NMR),  microscopy and x-ray crystallography
have  been  used  to  analyse  the  secondary  structures  further.  They  have
shown that  the  α-helix  consists  of  3.6  residues per  turn  and  is  stabilised
through  inter-strand  hydrogen  bonding  parallel  to  the  axis  of  the  helix.
Bonding occurs between the nitrogen atom in a peptide bond with the oxygen
4  residues  down  the  chain.  The  distance  between  adjacent  amino  acid
residues in the backbone is approximately 1.5Å – the length of a hydrogen
bond – and due to the chiral nature of the amino acids, helices are also chiral.
An α-helix is specifically right handed. The variable side chains in a helix point
outwards and thus allow for  compactibility  of  the  structure.  Also,  the  side
chains are responsible for dictating the hydrophobic/hydrophilic nature of the
helix (Bolsover et al. 2003). 
There is an exception to this in the case of the amino acid proline. Proline, in
general, cannot take part in a helix although it is sometimes present as one of
the  first  four  residues.  Its  looped side  chain  prevents  the  α-nitrogen from
forming  hydrogen  bonds  and  a  kink  is  produced  instead  (Woolfson  and
Williams 1990).
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The β-HelixPleated sheet
In contrast to the relatively compact helix, the β-pleated sheet is almost fully
extended.  It is referred to as ‘pleated’ as geometry prevents it from being
completely flat. The sheet is composed of adjacent but separate strands, 5-8
residues long, bound together in the form of a sheet. The sheet is stabilised
by hydrogen bonding between the amine (N-H) and carboxyl (C=O) groups of
adjacent strands with the side chains protruding above and below the sheet
alternatively. The axial distance between adjacent amino acids is 3Å and the
β-sheets can be described as either parallel or anti-parallel depending on the
direction of each strand. Those with strands running in the same direction as
each other  are referred to  as parallel  where as those running in opposite
directions are anti-parallel (Sipe, 2006). 
The anti-parallel form is preferred over the two. This is due to that fact that
when  in  this  form,  the  alternate  directions  of  the  β-strands  allow  the  N-
terminus of one strand to be directly adjacent to the C-terminus of the next.
This  produces  the  strongest  inter-strand  stability  as  the  hydrogen  bond
between the carbonyls and amines are planar. In the case of parallel strands,
all the N-termini of successive strands are oriented in the same direction. This
is  unfavourable  as  it  introduces non-planarity  in  the  inter-strand hydrogen
bonding pattern (Gailer and Feigel 1997) (Figure 5) (Figure 6). 
β-HelixTurns
Beta  turns  are  formed  of  4  residues  and  are  located  on  the  surface  of
proteins. They are stabilised by hydrogen bonding between the end residues
and their structure provides compatibility of the protein structure. They are
formed predominantly by glycine and proline residues. Each of these lack a
large side chain and thus allow close proximity of the beta turn residues and
the protein as a whole (Lodish, Berk, and Kaiser 2007). 
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Figure 5: A detailed look at the α-helix and β-pleated sheet. The α-helix
consists of 3.6 residues per turn. This allows the nitrogen atom in each
peptide bond to form a hydrogen bond with the oxygen 4 residues down
the  chain.  The  side  chains  point  outwards  in  a  helix  allowing
compactibility.  The distance between adjacent amino acid residues in
the backbone is 1.5Å. An α-helix is right handed due to the chiral nature
of the amino acids. The β-pleated sheet is composed of adjacent but
separate  strands 5-8  residues  long  bound together  in  the  form of  a
sheet. The sheet is stabilised by hydrogen bonding between the amine
(N-H)  and  carboxyl  (C=O)  groups  of  adjacent  strands  with  the  side
chains protruding above and below the sheet alternatively.  The axial
distance between adjacent amino acids of 3Å. Strands running in the
same direction as each other are referred to as parallel where as those
running  in  opposite  directions  are  anti-parallel  (Madej  et  al.  2014)
(Cooper and Hausman 2009).
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Figure 6: Diagrams representing the two types of  β-sheet. Anti-parallel
sheets are represented on the left. They occur when the strands run in
opposite directions. Parallel strands are shown on the right and they
occur  when  the  strands  run  in  the  same direction.  Both  sheets  are
almost fully extended and stabilised by hydrogen bonding between the
amine (N-H) and carboxyl (C=O) groups of adjacent strands. The anti-
parallel form is preferred as when in this form, the N-terminus of one
strand  is  directly  adjacent  to  the  C-terminus  of  the  next.  Hydrogen
binding is planar and strong. In the case of parallel strands all the N-
termini of successive strands are oriented in the same direction. This is
less stable as inter-strand bonding is non-planar. The side chains of
each protrude above and below the sheet  alternatively  and the axial
distance between adjacent amino acids is 3Å. 
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Tertiary Structure
Generally, a protein folds into a mixture of α-helices and β-sheets although is
it possible to be constructed exclusively of one or the other. The term tertiary
structure refers to the overall shape that a single protein molecule will make;
i.e. the spatial relationship of the secondary structures to one another. 
Unlike secondary structures, which are stabilized by strong hydrogen bonds,
tertiary structures are stabilized by non-local interactions. These interactions
are influenced most commonly by the formation of a hydrophobic core, but
also through salt  bridges,  hydrogen bonds, disulfide bonds,  and even post-
translational  modifications.  Although  considered  ‘weak’,  compared  to
hydrogen bonding  tertiary  structure  bonds  are  much higher  in  number  so
overall produce a stable structure (Bolsover et al. 2003).
The  strongest  of  these  tertiary  influences  would  be  the  formation  of  the
hydrophobic  core.  Protein  folding  is  critically  dependent  on  the  effect  of
solvent (water) on non covalent interactions. Side chains which react strongly
with water are called hydrophilic residues and those which do not are called
hydrophobic.  Hydrophobic  molecules  force  water  around  them to  become
more organised in the form of cages. This is undesirable as is disrupts the
hydrogen binding in bulk water. In protein folding, cage formation is minimised
by  the  clustering  together  of  such  molecules  into  a  hydrophobic  core  in
something named the ‘hydrophobic effect’. 
Thermodynamic studies have shown that a polypeptide with hydrophobic and
hydrophilic  residues  will  spontaneously  adopt  a  configuration  where
hydrophobic residues are not exposed to water either though a lipid bi-layer
or through central clustering of those residues. i.e. Polypeptides prefer folding
in  the  context  of  the  solvent  rather  than  be  fully  extended  and  having
maximum  interaction  with  the  solvent  (Sharp,  1991).  If  positively  and
negatively charged residues are buried in the hydrophobic interior core they
will attract each other and the force between them will be stronger than if they
had interacted with water. Such an electrostatic interaction is called a salt
bridge.
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Protein Folding Thermodynamics
Although the steric restrictions of the peptide bond and the hydrophobic effect
are  both  essential  in  creating  a  compact  and  stable  structure,  neither  is
actually responsible for initiating the protein folding pathway. What drives the
direction of the reaction specifically from unfolded to folded? How does the
protein know when it has obtained its final, native state? Both these questions
can be answered using thermodynamics.
All natural processes are subject to two laws of thermodynamics. 
1 – Energy is conserved (it cannot be made or destroyed) 
2 – Entropy is always increasing.
The laws of thermodynamics govern the energy and entropy differences in
processes in which a system goes from one stable form to another. The first
law does not distinguish between the direction of the reaction but the second
law does. The reverse of a spontaneous process is not a natural process.
This can be looked at in terms of heat. If a hot object is put in contact with a
cold object, heat will spontaneously travel from the hot to the colder one (law
2) and the heat absorbed by the cold one will be equal to amount given (law
1). 
The second law tells us which processes are spontaneous and thus tells us
about equilibrium. Equilibrium is described as being the state of a chemical
reaction  in  which  its  forward  and  reverse  reactions  occur  at  equal  rates.
Overall this means that the concentration of the reactants and products does
not change with time.
Equilibrium is governed by Gibbs free energy:
G = H-HelixTS
H = enthalpy, T = temperature and S = entropy
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A system held at constant temperature and pressure will be at equilibrium if
the Gibbs free energy is at  a minimum. At the minimum, any infinitesimal
change in the state of the system will leave G unchanged, therefore ΔG = 0 isG = 0 is
the criterion for equilibrium at any constant temperature and pressure (Lesk
2010).  
For a system to be in equilibrium it must be in a state that is not the initial
state of a spontaneous reaction and a compromise of demands of energy and
entropy must  be made.  For  example,  in  terms of  proteins,  the equilibrium
between native and denatured states of a protein at the melting point is a
balance between the higher cohesive forces in the compact native state and
the  greater  conformational  freedom  in  the  ensemble  of  denatured
conformations. 
The Levinthal Paradox
When in its native form a protein is in its most stable form as the Gibbs free
energy is at its lowest point. However, protein structures are only stable and
functional over a small range of environmental conditions. Outside this range
the  interactions  destabilise,  the  structure  is  disrupted  and  the  molecule
denatures.
Denaturation can be caused by a number of factors. These include excessive
temperatures,  sequence  mutations,  fragmentation,  pH  changes  and
detergents. Once denatured, the protein usually remains in its new form even
after the environmental conditions have been rectified. The exception to this
is when using urea. As expected, upon exposure to 6-8M urea, non covalent
interactions are disrupted and proteins lose their higher level of structure. The
polypeptide chains adopt random, changing conformations and there is an
increase in entropy. However, upon removal of the urea, either by dialysis or
dilution,  the  protein  refolds  and  regains  its  original  structure  and  activity
(Bolsover et al. 2003). 
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The ability of the protein to return to its native state indicates that the final
structure  is  pre-determined  by  the  sequence  and  that  refolding  after
denaturation is not random. A small protein of only 100 residues would take
1050 years to attempt every structural conformation, not the seconds it takes in
vivo. This can be described by the Levinthal paradox. This states that proteins
cannot  fold by random search in conformation space.  Proteins must  have
effective ways of folding encoded in their sequence. A folding pathway must
exist (Zwanzig, Szabo, and Bagchi 1992).
Unfortunately,  it  is  extremely  difficult  to  visualise  this  pathway  as,  in
denaturation experiments, a two stated equilibrium is observed with no stable
intermediates; i.e. upon the increase of temperature or denaturant, there is a
sharp  transition  from  the  native  to  the  denatured  state.  If  no  stable
intermediates are observed it  is  impossible  to  map the pathway taken for
protein folding. Is there a single route per protein or are there various? 
The current view of the folding process is that of a funnel. The funnel is wide
at the top to encompass the different denatured conformations (high energy)
and narrow at the bottom the represent the single native form (low energy).
You can get  to  the  native  from the  denatured via  many routes  but  these
eventually coalesce at the narrow part of the funnel (Bryngelson et al. 1995).
Although there is not necessarily a single direct pathway for protein folding,
certain factors must influence the final  structure. For example, interactions
between regions nearby in the sequence should form more easily than those
in the distance. This provides guidance for the secondary structures to form.
Secondary  structures  are  more  stable  than  unfolded  structures  and  once
formed, the globular protein only needs to compact itself (Figure 7).
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Figure  7: The current view of the folding process - a funnel.  The blue
surface shows the multitude of conformations 'funnelling' to the native
state  via  intramolecular  contacts.  The  funnel  is  wide  at  the  top  to
encompass the  different  denatured  conformations  (high  energy)  and
narrow at the bottom the represent the single native form (low energy).
The purple area shows the conformations moving toward amorphous
aggregates or amyloid fibrils via intermolecular contacts. Both parts of
the  energy  surface  overlap.  Aggregate  formation  can  occur  from
intermediates populated during de novo folding or by destabilization of
the native state into partially folded states and is normally prevented by
molecular chaperones. Cell-toxic oligomers may occur as off-pathway
intermediates of amyloid fibril formation (Hartl and Hayer-Hartl 2009).
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To go from a higher energy (denatured) to lower energy (native) the proteins
sometimes have to overcome an energy barrier to enter the transition state. In
a regular chemical reaction one would overcome this barrier by increasing the
pressure,  concentration  or  temperature  of  the  solution.  In  doing  so  it
increases the energy and rate at which particles collide and hence increases
the likelihood of a reaction. Although effective, each of these methods are not
always ideal for protein folding as fluctuations in temperature and pressure
often cause secondary and tertiary structure disruption. In order to overcome
the energy barrier without effecting protein fold a chaperone is typically used
(Hartl and Hayer-Hartl 2009). 
Chaperones 
Chaperones are protein molecules which act as folding catalysts. They are a
large group of unrelated proteins with a range of roles all related to protein
folding. These include de novo folding of polypeptides, refolding of mis-folded
proteins,  solubilization  of  protein  aggregates,  degradation  of  proteins,
translocation of proteins across membranes, assembly and disassembly of
oligomeric  complexes and the regulation of  stability  and activity  of  certain
natively folded proteins. Some chaperones are non-specific and act with a
variety of polypeptide chains where as others are restricted to specific targets.
They often use ATP hydrolysis to assist in intermediate folding but they do not
interact  with  native  proteins  and they do not  form part  of  the  final  folded
structure (Gething and Sambrook 1992).
Chaperones are  evolutionarily  conserved across all  organisms highlighting
their importance in in vivo protein folding. There are two types of chaperones:
molecular chaperones, which bind and stabilise unfolded proteins preventing
aggregation, and chaperonins which form a small folding chamber into which
an unfolded protein is presented to the appropriate environment for folding.
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Molecular Chaperones
The heat shock proteins are examples of molecular chaperones. They range
in size between 10-100kDa and are named according to their  size. When
bound to ATP the heat shock proteins assume an open form which exposes
central hydrophobic regions. The hydrophobic regions of an unfolded protein
bind to this and cause the hydrolysis of the ATP to ADP. Once folded, the
protein is released and the chaperone reverts back to its closed position. 
Take  for  example  the  heat  shock  protein  Hsp70.  As  the  name suggests,
HSP70 is 70kDa in size.  It  is composed of three domains: the N-terminal
ATPase domain, the substrate binding domain and the C-terminal domain.
The n-terminal ATPase domain is the location for ATP binding. The energy
molecule lies at the bottom of a deep cleft held between two lobes. It is the
exchange  of  ATP  and  ADP  which  is  responsible  for  the  conformational
changes of the other two domains into the open and closed positions (Mayer
2010). 
In Hsp70 the substrate binding domain is composed of an α-helix subdomain
10kDa in size and a β-sheet subdomain 25kDa in size (Zhu et al. 1996). The
β-sheet domain consists of two twisted sheets arranged into a barrel with its
connecting  loops  protruding  upwards.  It  is  in  this  barrel  that  the  protein
intermediate  is  contained.  The  intermediate  is  held  in  place  within  the
substrate binding domain via a groove with affinity for hydrophobic residues .
The groove is long enough to interact with peptides up to seven residues in
length.
The final c-terminal domain acts as a lid for the substrate binding domain. It is
composed of five α-helices. Helices A and B pack against two sides of the β-
sheet sub-domain, stabilizing the inner loops L1,2  and L4,5. In addition, helix B
forms a salt bridge and several hydrogen bonds to the outer Loops L3,4 and
L5,6, the so-called latch, thereby closing the substrate-binding pocket like a
lid. Helices C through E, together with the distal part of helix B, form a second
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hydrophobic core. The function of this second hydrophobic core has yet to be
defined  however  it  is  believed to  aid  in  the  stabilisation  of  helix  B,  since
removal of helices C through E leads to unfolding of the distal part of helix B
(Jiang et al. 2005). 
When a Hsp70 protein is ATP bound, the lid is open and peptides bind and
release relatively rapidly.  When Hsp70 proteins are ADP bound,  the lid is
closed and peptides are tightly bound to the substrate binding domain. 
Chaperonins 
In  contrast  to  molecular  chaperones,  chaperonins  are  huge  cylindrical
structures formed of two rings of oligomers. GroEL is an example found in
e.coli. It is a homo-oligomer formed of 7 identical subunits per ring, 57kDa in
size, packed back to back.  An unfolded protein of 60kDa or smaller enters
one of the rings and binds to the inner wall via hydrophobic interactions with
several  of  the subunits.  From then on the ring containing the substrate is
referred to as the “cis” ring. When ATP binds to the cis ring it allows the co-
chaperone GroES to  bind  and  enclose the  substrate  within.  Formation  of
GroEL-GroES requires a large conformational change and causes the interior
surface  of  cis  to  go  from  hydrophobic  to  hydrophilic  giving  the  unfolded
protein a chance to fold.  After approx 20 seconds ATP is hydrolysed and
GroES  and  ADP  are  released  leaving  the  barrel  to  take  a  more  open
conformation  (Horwich et al. 2007). The protein is released whether it  has
folded or not. At which point it can either re-enter the same chaperonin or
enter  another  to  try  again.  The  cis  and  “trans”  ring  act  allosteric  to  one
another.  Substrate enclosure in one ring leads to substrate release in the
other (Yifrach and Horovitz 1995) (Figure 8).
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Figure 8: A diagram showing assisted protein folding by the chaperonin
GroEL. GroEL is formed of 2 rings each containing 7 subunits packed
back to back.  As an unfolded protein enters a barrel, an ATP molecule
and the assistant chaperone GroES enclose the structure and induce a
large conformational  change. Formation of GroEL- GroES causes the
interior  surface  to  go  from  hydrophobic  to  hydrophilic  giving  the
unfolded protein a chance to fold. After approx 20 seconds the ATP is
hydrolysed releasing a phosphate molecule and the GroES cap. This
conforms  the  ring  into  a  more  open  form,  causing  it  to  release  the
protein whether it has folded or not. At this point it can either re-enter
the same chaperonin or enter another to try again (Lin, Madan, and Rye
2008)
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An Introduction to Amyloid
When one takes into account the vast array of jobs performed by proteins;
receiving cell signals, regulation of waste and maintaining structure of tissues
and  organs,  it  becomes quite  clear  why  the  body  makes  great  efforts  to
ensure  a  protein  reaches  its  native  state  in  a  fast  and  reliable  manner.
Proteins are responsible for almost every task of cellular life but they can only
carry out these tasks when in their native state. This is because the native
state is the only structural formation in which the proteins compliment their
three  dimensional  ligands  in  shape  and  charge.  For  this  reason,  any
disruption  of  the  three-dimensional  shape  can  lead  to  disruption  in  cell
regulation. Some of these disruptions are manageable. Drugs can often be
used  to  control  the  physiological  imbalance  and  reduce  any  symptoms
however  this  is  not  always  the  case.  Sometimes  the  effects  of  protein
denaturation  can  be  more  destructive  and  have  a  more  consequential
outcome; i.e. a disease can develop.
This thesis focuses on a specific group of protein related diseases; amyloid. 
Amyloidosis  is  the  name  given  to  a  group  of  specific  protein  mis-folding
diseases. It occurs when proteins unfold from their native state and fold into a
highly regular cross β-sheet aggregate structure known as an amyloid fibre.
This cross β-sheet fibre structure is present in all amyloid regardless of the
protein  involved.  Amyloid  fibres are insoluble,  rigid and thermodynamically
stable compared to their native counterparts and once formed, amyloid fibres
associate  with  extracellular  matrix  proteins  and  proteoglycans  to  form
structures referred to as amyloid deposits. These deposits invade tissues and
organs disrupting tissue structure and function (Sipe 2006) (Figure 9).   
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Figure 9: Photograph of a kidney tarnished with sticky, yellow amyloid
deposits (Gertz and Rajkumar 2013).
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The  mechanism  behind  amyloid  tissue  damage  is  not  fully  understood,
however,  it  is  generally believed to be a mechanical  or structural  problem
rather  than  a  cytotoxic  one.  Cytotoxic  protofilaments  are present  in  vivo,
however,  it  is  the  structurally  disruptive  deposits  which  appear  to  have a
greater contribution to disease,  e.g.  the deposition of  β2M amyloid in the
glomerulus  stiffens this  vessel,  preventing blood from being filtered in  the
kidneys  (M. B. Pepys 2001). Be that as it may, more recent evidence has
suggested that at least in the case of Alzheimer’s disease, the presence or
absence of amyloid plaque is insufficient to fully account for the damaging
role of elevated Aβ protein in amyloid-beta derived diffusible ligands (ADDLs).
The soluble oligomers of Aβ - the ADDLs - accumulate and cause functional
defects  prior  to  neuronal  cell  death  or  plaque  deposition  (Catalano  et  al.
2006).
Various conditions are known to induce amyloid fibre growth. These include
fragmentation  of  the  protein,  mutations  and  inheritance  of  a  degenerative
protein  variant.  Further  causes  include  deamination  of  asparagines  and
glutamine into their aspartic and glutamic acid counterparts, oxygenation of
the  backbone  carboxyl  and  amine  groups  and  unregulated  translational
modifications such as methylation and hyperphosphorylation (Goedert 1993).
All of which result in an unstable structure, prone to mis-folding, being formed.
Even age can be another inducing factor for protein instability as with the
development of senile systemic amyloidosis (SSA). In this particular case, the
mutated Transthyretin (TTR) protein only becomes amyloidogenic after years
of accumulation (Westermark et al. 1990). 
The History of Amyloid
Amyloid structures were originally discovered in 1854 by Virchow and Meckel
through  their  histopathological  studies  on  human  patients.  They  originally
mistook it for starch and used iodine staining as an analytical technique to
debate as to whether amyloid had a cellulose or cholesterin nature (Virchow
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1854).  However,  Friedreich and Kekule’s  subsequent  chemical  analysis  in
1859 revealed that amyloid deposits were actually of protein origin and this
was verified 50 years later when Hanssen successfully digested amyloid with
pepsin  –  a  protein  digestion  enzyme.  In  1922,  Bennhold  introduced  the
Congo  red  staining  method  of  detecting  amyloid.  The  associated  green
birefringence suggested that amyloid was not an amorphous aggregate as
originally thought,  but instead an organised pattern of protein  (Sipe 2006).
Cohen  and  Calkins  confirmed  the  fine  ultrastructure  using  electron
microscopy (EM) in 1959 but it was Glenner in 1975 who confirmed that the
structure was cross ß-sheets using x-ray diffraction. This cross ß-sheet motif
is present in all amyloid deposits and is identical in structure regardless of the
protein involved (G G Glenner 1975).
Amyloid Diseases
Although the structure of amyloid fibre is always cross β-sheet in nature, the
location of the amyloid deposit varies depending on the protein involved. As a
result of this, it is not always possible to predict which organ will be affected
making diagnosis a difficult task. If multiple organs are affected it is referred to
as systemic amyloidosis. This is the most common form of amyloidosis and it
can occur in any organ with the exception of the intra-cerebral area (Mark B.
Pepys 2006). Various examples of systemic amyloidosis are serum amyloid A
amyloidosis (AA) amyloid light chain amyloidosis (AL), and TTR amyloidosis
(ATTR).  AA  amyloidosis  is  the  most  common  type  worldwide  however
systemic AL amyloidosis is the most common type in developing countries
accounting for approximately 55% of the patients in the UK alone  (Real de
Asúa et al. 2014). 
In  the case of  AL amyloidosis,  a  plasma cell  dyscrasia leads to  the  over
production of immunoglobulin chains (light or heavy) with the propensity to
form amyloid. Although AL amyloidosis it is one of the most common forms of
systemic  amyloidosis,  its  wide range of  symptoms can make it  difficult  to
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diagnose. AL has the largest spectrum of organ involvement of all the amyloid
diseases but most typically affects the kidneys, heart and peripheral nervous
system  (PNS).  It  causes  symptoms  such  as fluid  retention,  shortness  of
breath, heart failure and palpitations; symptoms which are more commonly
associated  with  coronary  heart  disease,  bronchitis  and  pneumonia.  Other
symptoms can include stroke, diminished organ function and weight loss. It is
diagnosed through the detection of high concentrations of light chains in the
blood  and  urine  and  is  treated  via  chemotherapy  and  bone  marrow
transplantation (Gertz and Rajkumar 2013). In contrast to this, Aβ2M typically
affects the kidneys and the musculoskeletal system whereas ATTR generally
affects the heart and liver. 
In  the  rarer  cases  where  amyloidosis  is  restricted  to  a  single  organ  it  is
referred to as localised amyloidosis. This form of amyloid is usually secondary
to a non-infectious chronic inflammatory disease and is caused by localised
excess of hormone protein. An example of this is during insulin amyloidosis.
Here,  large  concentrations  of  insulin  are  noted  at  the  injection  site  of
diabetics. The deposits are seen to form a hard nodule at the injection site
and are known to release unpredictable amounts of insulin at any given time.
Cases  of  severe  hypoglycaemia  have  been  reported  due  to  the  irregular
absorption from the affected site and weight gain is commonly observed. In
these cases treatment involves removal of the hard nodule through surgery
and avoidance of injections at the amyloidosis site (Sipe 2006).
Proteins Associated with Amyloidosis
At present, a total of 36 proteins have been associated with amyloid disease
and cross β-sheet folding in vivo according to the International Committee on
Nomenclature  of  the  Amyloid  Proteins  (Sipe  et  al.  2016).  Nevertheless,
Rochet et al have shown that non amyloidogenic proteins can also form fibres
when subject to low pH and high temperatures in vitro (Rochet, Conway, and
Lansbury 2000).  Based on these findings  Dobson  in  2002 suggested that
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fibrillisation  is  a  component  of  all  protein  molecules  and  not  just  those
involved in disease. Dobson believes that fibrillisation can be triggered in any
protein if they were to become exposed to the correct conditions (Table 1). 
The  human body  hosts  more  than  50,000  proteins,  each of  which  has a
unique  amino  acid  sequence.  It  is  difficult  to  understand  how proteins  of
unique tertiary structures and sequences would be able to form a universal
structure. A protein sequence of 10 residues alone already processes 1020
sequence  possibilities  not  to  mention  proteins  with  hundreds  of  residues.
Even proteins which are composed of mostly β-sheets such as TTR and β2-
microglobulin would still require major conformational changes to convert to
the  cross  β-sheet  structure  never  mind proteins  composed primarily  of  -ɑ-
helices. 
The existence of the cross ß-fold amongst such a diverse array of proteins
demonstrates  its  superior  thermodynamic  stability  compared  to  wild  type
proteins  and  explains  its  resistance  during  treatment.  However,  when
researching amyloidosis one will notice that there are certain points which are
not explained in the literature. Scientists are uncertain if all proteins truly have
the potential to form amyloid. Also, it is unclear as to why amyloid forms at all
when the native state of a protein is so stable. 
The fact that proteins do not all spontaneously form fibres, especially in vivo,
could be explained by a number of points: The first being the presence of
chaperones  in  vivo.  These  assist  in  the  folding  of  peptide  chains  into
functional native states. The second reason is that physiological conditions do
not necessarily induce the initial unfold required of proteins to make the cross
β-sheet fold. One must remember that the native state of a protein is a highly
stable structure which is not easy to disrupt. A pH of 7.4 and a temperature of
37°C are maintained in  a  body.  These conditions are not  likely  to  induce
protein mis-folding without the additional factors of sequence mutations, and
fragmentation.
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Fibril 
Protein
Precursor Protein Systemic / 
Localized
Acquired / 
Hereditary
Target Organs
AL Immunoglobulin light 
chain
S, L A, H All organs, usually except CNS
AH Immunoglobulin heavy 
chain
S, L A All organs except CNS
AA (Apo) Serum amyloid A S A All organs except CNS
ATTR Transthyretin, wild type S A Heart mainly in males, ligaments, tenosynovium
Transthyretin, variants S H PNS, ANS, heart, eye, leptomeninges
Aβ2MM β2M-Microglobulin, wild Microglobulin, wild 
type
S A Musculoskeletal system
β2M-Microglobulin, wild Microglobulin, variant S H ANS
AApoAI Apolipoprotein A I, 
variants
S H Heart, liver, kidney, PNS, testis, larynx (C-Microglobulin, wild terminal 
variants), skin (C-Microglobulin, wild terminal variants)
AApoAII Apolipoprotein A II, 
variants
S H Kidney
AApoAIV Apolipoprotein A IV, wild 
type
S A Kidney medulla and systemic
AApoCII Apolipoprotein C II, 
variants
S H Kidney
AApoCIII Apolipoprotein C III, 
variants
S H Kidney
AGel Gelsolin, variants S H PNS, cornea
ALys Lysozyme, variants S H Kidney
ALECT2M Leukocyte chemotactic 
factor-Microglobulin, wild 2M
S A Kidney, primarily
AFib Fibrinogen α, variants S H Kidney, primarily
ACys Cystatin C, variants S H PNS, skin
ABri ABriPP, variants S H CNS
ADan ADanPP, variants L H CNS
Aβ Aβ protein precursor, 
wild type
L A CNS
 Aβ protein precursor, 
variant
L H CNS
AαSyn α-Microglobulin, wild Synuclein L A CNS
ATau Tau L A CNS
APrP Prion protein, wild type L A CJD, fatal insomnia
 Prion protein variants L H CJD, GSS syndrome, fatal insomnia
Prion protein variant S H PNS
ACal (Pro)calcitonin L A C-Microglobulin, wild cell thyroid tumors
AIAPP Islet amyloid polypeptide L A Islets of Langerhans, insulinomas
AANF Atrial natriuretic factor L A Cardiac atria
APro Prolactin L A Pituitary prolactinomas, aging pituitary
AIns Insulin L A Iatrogenic, local injection
ASPC Lung surfactant protein L A Lung
AGal7 Galectin 7 L A Skin
ACor Corneodesmosin L A Cornified epithelia, hair follicles
AMed Lactadherin L A Senile aortic, media
AKer Kerato-Microglobulin, wild epithelin L A Cornea, hereditary
ALac Lactoferrin L A Cornea
AOAAP Odontogenic ameloblast-Microglobulin, wild 
associated protein
L A Odontogenic tumors
ASem1 Semenogelin 1 L A Vesicula seminalis
AEnf Enfurvitide L A Iatrogenic
Table 1: A list of the 36 proteins involved in human amyloidosis (Sipe et al. 2016).
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Fibre Formation
As explained previously, all amyloid fibres share this common cross ß-sheet
motif regardless of the protein involved, however the precise mechanism of
cross β-sheet folding is not fully understood. Findings from  Booth et al.  in
1997 indicate  that  cross  β-sheet  formation  is  achieved  through  an  initial
unfolding of the protein, either fully or partially, from its native state into an
aggregation prone intermediate. Booth discovered this whilst experimenting
with two thermically unstable variants of lysozyme. He found that they - unlike
their wild type counterpart - were able to form amyloid fibres from partially
folded intermediates. This was later confirmed by Dumoulin et al. in 2005. Of
course, in cases where the protein is natively unfolded i.e. amyloid β (Aβ), the
initial  unfolding  witnessed  with  lysozyme is  inapplicable.  In  that  particular
case, one would assume that cross β-sheet folding was due to an increased
concentration and proximity of amyloid prone isomers (Figure 10). 
Fibre  growth  is  very  similar  to  crystal  growth  in  crystallisation;  it  is  a
nucleation dependent form of oligomerisation. This type of growth creates a
sigmoidal curve which can be divided into three stages: nucleation, growth
and stationary.
Nucleation 
The  nucleation  stage  involves  a  protein  solution  exceeding  a  critical
concentration  of  amyloid  prone  intermediates  in  order  to  form  a  stable
nucleus.  The formation  of  amyloid  nuclei  is  responsible  for  the  lag phase
typically seen in fibre growth as it is the rate limiting step of the process. Once
formed,  the  remaining  intermediates  quickly  assemble  into  nuclei  and are
elongated to form single stranded protofilaments  (Joseph T.  Jarrett  1993).
Until recently it was believed that protofilaments were elongated at both ends
however, Heldt  et. al have provided evidence to the contrary. Using Alexa
Fluor  568  labelled  insulin  protofilaments,  they  found  that  the  majority  of
protofilaments propagated along one end of the nuclear seed although some
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cases were seen at both. This indicates that, at least in the case of insulin,
protofilaments are asymmetric (Heldt, Zhang, and Belfort 2011). 
It should be noted that the lag phase can be avoided through the addition of
pre-formed  fibre,  a.k.a. “seeding”.  This  eliminates  the  nucleation  step
completely  as  the  cross  β-sheet  nuclei  are  already present  and  act  as  a
catalyst for subsequent fibre growth (Cohen et al. 2012). Seeding is normally
performed between variants of the same protein however there have been
cases  of  seeding  between  different  proteins  where  significant  tertiary
structural similarity with the host protein is observed (Ma and Nussinov 2012).
Both seeded and unseeded fibre growth can occur in fibrillisation, however,
seeded  growth  is  hyperbolic  and  is  restricted  to  in  vitro fibre  assembly.
Unseeded growth is more commonly seen and can occur both in vivo and in
vitro. The growth phase of fibres occurs at an exponential rate until a plateau
is reached and soluble intermediate concentration is diminished (Sipe 2006). 
Growth 
A minimum of two protofilaments will  arrange themselves around a hollow
channel to make a rope-like structure approximately 10nm in diameter and of
indefinite length. This rope-like structure is referred to as an amyloid fibre
(Mark B. Pepys 2006). It is not known for certain how many protofilaments are
required to make amyloid fibres, however, studies have shown cases of fibres
ranging  from  two  to  six  protofilaments  (Serpell  et  al.  2000).  One  would
assume that the number is dependent on the protein involved. For example, if
one believes the theory that fibres are similar (if not identical) in diameter,
then aggregates of smaller proteins must require more protofilaments to form
a fibre of similar size to that of larger, bulkier proteins. Regardless of this, all
fibre organisation requires hydrogen bonding and thus is dependent on pH
and  ion  composition  of  the  surrounding  environment  (Fraser  et  al.  1991)
(Figure 11). 
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Figure  10:  Proposed  formation  of  cross  β-sheet  fibres  from  native
protein state. Red represents α-helices, purple represents β-sheets and
the dots represent disorganised regions (Selkoe 2003). Details of each
step are listed below: 
Protofilament assembly:
a – Protein in its native state
b – Partially unfolded intermediate. When in this state the protein may follow one of
three steps: (a) Refold back into its native state through aid of protein chaperones. (c)
Form amorphous aggregate with other unfolded protein monomers. (d) Spontaneously
fold into a cross β-sheet nuclei.
c – Protein as an amorphous aggregate
d – Cross β-sheet Nucleus. Once formed, other unfolded intermediates are able to join
at each end to create a long protofilament  
e – Protofilament made of stacked β- sheets
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 Figure  11:  Model  of  an  Insulin  amyloid  fibre  composed  of  four
protofilament  strands.  The  strands  are  arranged  around  a  hollow
channel to make a rope-like structure approximately 10nm in diameter
and of indefinite length (Jiménez et al. 2002).
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Stationary
Once fully  formed,  the  rate  of  growth  decreases until  a  steady plateau is
reached. In this so called stationary phase, the lack of visible ‘growth’ can
cause one to  believe  that  fibres exist  as inactive structures.  However,  an
interesting behavioural trait has been observed. Amyloid deposits are known
to regress if circulating fibre precursors are depleted i.e. after transplantation
or immunization (Holmgren et al. 1993) (Schenk et al. 1999) This shows that
fully formed fibres are not inactive structures but are, in fact, dynamic. Many
believe that the amyloid fibres are constantly disassembling and reforming
themselves  and  that  the  rate  at  which  fibres  degrade  and  reform  must
therefore  be  equal.  Only  when  the  rate  of  growth  falls  below the  rate  of
degradation will the fibres begin to break down. As of yet, there has been no
clarity as to when the degradation process starts or to the duration of this
stage. Due to the extreme stability of amyloid fibres, they are resistant to such
an event. Any degradation would likely fall far from the time constraints of the
sigmoidal curve; possibly years after growth.
Fibre Structure 
When subject to x-ray analysis, the cross β-sheet fibre produces a smeared
diffraction pattern instead of the spots typically seen in this type of analysis.
This is due to the irregularity of the R-side chains. When analysed further, the
results  illustrate  the  cross  beta  sheet  as  a  stacked  structure  containing
multiple sheets of  parallel  β-strands.  Instances of anti-parallel  stacks have
been noted in literature however this is quite rare. The distance between each
sheet is 10.7Å and the distance between each strand in the sheet is 4.8Å -
the equivalent of 3 sets of hydrogen bonding (Serpell 2000) (Figure 12). 
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Figure  12:  Left  –  A proposal  for  the  arrangement  of  cross  β-sheet  fibres.  They  are  composed of  stacked  β-sheets
containing parallel β-strands (arrows). The distance between each strand in the sheet is 4.8Å - the equivalent of 3 sets of
bonding (Right, bottom) - and the distance between each sheet is 10.7Å. This arrangement is believed to be identical
regardless of the protein involved (Serpell 2000). There have been instances of anti-parallel stacks however this is rare as
anti-parallel binding is less stable than parallel. Right (Top, boxed) – A typical x-ray diffraction pattern of parallel amyloid
fibres. Note that the diffraction pattern appears as smears rather than the spots typically seen in this type of analysis due
to the irregularity of the R-side chains. 
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The choice  of  parallel  stacks  in  fibres  instead  of  anti-parallel  stacks  is  a
surprising result. In regular protein folding, the anti-parallel form is preferred
over the two due to that fact that hydrogen bonding between the carbonyls
and amines are planar.  It  is  unusual  that  the reverse is  seen in  cross  β-
sheets. Cross β-sheets have proven to be more stable than native proteins so
one would expect them to be constructed of the more stable of the two  β-
sheet  formations.  Alternatively,  one could  argue that  although the  parallel
form is less stable, it may be better suited for “stacking”. Perhaps stacking is
more compact in the parallel form as the R groups are not directly opposite
each other. Also, protofilaments twisting may be easier if hydrogen bonding in
the stacks is not as rigid.
Native State Stability 
The native state of a protein is described as the conformation at which the
Gibbs free energy of the system is at its lowest; i.e. the native conformation is
determined by the totality of inter-atomic interactions and hence by the amino
acid sequence itself  (Anfinsen 1973).  With  that  said,  cross  β-sheets have
shown to be even more thermodynamically stable. They, unlike their native
counterparts, have the ability to maintain structure in extreme temperatures
and in the presence of denaturing solvents provides.
Unfortunately is impossible to directly compare the thermodynamic stability of
cross  β-sheets  with  their  native  state  equivalents.  This  is  due  to  the
insolubility, heterogeneity and high degree of polymerisation of the amyloid
fibrils. However, β-sheet rich oligomers can be compared to native proteins as
they, unlike regular cross β-sheets, are soluble. 
Multiple studies have been performed using prion protein (PrP). The different
states  of  PrP were analysed and used as a reference in  the  energy free
diagram. The results show that the native protein state does not have the
lowest  Gibbs  free  energy  and  that  the  cross  β-sheet  is  far  more  stable.
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However, this cannot be taken as fact. The oligomers may not be the true
global  energy  minimum  as  they  themselves  may  undergo  additional
transitions to form polymeric amyloid forms (Hartl and Hayer-Hartl 2009). 
Considering its supremacy on stability one would wonder why the cross β-
sheet form is not accessible during folding under native conditions. This has
already been discussed in literature and agreed to be due to the fact that β-
sheets have a slower folding rate compared to  folding of the native form.
There must  be a large energy barrier  separating the native from the beta
sheet (Baskakov et al. 2001). Also, analysis of the kinetic traces indicates that
the  process  of  folding  into  the  β-sheet  represents  a  transition  with  an
apparent reaction order of 3 or higher  (Sokolowski et al. 2003). An order of
reaction is defined as a number that relates the rate of a chemical reaction
with the concentrations of the reacting substances. The high order of reaction
presented above suggests that transition depends highly on the concentration
of the transition state.
Identification of Amyloid Fibres 
There are various ways in which to identify amyloid fibres, the most common
being the use of dyes Congo red and Thioflavin T (ThT). 
Despite their common use in the diagnosis of amyloid fibres in ex vivo, in
vitro, and animal model studies, not much is known about their mechanisms
of amyloid binding.  A large number of  studies have examined the binding
mode, but  a  high-resolution characterization  has so  far  not  been possible
because of the insolubility  and often heterogeneous nature of the amyloid
fibres.  In  spite  of  this  poor  understanding,  various  theories  have  been
presented throughout the years.
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Thioflavin T
Thioflavin  T  (ThT)  is  a  cationic  benzothiazole dye  that  shows  enhanced
fluorescence upon binding to amyloid at a wavelength of 420nm.  It is often
used to diagnose amyloid in tissue sections using fluorescence microscopy
and to monitor extracted amyloid and  in vitro  amyloid fibre formation using
fluorescence spectroscopy (Figure 13). 
ThT has a minimal effect on the fibrillation kinetics and is independent of the
number or length distribution of fibres. When analysing amyloid fibre formed
from specific protein under given conditions, the fluorescence intensity of ThT
has been shown to be proportional to the concentration of fibres. However,
extreme care should be taken when comparing fibre formation under different
conditions since a number of factors may affect the fluorescence intensity.
These include the specific protein forming the fibril,  fibril  morphology, ThT
concentration, pH, and ionic strength (H. LeVine 1997) (Harry LeVine 1995). 
The concept of using ThT as an indicator of amyloid was first introduced by
Vassar and Culling in 1959. They demonstrated that the detection of amyloid
in  the  kidneys with  ThT after  differentiation  in  acidic  solutions  was highly
specific. This was later confirmed in 1967 by Saeed and Fine. Unfortunately
they found that ThT was also able to bind to other connective tissues such as
cartilage matrix  and elastic  fibres.  Furthermore,  it  demonstrated enhanced
fluorescence when bound to DNA and RNA. To help improve the specificity of
ThT  to  amyloid,  Kelenyi  modified  the  staining  conditions  to  a  lower  pH
(between 0.8-2.8) with success (Kelényi 1967).
It is important to note that the inter-strand spacing along the fibril axis of 4.8 Å
is  unchanged  in  insulin  fibrils  upon  ThT  binding.  This  indicates  that  ThT
binding is exclusive to the surface of amyloid fibres as an increased β-strand
distance would have been evident in X-ray fibre diffraction data if ThT had
bound between the β-strands (Groenning et al. 2007). Krebs et al. have since
used confocal  microscopy to  show that  the  dye dipole excitation axis  lies
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parallel to the long molecular axis of the fibre. In other words, ThT binds to
amyloid fibres such that their long axes are parallel i.e. in the ‘channels’ that
run  along  the  length  of  the  cross  β-sheets  (Krebs,  Bromley,  and  Donald
2005). 
It has been proposed that ThT may bind to fibres in the form of micelles. A
micelle is a form of molecular aggregation where various identical molecules,
containing both a polar and a hydrophobic end, form a shell. The hydrophobic
ends of each molecule are enclosed within the shell with the polar ends on
the edges. In ThT the hydrophobic end consists of a dimethylamino group
attached to a phenyl  group and the polar end consists of  a benzothiazole
group. In 2005 Khuana et al. discovered that the fluorescence excitation and
emission of ThT were dependent on the micelle formation. They noticed a
correlation between micelle formation and transmission. The more micelles
present the more transmission observed.  The micelles were visualised using
atomic  force  microscopy.  They  were  3nm  in  diameter  and  were  bound
proportionally along the length of the fibres. Upon disruption of the micelles
using a pH of 3 or lower, binding of thioflavin T to amyloid fibres was also
reduced. This suggests that the positive charge on the thioflavin T molecule
has a role in its micelle formation that then bind the amyloid fibres (Groenning
2009). Although an interesting theory, the micelle proposal is inconsistent with
the fact that ThT prefers to bind parallel to fibres. Perhaps the micelle theory
is limited by ThT concentration or alternatively can be interpreted as stacking
of ThT rotated along its lateral axis.
It  is  important  to  note  that  when  looking  at  the  level  of  fluorescence  or
fluorescence intensity on a spectrophotometer, the values obtained from one
machine cannot be directly compared to those from another. This is because
the resulting values are determined by the software, the detector systems, the
electronics and filtering,  etc  of  the machine in  question.  Due to  this,  ThT
fluorescence in relation to cross β-sheet fibres is not given units. With that
said, although the arbitrary values are not meaningful, they can be used for
relative,  ratiometric  quantification  of  results  obtained  from  one  particular
machine. 
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Congo Red
Congo red  is  a  palindromic  structure  which  demonstrates  a  characteristic
apple green birefringence under polarised light when bound to amyloid. When
examined between crossed polarizer and analyzer, a characteristic shift  in
absorbance maximum from about 490 nm to about 540 nm is seen. Congo
red is not well  suited for in situ detection, since Congo red interferes with
processes of protein  misfolding and aggregation, and is reported either to
inhibit or enhance amyloid fibre formation for several proteins. Instead, Congo
red is most often applied in diagnosis of amyloid in ex vivo tissue sections.
This is usually done using polarization microscopy, but light microscopy and
fluorescence microscopy can also be used.  (Groenning 2009) (Figure 14,
Figure 15).
The use of Congo red as an detector of amyloid was first established in the
1920s by Benhold and Divry  (Benhold 1922) (Divry 1927).  They originally
thought  that  the  dye  bound  fibres  in  a  crystal-like  fashion  with  colour
distribution being an indication of thickness. More recent work by Khurana et
al. has shown that Congo red binds parallel to the β strands along the edges
or the middle of the sheet  (Khurana et al. 2001).  They achieved this result
through the use of circular dichroism (CD). Congo red binding was carried out
with various proteins of different secondary structure classes. Throughout the
course of their experiment they noticed that their CD bands were different
from  the  tissue-extracted  amyloid  described  by  Benditt  et  al.  (Benditt,
Eriksen,  and Berglund 1970).  They concluded that  these differences were
most  likely due to “contaminants”  such as glycosaminoglycans and serum
amyloid protein present in the ex vivo extracts.
Khurana et al. also noted that Congo red was able to bind to proteins in their
native state.  Pectate lyase, carbonic anhydrase (CA),  β-lactoglobulin,  IL-2,
and lysozyme all demonstrated this however, after binding to the dye, each
protein proceeded to oligomerise leading to the idea that stable Congo red
binding is exclusive to multi-meric structures. In addition, CD peaks were 10
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times smaller in the native bands than their fibre counterparts indicating that
native proteins have fewer binding sites for the dye.
The  binding  of  Congo  red  to  such  a  variety  of  proteins  in  various  forms
indicates that amyloid binding is not structure specific for Congo red. Perhaps
Congo  red  binding  is  limited  to  specific  hydrophobic  and  electrostatic
interactions which are more accessible in the fibre structure compared to the
native counterparts. Most studies suggest that ionic interactions are important
for Congo red binding to amyloid fibres. For example, the stoichiometry of
Congo red binding  decreases as  pH increases in  the  binding  of  β-poly-L-
lysine (Klunk, Pettegrew, and Abraham 1989). This suggests that protonation
of the poly-L-lysine is important for binding. Furthermore, the importance of
the  ionizable  group  for  binding  of  Congo  red  is  demonstrated  upon  its
removal. By removing one of these groups the affinity of Congo red to bind
fibres is reduced dramatically (Cai, Innis, and Pike 2007).
Studies have also shown that hydrophobic interactions play an important role
for burial of the hydrophobic part of the Congo red molecule (Wu et al. 2007).
This would suggest that Congo red molecules are stabilized upon insertion
into  the  grooves  on  the  β-sheet  surface.  In  addition,  an  increase  in
hydrophobicity shifts the absorption band of the dye to around 498 nm. This is
similar to the shift  observed in amyloid fibres but on a much smaller scale
(Miura et al. 2002). 
When used to analyse tissue samples, Congo red binding is not exclusive to
protein let alone amyloid. Frequent binding to elastin, collagen fibres, RNA
polymerase  and  cytoskeletal  protein  often  results  in  false  positive  results
(Woody, Reisbig, and Woody 1981) (Kagan, Hewitt, and Franzblau 1973). In
an  attempt  to  prevent  this,  tissue  assays  are  performed  under  extreme
conditions of 50–80% ethanol, high salt and alkaline pH conditions to yield
binding to amyloid.
Although the mechanisms behind ThT and Congo red binding have been
speculated various times in literature they are still not fully understood. The
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one notion that  can be concluded is that they bind to different sites on the
amyloid fibre. This is derived from the fact that each has a different charge;
ThT is positively charged whereas Congo red is negatively charged. Also, the
binding kinetics of  Congo red to amyloid fibres is slower than that of  ThT
suggesting that Congo red may not have easy access to its binding site most
likely due to its size (Nilsson 2004).
It should also be noted that commercial stocks of these dyes are not always
100%  pure  (in  accordance  with  the  Sigma  Aldrich  website).  ThT  has  a
reported purity of only 65–75% with its main impurities being salts containing
sodium, chloride, and sulphur. Commercial Congo red is contaminated with
sodium  chloride  and  water,  making  quantification  by  weight  inaccurate.
Recrystallization  is  likely  to  improve  the  purity  of  each  and  make
quantification  by  weight  possible.  However,  many  authors  seem  to  be
unaware of this so it is difficult to directly compare their results. 
Both ThT and Congo red are regularly used as a diagnostic tool but neither is
100% accurate or practical. Not only are both prone to bind bacteria and other
tissue matter,  but they can cause patients to go into anaphylactic shock if
injected  intravenously.   This  is  a  severe  form  of  allergic  reaction  with
symptoms such as swelling facial features, rash, wheezing, unconsciousness,
nausea and vomiting. Due to this, other methods have been developed in
order  to  analyse  amyloid  fibres.  These  include  transmission  electron
microscopy (TEM), circular dichroism (CD) and x-ray crystallography.  
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Figure  13:  Diagram  of  Thioflavin  T  (ThT).  It  is  constructed  of  a
hydrophobic end and a polar end. The hydrophobic end consists of a
dimethylamino  group  attached  to  a  phenyl  group  and the  polar  end
consists of a benzothiazole group. ThT is thought to bind proportionally
to  the  channels  which run parallel  to  the β-sheet.  When bound ThT
produces fluorescence at wavelength 420nm.
 
Figure  14:  A  diagram  of  Congo  red.  Congo  red  is  a  palindromic
structure which binds parallel to the β strands along the edges or the
middle  of  the  sheet  using  both  hydrophobic  and  electrostatic
interactions. A characteristic apple green birefringence is demonstrated
under polarised light when Congo red binds to amyloid.
63
 
Figure 15: A photograph of insulin fibres grown in TE buffer and stained
with Congo red.  The sample was viewed under polarised light in order
to see the apple green birefringence typical of cross-β sheets. Image
was viewed using a Zenith Microlab ML-1000M Monocular Laboratory
Microscope 60040 at a magnification of x40.
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Transmission Electron Microscopy
Transmission Electron microscopy (TEM) is the gold standard for visualising
amyloid fibres as it provides an actual photograph of the structures. TEM is a
microscopy technique that uses electrons as a way to illuminate thin films of
samples similar to the way optical microscopes use light (Figure 16). 
In order to carry out TEM, the specimen or sample must exist in one of two
forms: either as an ultrathin section less than 100 nm thick or as a suspension
on a copper grid. The reason behind such thin samples is to allow the beam
of  electrons  to  transmit  through  the  sample  and  interact  with  it.
Electromagnetic fields focus the electrons in a way analogous to a lens in a
light microscope however, unlike light in regular microscopes, the beam of
electrons must be contained within a vacuum. This is due to the fact that
electrons can easily be absorbed by air at atmospheric pressure. The use of
electrons allows higher magnifications to be achieved in comparison to light
microscopes. Electrons have smaller wavelengths than light so are able to
interact with smaller objects.  The image is then magnified and focused onto
an imaging device, such as a fluorescent screen, a layer of photographic film,
or a sensor such as a charge-coupled device.
Although a reliable way to identify amyloid fibres, TEM is a specialised form of
analysis. The microscope itself is expensive and its use requires extensive
training (D. B. Williams and Carter 1996) (J. C. Williams and Paton 1978). 
Circular Dichroism
Circular Dichroism (CD) is an alternate technique which can be used. It works
by using polarised light as a way to analyse chiral molecules of all types and
sizes. It is a favoured technique as it is non-denaturing  and has the ability to
take into consideration any sensitivity  of  the sample towards environment,
temperature and pH. 
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Figure  16: Cartoon comparing a light microscope with a transmission
electron  microscope  (TEM).  In  a  light  microscope,  the  source  of
illumination is optical light. The light waves are condensed, focused and
projected using glass lenses and the final image is viewed by the naked
eye.  It  has  a  magnification  of  1000-2000x  which  is  a  physical  limit
imposed by the wavelength of light. In comparison, in TEM the source
of illumination is electrons. They are contained within a vacuum and are
focused via magnets. An image is created on a computer screen when
the electrons reflect from a metal coated sample and are detected by an
electron  detector.  TEMs  have  a  much  higher  resolution  than  light
microscopes – up to 2 million times – however they are very expensive
and require special training to use. 
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The need for chirality in CD makes it an ideal way to analyse proteins as they
themselves are large chiral molecules (i.e. non super-imposable molecules).
Chiral molecules exist as pairs of mirror-image isomers which are known as
enantiomers. The physical and chemical properties of a pair of enantiomers
are identical with two exceptions. They interact with polarised light differently
and they also interact with other chiral molecules differently. It is the first of
these exceptions which is taken advantage of in CD techniques.
In order to carry out CD, one must have two circularly polarised lights (CPL)
of  equal  magnitude;  one  rotating  clockwise  and  the  other  rotating  anti-
clockwise. These opposing circularised lights are passed through a solution of
the optically active medium and measurements are carried out in the visible
and UV region of the electromagnetic spectrum over a range of wavelengths.
A spectopolarimeter monitors the electronic transitions. If the molecule under
study is indeed chiral, then one CPL state will be absorbed to a greater extent
than  the  other.  This  causes  the  CD  signal  over  the  corresponding
wavelengths to be non‐zero (Atkins and Paula 2005) (Figure 22). 
It is this difference in absorbance between the two wavelengths which is used
as an  indicator of  the secondary structure of the protein  (Kelly,  Jess,  and
Price 2005). A CD signal can be positive or negative, depending on whether
the anti-clockwise  CPL is absorbed to a greater extent than the clockwise
CPL (CD signal positive) or to a lesser extent (CD signal negative). 
In order to truly understand circular dichroism, one must first understand the
basics  of  polarisation  beginning  with  unpolarised  light.  A  light  wave  is  a
transverse electromagnetic wave. It is produced by oscillating electric charges
and has both an electric and a magnetic component. When travelling through
space,  although  travelling  in  a  linear  direction,  the  electric  and  magnetic
oscillations of an electromagnetic  wave occur in numerous planes. A light
wave that is vibrating in more than one plane is referred to as unpolarised
light. Linearly polarised light occurs when these oscillations are confined to a
single  plane.  This  can  be  achieved  through  a  number  of  ways  including
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transmission, reflection, refraction and scattering. In CD however, polarisation
occurs through use of a polaroid filters a.k.a. wave plates (Singh 2010).
Wave plates are made of a special material that is capable of blocking all but
one of the planes of vibration of an electromagnetic wave. When unpolarised
light is transmitted through a wave plate,  it  emerges on a single plane. A
wave plate is able to polarize light because of the chemical composition of the
filter material. The filter can be thought of as having long-chain molecules that
are aligned within the filter in the same direction. As unpolarised light strikes
the  filter,  the  portion  of  the  waves  vibrating  parallel  to  the  long  chain
molecules are absorbed by the filter. The alignment of these molecules gives
the filter a polarization axis. This polarization axis extends across the length
of the filter and only allows vibrations of the electromagnetic wave that are
parallel to the axis to pass through. Any vibrations that are perpendicular to
the polarization axis are blocked by the filter. 
To  simplify  matters,  light  waves  are  visualised  as  having  their  coupled
oscillating electric field and magnetic field as perpendicular to one another. All
polarised light states can be described as a sum of those two linearly states
at right angles to each other, usually referenced as vertically and horizontally
polarised light. If for instance we take horizontally and vertically polarised light
waves of equal amplitude that are in phase with each other, the resultant light
wave  is  linearly  polarised  at  45  degrees.  Circularly  polarised  light  occurs
when the two polarisation states are out of phase. For example, if one of the
polarised states is out of phase with the other by a quarter-wave, i.e. one of
the linear components of the beam is slowed down with respect to the other
so that they are one quarter-wave out of phase, the resultant will be a helix
and is known as circularly polarised light (CPL). The helices can be either
right‐handed  (R‐CPL)  or  left‐handed  (L‐CPL)  and  are  non‐superimposable
mirror  images.  On  traversing  the  solution  of  chiral  medium,  the  phase
relationship between the circularly polarised waves changes and the resultant
linearly polarised wave rotates. This is the origin of the phenomenon known
as optical rotation, which is measured using a polarimeter  (Avadhanulu and
Kshirsagar 2014). 
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There are both advantages and disadvantages for using circular dichroism to
determine the presence of amyloid. It  is a rapid, non-destructive technique
which has the ability to determine native structural features, stereochemistry
and can measure exchanging structures in changing environments. However,
it cannot give structural information at the atomic level, it requires relatively
concentrated (0.5mg/ml) sample solutions in order to produce results and it
cannot be used for mixed sample solutions. It is limited to a single protein at a
time. 
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Figure 17: (Above) A graph showing the typical Circular Dichroism (CD) spectra for alpha helices (gold), beta sheets or
strands (blue) and random coiling (red). The alpha helices produce a spectra consisting of a peak and double depression
in the positive and negative mdeg axis respectively. The beta sheets/strands produce a spectra consisting of a peak and
single depression in the positive and negative mdeg axis respectively with a shifted x axis interception point to the right.
Random coils produce spectra consisting of a depression followed by a low but broad peak. (Below) Image depicting the
creation  of  circularly  polarised  light.  The  electric  and  magnetic  oscillations  of  an  electromagnetic  wave  occur  in
numerous planes in un-polarised light. Linearly polarised light is obtained in CD when these oscillations are confined to a
single plane through use of a wave plate. When two polarisation states are out of phase with one another circularly
polarised light is formed (Chu et al. 2015). 
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X-HelixRay Crystallography
X-ray crystallography is the most difficult method used for analysing amyloid.
In this technique the atoms of the sample are placed in the path of an x-ray
and this obstruction causes a beam of incident X-rays to diffract into many
specific directions. The refracted beams are monitored using a detector and
processed into a pattern of spots. The dispersion and intensity of the spots
are measured by a detector are later used by a computer to determine the
atomic and molecular structure of the sample. – Further details in Chapter 4:
“X-Ray Crystallography” 
The reason this method is described as difficult  is because it  requires the
sample  to  be  in  crystalline  form.  Turning  a  sample  into  a  crystal  is  an
extremely time consuming process. It requires various steps, each of which
must  occur  successfully  in  order  for  a  crystal  to  form.  Firstly,  the  desired
protein  must  be  successfully  expressed  and  purified  through  use  of
prokaryotic  or  eukaryotic  recombinant  techniques.  Once  achieved,  protein
crystals must be grown to an adequate quality and size, harvested and frozen
without causing any damage to the fragile structure. Finally, diffraction must
occur at a high enough resolution in order to reveal atomic detail. Each of
these steps is incredibly time consuming, may not necessarily work, and can
require great amounts of trial and error (G Wagner, S G Hyberts, and Havel
1992).
TEM, CD and x-ray crystallography methods are all  frequently used for  in
vitro studies of amyloid fibres and are often referred to in the literature. They
are  each  a  more  reliable  method  of  detecting  and  analysing  amyloid
compared  to  Congo  red  and  ThT  dyes.  However,  they  are  also  more
expensive, require more skill to administer and take far longer to complete.
The use of Congo red and ThT dyes is quicker and easier which explains
their continued use today as a research and diagnostic tool.   
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Scintigraphy
There is  one final  method used for  analysing amyloid  called  scintigraphy.
Scintigraphy is slightly different to the previous examples as it is performed in
vivo (Figure 18). 
Scintigraphy  involves  using  a scintillation  counter  alongside  a  radioactive
tracer  in  order  to  obtain  an  image  of  a  bodily  organ  or  a  record  of  its
functioning. In the case of amyloidosis, the protein Serum Amyloid P (SAP) is
used as the radioactive tracer. SAP is a 125kDa pentameric protein with an
affinity for amyloid. It is found in the serum and has a half life of 1 day. In
1988 Hawkins  et al performed  in vivo studies involving iodine-123 labelled
SAP. These involved injection of the radio-labelled SAP into affected patients
and  monitoring  its  distribution  through  use  of  a  gamma  camera.  Those
suffering  from  amyloidosis  demonstrated  an  accumulation  of  the  radio-
labelled SAP preventing a clearance of it from the body and increasing its
half-life from 1 to 30 days (Hawkins, Lavender, and Pepys 1990; Hawkins et
al. 1988). Sørensen et al. in 2000 proved that these interactions were calcium
dependent by demonstrating that complexes could not be formed in plasma
containing EDTA (a metal chelator). 
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Figure  18: Radio-labelled SAP scans from a patient suffering from AL
amyloidosis. Iodine-123 labelled SAP was injected and monitored via a
gamma  camera.   Darkened  areas  represent  SAP  accumulation  -  i.e.
amyloid deposit.
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An Introduction to Serum Amyloid P Component
(SAP) 
Serum amyloid P component (SAP) is referred to as a universal component of
Amyloid. Various macromolecules have the ability to bind to amyloid fibres to
form the structures referred to as amyloid deposits, however, the majority of
these  macromolecules  bind  specifically  to  amyloid  fibres  of  a  particular
protein. SAP and glycosaminoglycans  are the only components universal to
all  deposits  regardless of  the protein  involved  (Ancsin 2003) (Skinner  and
Cohen  1988).  The  roles  of  SAP  and  glycosaminoglycans  are  unknown,
however  it  is  believed that  they are involved in  protecting amyloid  against
degradation and may even enhance fibril folding (Tennent, Lovat, and Pepys
1995). 
SAP is a plasma glycoprotein of unknown function which makes up to 15%
total mass in all amyloid deposits  (Calkins 1983). It is made in the liver and
travels in the plasma at a concentration of 30-45mg/L  (Rubio et al.  1993).
SAP belongs to the pentraxin family of  proteins and like the others in this
family,  exhibits  calcium  dependent  ligand  binding.  It  has  a  ring/disc-like
structure  consisting  of  5  identical  subunits  arranged  non-covalently  in
pentameric radial symmetry and is often referred to as an SAP pentamer (M.
B Pepys et al. 1977) (Figure 19).
 
SAP Structure
SAP crystals were first observed in 1986 however crystallisation proved to be
difficult due to SAP’s tendency to precipitate in the presence of calcium ions.
Fortunately  this was overcome by Wood  et  al in  1988 through the use of
calcium site ligands and the structure was finally published in 1994 by Jonas
Emsley  (Jonas  Emsley  1994).  The  resulting  crystal  structure  shows  a
symmetrical disc (pentamer) 100Ǻ in diameter, 35 Ǻ in depth with a 20Ǻ hole
in the middle. 
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Figure  19:  Ribbon  diagram  of  a  SAP  pentamer  (A-Face).  Loops  are
represented in white, β-strands in gold and α-helices in magenta. The
resulting crystal structure shows a symmetrical disc (pentamer) 100Ǻ in
diameter, 35 Ǻ in depth with a 20Ǻ hole in the middle.  The 5 subunits
interact non-covalently through the N and C termini of adjacent subunits
via Van der Waals and hydrogen bonding. Each identical SAP subunit is
204 residues long, 25kDa in size and folded into 2 layers of anti-parallel
strands which sandwich a hydrophobic core between them. The tertiary
structure  is  stabilized  through  disulphide  bridge  linking  of  cysteine
residues 36 and 95 (Ozawa et al. 2016) (PDB code: 1SAC).
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Each identical SAP subunit is 204 residues long, 25kDa in size and contains a
sequence  signature  core  common  to  all  pentraxins  (HxCxSx/TWxS)
(Handbook of animal  lectins: properties and biomedical  applications 2000).
The pentraxin domains are of jellyroll  topology and consist of  the following
components: ß-sheets, ß-turns, unknown structures (e.g. random coiling) and
α-helixes to the ratio 54:25:19:2 respectively  (Dong, Caughey, and Du Clos
1994).  These  components  fold  into  2  layers  of  anti-parallel  strands  which
sandwich a hydrophobic core between them containing the residues leucine
62, tyrosine 64 and tyrosine 74 (Srinivasan et al. 1994). This tertiary structure
is further stabilized by the disulphide bridge linking cysteine residues 36 and
95,  as  well  as  the  N-  linked  attachment  of  a  single  biantennary
oligosaccharide attached to asparagine 32 (Hohenester et al. 1997) (Alun W
Ashton 1997).  The 5 subunits interact non-covalently through the N- and C-
termini of adjacent subunits via Van der Waals and hydrogen bonding (Dong,
Caughey, and Du Clos 1994) (Mark B. Pepys 2006) (Figure 20, ).
SAP Calcium Binding 
One side of each subunit is flat and contains an -helix and is so named theɑ-
A-face whereas the other side, known as the B-face, is twisted and has a
crevice  created  by  neighbouring  loops.  It  is  this  B-face  crevice  which  is
responsible for calcium ion binding (Kinoshita et al. 1992). 
A  total  of  2  calcium  ions  are  able  to  bind  to  each  subunit  leading  to  a
maximum of 10 calcium ions per SAP pentamer. The calcium ion pairs bind
4.2Ǻ apart and are stabilised via interactions between carboxylate and amide
residues in the binding site  (Jonas Emsley 1994).  The first of each pair of
calcium ions binds via interactions with aspartate 58, asparagine 59, glutamic
acid 136, glycine 137 and aspartic acid 138, and the second with glutamic
acid 36, aspartic acid 138 and glutamine 48 in a water mediated hydrogen
bond  (Gewurz,  Zhang,  and  Lint  1995).  In  the  absence  of  calcium,  some
enzymes such as pronase and α-chymotrypsin are able to cleave the exposed
calcium loop  causing  the  formation  of  a  less  stable  structure  (István Likó
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2007).  Experiments have shown that the binding of calcium ions leads to the
SAP  structure  becoming  very  stable  and  highly  resistant  to  proteolysis
(Tennent,  Lovat,  and Pepys 1995).  This is thought to explain why amyloid
fibres are so resistant to degradation when bound by SAP (Figure 22).
SAP Conformations
The SAP ring has polarity due to the presence of the calcium binding sites on
its B-face  (Hohenester et al.  1997). Crystal analysis has shown that  in the
absence of calcium and at a pH of 5.5 or higher, two individual SAP molecules
have the ability to interact through ionic interactions to form a B-face to B-face
decamer  (O’Hara et al. 1988). Thompson  et al. scrutinised this further and
demonstrated  that  SAP  actually  exists  as  a  mixture  of  pentamers  and
decamers in these conditions; SAP does not exclusively form decamers  (D
Thompson 2002). 
That being said, one would expect SAP to exist as a decamer mixture in the
serum.  Serum  has  a  physiological  pH  of  7.35-7.45  with  a  low  calcium
concentration  of  8.5-10.2mg/dL  of  which  only  4.8-5.7mg/dL  exists  as  free
ionised ion in serum. This is not sufficient to saturate the SAP when their
diverse molecular masses are taken into consideration. However, Sorensen
et al. disproved this in 1995. They purified fresh samples of human SAP and
analysed them via  various methods including  permeation  chromatography,
quantitative  immunoelectrophoresis,  Western  blotting,  and  electron
microscopy. Their results showed that SAP travels in the blood exclusively in
the pentameric form and not in the decameric form expected (Sørensen et al.
1995). The reason behind this is uncertain however their data indicated that
native  SAP may form a complex  with  other  serum proteins  such as C4b-
binding protein. In doing so it is unable to interact with another of its kind. 
The fact that the decamer is only observed in vitro  shows that it is probably
caused  from  ligand  mediated  contact  or  from  electrostatic  interactions
between  the  2  faces  (Hutchinson,  Hohenester,  and  Pepys  2000).  It  was
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originally  thought  to  be formed by A-face to  A-face interactions.  Scientists
believed  this  because  SAP  decamers  are  susceptible  to  cleavage  at  the
calcium loop located on the B-face. This loop was only thought to be exposed
in an A-face interaction. Recent crystallographic data, however, has shown
that the loop is actually on the outer edge of the B-face and, subsequently,
does not obscure B-face interactions (Alun W Ashton 1997).
SAPs  tendency  to  auto-aggregate  is  a  common  problem  during  in  vitro
experimentation.  Crystal  forms  of  SAP  suggest  that  in  the  case  of  auto-
aggregation, an A-face to B-face interaction occurs instead. Here, glutamic
acid 87 on the -helix  N-terminus of  one pentamer protrudes towards theɑ-
calcium binding site of the B-face of the adjacent pentamer. This issue can
been  resolved  through  the  use  of  calcium  dependent  ligands  and  supra
physiological  concentrations  of  salt.  Additionally,  point  mutagenesis  of  this
residue to either a glutamine or a serine abolishes auto-aggregation. In the
cases  where  calcium dependent  ligands  are  involved,  glutamic  acid  87  is
unable to interact with a neighbouring pentamer as the ligand is occupying the
calcium binding site. Kolstoe’s studies in 2005 showed that in high salt and
calcium concentrations it is the chloride aspect which is most likely preventing
the glutamic acid 87 interaction. The reason in which the concentrations need
to be so high is so to ensure full saturation of all five calcium binding sites
present on each pentamer (Kolstoe, S.E. 2005) 
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Figure 20: The primary sequence of an SAP domain with its associated
secondary structures marked: ß-strands, ß-turns, and α-helixes to the
ratio 54:25:2 respectively. These components fold into 2 layers of anti-
parallel  strands which sandwich a hydrophobic core between.  This  is
stabilized  by  a  disulphide  bridge  linking  cystein  residues  36  and 95
(highlighted in yellow), as well as an N- linked attachment of a single
biantennary oligosaccharide to asparagine 32. The residues involved in
calcium binding are highlighted in green and the pentraxin signature
sequence common to all pentraxins is underlined in black.
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Figure  21: Ribbon diagram of an SAP domain A-face (top) and B-face
(bottom). The β-strands are labelled A to O from the N- to C- terminus
and are folded into a jellyroll topology.  The  α-helix present on the A-
face is highlighted in green and the stabilising cysteines 36 and 95 are
represented in yellow (Jenvey, 2006).
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 Figure 22: Calcium binding site of SAP. Calcium ions are represented in
yellow. A total of 2 calcium ions are able to bind to each subunit leading
to a maximum of 10 calcium ions per SAP pentamer. The calcium ion
pairs  bind  4.2Ǻ  apart  and  are  stabilised  via  interactions  between
carboxylate and amide residues in the binding site (Jonas Emsley 1994).
The  first  of  each  pair  of  calcium  ions  binds  via  interactions  with
aspartate 58, asparagine 59, glutamic acid 136, glycine 137 and aspartic
acid 138, and the second with glutamic acid 36, aspartic acid 138 and
glutamine 48 in a water mediated hydrogen bond (Gewurz, Zhang, and
Lint 1995). 
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SAP Function 
Despite the structure of SAP being well defined, its physiological role is still
unclear. SAP has many ligands including DNA, chromatin, C1q and PE but
their relevance has not been determined. 
SAP is the only serum protein which specifically binds to DNA and long, native
chromatin and is able to displace the H1 histones  (M. B. Pepys and Butler
1987). Histones are responsible for compressing and packaging of DNA into
the cell nucleus. In vitro studies have shown that their displacement results in
the solubilisation of  chromatin  in  buffers  of  physiological  strength.  In  1992
Hicks et  al  discovered that  SAP actually  has the ability  to bind directly  to
histones  with  the  resulting  complex  activating  the  classical  pathway  of
compliment. In doing so it allows antibodies and phagocytic cells to remove
phagocytes from the body (Hicks et al. 1992). SAP has also been known to
bind chromatin in vivo. This is seen, in particular, in biopsies from patients
with systemic lupus erythematosus (SLE); an autoimmune disease in which
the body’s immune system mistakenly attacks healthy tissue. In this case, the
plasma concentration of SAP remains at 30mg/L regardless of an immune
response indicating SAP does not have an immunological role (Breathnach et
al. 1989).
SAPs affinity for both single and double stranded DNA suggests that it could
be involved in  the removal  of  apoptotic  debris  and possibly  have an anti-
inflammatory  role.  When  cells  die in  vivo the  leakage  of  plasma  proteins
triggers an immune response in the form of leukocyte recruitment. An immune
response  is  necessary  in  such  situations  as  it  alerts  the  host  to  “danger
zones”  and  prevents  the  pathogenesis  of  a  number  of  diseases.  The
increased vascular permeability of the “danger zone” very rapidly increases
the delivery of blood borne defences such as antibodies to the affected site in
an attempt to clear them. SAP, being an extracellular protein, would never
have access to DNA other than after cell death so an anti-inflammatory role is
plausible considering its affinity for DNA (Rock and Kono 2008) (Sipe 2006). 
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Another  explanation  for  this  interaction  could  be  to  prevent  anti-DNA
antibodies forming such as those seen in SLE. This was shown in a knockout
mouse study by Bickerstaff et al 1999. The mice accumulated pathogenic anti-
nuclear  antibodies  to  DNA,  chromatin  and  even  histones.  Also,  a  high
proportion  of  test  subjects  developed  proliferative  glomerulonephritis  -  a
phenotype reminiscent of human SLE (Bickerstaff et al. 1999).
The Involvement of SAP in Amyloidosis
In 1987 Hamazaki demonstrated that SAP binds specifically to the heparin
and  dermatan  sulphate  components  present  on  the  surface  of  amyloid
deposits.  These  interactions  occur  in  a  calcium dependent  manner  under
physiological  conditions  (Hamazaki  1987).  In  1995 however,  Tennent  et  al
showed that  SAP is  able  to  bind  amyloid  formed from pure  proteins  and
peptides in vitro with the same affinity. This indicates that SAP has a binding
affinity to the structural motif of amyloid fibres, not to the substrates bound to
them. Upon attempting to bind SAP with those proteins in their native form
(insulin,  TTR  and  Aβ),  Tennent  found  that  binding  did  not  occur.  This
demonstrates that this structural motif is exclusive to amyloid –  i.e. the cross
β-sheet (Sipe 2006).
As previously discussed, SAPs role and function is yet to be fully established.
Nonetheless, certain behaviours have been observed  in vivo and  in vitro  in
relation to amyloid fibres.  In vivo studies have shown SAP to have an anti-
opsonin role. The immune system is normally able to recognise amyloid but
SAP  provides  a  protective  coat  around  the  fibres.  This  in  turn  prevents
phagocytic  cell  recognition  and thus prevents  an  immune response in  the
presence of amyloid deposits (O’Nuallain and Wetzel 2002). There have also
been other studies demonstrating this ‘pro-fibre’ behaviour of SAP such as
those carried out on SAP knock-out mice. Here, the genetically altered mice
exhibit a retarded deposition of amyloid and reduced total fibre mass (Botto et
al. 1997).  This would imply that SAP is involved in catalysing or enhancing
amyloid formation. 
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In vitro, Hamazaki, Webster and Rogers have been able to demonstrate SAPs
fibrillogenic  nature  using  amyloid-β  (Aβ)  fibres.  They  observed  that  fibre
concentrations  increased  upon  the  addition  of  SAP.  These  observations,
alongside the fact  that  SAP bound fibres are more stable and resistant  to
proteolysis in vitro suggests that SAP has a role as a fibrillogenic stabiliser or
enhancer (Hamazaki 1987).
Contrastingly, Janciauskiene et al. in 1995 observed the opposite effect; SAP
actually prevented Aβ fibres from forming in vitro. They also noted that SAP
has the ability to  bind amyloid fibres made out of any protein but could not
bind  to  these  proteins  in  their  native  state  suggesting  that as  well  as  its
fibrillogenic involvement, SAP may also have a role as an amyloid molecular
chaperone. These results began a set of debates between the two lab groups.
Neither could understand why these opposing results were being produced. 
Upon closer inspection one can see that there is a very important difference
between the  two experimental  methods.  Hamazakis group performed their
assays  in  the  presence  of  a  physiological  concentration  of  Ca2+ whereas
Janciauskienes group performed theirs in the absence of any calcium ions.
This introduction  has already established SAPs ability  to  exist  as either  a
pentamer or  a  decamer depending on its  surrounding environment.  In  the
absence of calcium and at a pH of 5.5 or higher, two individual SAP molecules
have the ability to interact through ionic interactions to form a B-face to B-face
decamer, or more precisely, as a mixture or decamers and pentamers. With
this  in  mind,  one  can  assume  that  SAP  was  in  its  pentameric  form  in
Hamazakis assays and in its decameric form in Janciauskienes assays.
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Experimental Aims
The overall  aim of  this thesis  is to  clarify  the role  of  SAP in  in  vitro  fibre
formation.  Does SAP behave as  a fibrillogenic  enhancer  as  suggested by
Hamazaki  or  does  it,  in  fact,  decrease  fibre  mass  as  implied  by
Janciauskiene? The most likely answer is that SAP behaves in both ways and
that  each  role  is  specific  to  a  particular  face  or  conformer. In  order  to
investigate this, cross  β-sheet fibres will  need to be exposed to each SAP
face/conformer independently and the behaviours of the fibres observed. 
When  in  the  pentameric  state  -  a  formation  achieved  in  the  presence  of
calcium -  SAP will  prompt  interactions  exclusively  with  its  B-face.  This  is
because in these conditions, the B side of SAP is bound to 10 calcium ions
and exhibits calcium mediated binding as explained in the literature. 
When in its decameric state - a formation achieved in the absence of calcium
at a pH of 5.5 or higher - SAP should prompt interactions exclusively with its
A-face.  In  these  conditions  the  B-faces  of  two  separate  SAP  molecules
interact with one another and so are unavailable for other interactions. Thus
far,  there  has  been  no  indication  in  the  literature  as  to  whether  A-face
interactions are possible between SAP and fibres however this seems the
most plausible explaination for the apparent dual behaviour of SAP.
Once the role of each face/conformer has been determined it would become
necessary  to  find  out  whether  this  behaviour  is  applicable  to  other  fibre
forming proteins. This would establish whether SAPs behaviour is consistent
among all amyloid proteins or just specific to one.
This thesis aims to conduct all its experiments at neutral pH. Normally, when
dealing with amyloid fibres, highly acidic conditions are usually implemented;
attempts have not been made at neutral pH. However, due to the inclusion of
SAP  in  these  experiments,  it  is  important  to  use  a  neutral  pH  as  the
85
denaturing  conditions  presented  by  a  low  pH  would  potentially  alter  SAP
structure  and  function  and  therefore  make  results  unreliable  and
incomparable.  In  addition,  the  stress  introduced  by  the  strong  acidic
conditions could also induce loss of SAP solubility and promote aggregation
due  to  exposure  of  its  hydrophobic  groups.  By using  more  favorable
conditions the risk of altering SAP structure or function is removed and the
results  obtained  are  not  compromised.  Furthermore,  at  a  neutral  pH  one
would  have  a  more  physiological  representation  of  SAPs  effect  on  fibre
formation. 
In addition to the functional studies described above, this thesis also intends
to carry out some structural work on the fibres and SAP molecule. TEM and
CD analysis will be used to compare the morphologies of fibres made from
different  proteins  and  in  different  conditions.  Although  it  is  known that  all
amyloid  fibres  share  the  cross  β-sheet  motif  regardless  of  the  protein
involved, it seems unlikely that they would all be completely identical in terms
of  morphology.  There  are  more  than  50,000  proteins  in  the  human  body
alone, each of which has a unique amino acid sequence. It would be absurd
to think that their individual sizes and chemical compositions would not have
any influence over their cross  β-sheet structure. Furthermore it is likely that
SAP  also  has  some  effect  on  fibre  morphology.  It  has  already  been
established that the presence of SAP can increase fibre stability. Does SAP
achieve this solely through binding to the fibres or does it have an influence
on structure? 
Finally,  this  thesis  aims  to  look  at  the  relationship  between  SAP  and
antibodies.  GlaxoSmithKline  have recently  developed antibodies  which are
specific to SAP. These anti-SAP antibodies have the ability to detach SAP
from amyloid  deposits  and  thus leave the  deposits  exposed to  the  host’s
immune system. The exact  mechanism behind this  is  not  fully  understood
however clinical trials have shown that following the removal of deposit bound
SAP from the  body,  deposits  are  dissociated  and  fibre  mass  is  reduced.
Although these results appear promising, more work needs to be carried out
in order to guarantee safety and effectiveness of the treatment.  As of yet,
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these  trials  have  shown  a  decrease  in  amyloid  but  they  have  yet  to  be
successful in complete amyloid eradication (further discussions in chapter 5).
To this date, extensive structural analysis has not been carried out on the
SAP:antibody complex. It is not known how or where they bind. By solving the
structure,  the  knowledge  on  how  to  create  or  optimise  amyloid  treatment
could then be deciphered. 
Concluding Remarks 
Interest  in  the  topic  of  amyloid  formation  by  proteins  has  increased
dramatically  in  recent  years.  It  has  been  transformed  from  a  puzzling
phenomenon associated with a small number of diseases into a major subject
of study in disciplines ranging from material science to biology and medicine.
Scientists are realising that amyloid is far more prominent in medicine than
previously thought. It has been hidden from research due to its vast array of
symptoms and its difficulty to differentiate from other diseases and as a result
of this, the knowledge on how to treat it is not very well established. 
Presently there is no general ‘cure’ or treatment for amyloidosis. The physical
effects of amyloidosis can only be reduced through drastic actions such as
surgery and transplantation. By understanding the factors that influence the
conversion of proteins into the fibre state one can begin to create therapeutic
strategies against it. For example, one could decrease the concentration of
the aggregation prone species in the serum or stabilise the variant. It  may
even  be  possible  to  block  the  growth  of  fibres  and/or  enhance  the
housekeeping  clearance  mechanisms.  Perhaps  the  supposed  chaperoning
activity of SAP could be used to eliminate amyloid fibres. 
SAP is a critical component of all amyloid deposits in vivo and a key factor in
preventing  its  removal  from  the  body.  By  understanding  the  mechanism
through which SAP interacts with fibres one could possibly devise a way in
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which to control it or manipulate it. In doing so, it could be possible to reverse
the symptoms of all 36 diseases with one simple solution.
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Chapter 2
Insulin Fibre Analysis
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Insulin Fibre Analysis
Chapter Aims
The  aim  of  this  particular  chapter  is  to  conclude  whether  SAP  has  two
independent roles in amyloidosis with respect to a single protein; one pro-
fibrillogenic and the other anti-fibrillogenic.  If  this is proven to be true, this
chapter will then look to see if these roles are specific to a particular face or
conformer of SAP. The resulting fibres will then be analysed using structural
methods such as TEM and CD in order to see what affect, if any, SAP has
had on their final morphologies.  
In  order  to  give  a  clear  indication  of  the  role  of  each  conformer  in  fibre
formation,  cross  β-sheet  fibres  must  be  exposed  to  each  face/conformer
independently. To enforce this, each experimental assay must be carried out
in slightly different conditions. The reason for this being that each conformer
requires different conditions in order for it  to form. For example, to prompt
interactions exclusively with the pentamer,  calcium must be present in the
solution. When in the pentameric state,  the B side of SAP is bound to 10
calcium ions exhibits calcium mediated binding. In order to prompt interactions
with the decamer, SAP must be in the absence of calcium at a pH of 5.5 or
higher.  When  existing  as  a  decamer,  the  B-faces  of  two  separate  SAP
molecules  interact  with  one  another  and  so  are  unavailable  for  other
interactions.  Thus far,  there  has been no indication  in  the  literature  as  to
whether A-face interactions are possible between SAP and fibres however
this seems the most plausible explanation for the apparent dual behaviour of
SAP.
Taking these factors into account the following steps were proposed:
 Produce protein fibres in vitro at neutral pH 
 Expose one set of fibres to SAP pentamers during growth.
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 Expose another set of fibres to SAP decamers during growth.
 Leave  one  final  set  to  grow  without  SAP  interference  to  act  as  a
control.
 Use dyes, electron microscopy and other analytical techniques in order
to  observe  the  effect  of  SAP  (or  lack  of)  on  fibril  formation  and
morphology.
By carrying out the above on a single amyloid forming protein one will get an
indication of SAPs role to that specific protein. However, in order to create a
general ‘rule’ and show SAPs role with relation to all proteins, analysis of its
interactions will have to be carried out on multiple sets of fibres; each made
from a different protein (further details in chapter 3).
It was vital that all fibre assays are performed at neutral pH rather than the
acidic conditions normally implemented for fibre formation. This was due to
the  inclusion  of  SAP  in  these  experiments.  The  denaturing  conditions
presented by a low pH would potentially alter SAP structure and function and
therefore make results unreliable and incomparable. In addition, the stress
introduced  by  the  strong  acidic  conditions  could  also  induce  loss  of  SAP
solubility and promote aggregation due to exposure of its hydrophobic groups.
By changing the conditions from an acidic to a neutral environment the risk of
altering SAP structure or function is removed and the results obtained are not
compromised.  Also,  at  a neutral  pH one would have a more physiological
representation of SAPs effect on fibre formation. 
Due to the need to perform these experiments at neutral pH it was deemed
important to choose a relatively cheap protein for experimentation. The lack of
literature on neutral fibres would reduce the amount of guidance available for
this work. As a consequence to this, creating an appropriate and successful
protocol  for  would  likely  require  trial  and  error.  This  can  be  both  time
consuming and costly as there is no guarantee things will work.
91
The first protein/fibres chosen to undergo SAP analysis was insulin. Insulin is
a relatively inexpensive protein which demonstrates a high tendency to form
amyloid fibres in vitro. Lab made insulin fibres have been reported many times
in literature. One example of this is by  Bouchard et al.  in 2000. This team
used a combination of  Fourier transform infrared spectroscopy (FTIR), CD,
and electron microscopy (EM) to follow the transition of insulin from a helical
structure to the rope-like twist associated with cross  β-sheet structure. They
achieved this by exposing the protein to deuterium chloride in a strong acidic
environment of pH 2.3. The solution was heated to 70°C and incubated for up
to 18 hours. In 2002 Jiménez et al.  produced the same results by incubating
bovine insulin at 60° in pH 2, hydrochloric acid.
As of yet, insulin fibres have only been produced in acidic conditions. In order
to create insulin fibres in vitro at neutral pH, an alternate protocol would have
to be devised. 
It was decided to use surface tension as a way to partially unfold the insulin
from its native state into amyloid prone intermediates. Surface tension is the
phenomenon which causes the surface of a liquid to act as an elastic sheet.
This term is typically used when liquid is in contact with a gas such as the air
although it can also be used to explain the relationship between water and oil.
Surface tension is caused by various intermolecular forces such as Van der
Waals. These intermolecular forces vary depending on the nature of the liquid
(e.g. water vs. gasoline) or solutes in the liquid such as detergents. 
In  the  case of  water,  the  water  molecules  attract  one another  due to  the
water's polar property. The hydrogen ends of one molecule, which are slightly
positive, are attracted to the slightly negative oxygen end of another.  This
causes the molecules to "stick" together. In a sample of water there are two
types of molecules: those that are on the exterior of the bulk liquid and those
in the interior. The interior molecules are pulled equally in every direction by
neighbouring liquid molecules, resulting in a net force of zero.  However, the
molecules at the surface do not have molecules on all  sides of  them and
therefore are pulled inwards.  This makes it  so that the energy state of the
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molecules on the interior is much lower than those on the exterior creating
internal pressure which  forces liquid surfaces to  maintain a minimal  surface
area. This in turn allows more molecules to have a lower energy state.
It  takes  a  certain  amount  of  energy  to  break  these  intermolecular  bonds.
Water in particular is one liquid known to have a very high surface tension
value which is difficult to overcome. By creating a continuous movement of
surface  tension  this  should  increase  the  internal  pressure  of  the  sample
during rotation and create enough force to denature the insulin monomers and
allow amyloid prone intermediates to form. 
To ensure another variable is not accidentally introduced, it is important that
all  rotation assays are carried out  in  identical  containers.  By doing so the
forces  responsible  for  denaturing  the  protein  are  equal  and  samples  are
subject to identical conditions. The results of each assay will be monitored by
ThT fluorescence. This method was chosen as the primary method due to its
quick and easy use. However, due to its unreliability, other methods such as
CD and TEM will be used in conjunction to ascertain that cross β-sheet fibres
have indeed been formed.
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An Introduction to Insulin
Insulin is a peptide hormone responsible for regulating normal blood glucose
levels. It is synthesised in the β cells of the pancreatic islets of Langherhans
and matures from the precursors pre-proinsulin and proinsulin. The way in
which insulin maintains blood glucose levels is by facilitating cellular glucose
uptake, regulating carbohydrate, lipid and protein metabolism and promoting
cell division and growth through its mitogenic effects. It is important to note
that insulin  does not carry out these functions directly, but instead triggers
various biological pathways depending on the glucose levels present at the
time. For example, in high glucose levels, high levels of insulin are secreted
which  help  to  promote  the  formation  of  fatty  acids  and  inhibits  glucose
production  in  the  liver.  Alternatively,  in  low  glucose  levels,  pathways
promoting the oxidisation  of  sugars  are activated instead  (Heilbrunn et  al.
1958). 
Insulin Function in vivo
Glucose  is  the  principal  stimulus  for  insulin  secretion  although  other
macronutrients, hormones, and neural input can modify this response. When
glucose  enters  into  the  β-cell,  i.e. when  there  is  a  high  concentration  of
glucose,  it  is  sensed by  the  enzyme glucokinase and phosphorylated  into
glucose-6-phosphate  (G6P).  This  causes  the  generation  of  ATP  and  the
closure  of  K+-ATP-dependent  channels. Closure  of  K+-ATP-dependent
channels  leads  to  membrane  depolarization  and  activation  of  voltage
dependent calcium channels. The resulting increase in intracellular calcium
concentration triggers insulin secretion (Soria et al. 2004).
In healthy individuals, glucose stimulated pancreatic secretion is biphasic and
often described as being pulsatile. It responds to a stimulus such as glucose
with an initial rapid phase of insulin secretion and is then followed by a less
intense but more sustained release of the hormone (Bratanova-Tochkova et
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al.  2002).  The first  phase of  insulin secretion represents release of insulin
already  synthesised  and  stored  in  secretory  granules.  The  second  phase
represents secretion of both stored and newly synthesised insulin (DeFronzo
et al. 2015) 
Insulin Synthesis 
The gene for insulin is located on the short arm of chromosome 11 (Schröder
and Zühlke 1982). It is synthesised in the ribosomes of the rough endoplasmic
reticulum (RER) as a precursor called pre-proinsulin. Pre-proinsulin is a single
chain,  100  amino  acids  in  length,  formed  by  sequential  synthesis  of  the
following  components:  a  signal  peptide,  the  B  chain,  the  connecting  (C)
peptide and the A chain.  The removal  of  the signal  peptide by the signal
peptidase SEC11 is the first step in insulin maturation. It shortens the chain to
a  structure  86  residues  long  referred  to  as  proinsulin.  At  this  point  the
shortened proinsulin chain is transferred from the RER to the Golgi apparatus
via secretory vescicles. It is here in the Golgi apparatus that proinsulin fully
matures into insulin through the cleavage of the c-peptide by the enzymes
Proprotein  convertase  2 (PC2)  and  proprotein  convertase  1(PC  1/3)
(DeFronzo et al. 2015) (Figure 23).
Insulin Structure
When in its fully matured state, insulin actually exists as a di-peptide monomer
formed of the remaining A and B chain. Each of these chains varies slightly in
their secondary structure. The A chain, which is 21 residues long, contains an
intra  di-sulphide bond and an N-terminal  helix linked to  an anti-parallel  C-
terminal helix. The B chain on the other hand is 30 residues in length and has
a central helical segment. The two chains are linked together via two inter di-
sulphide  bridges  resulting  in  a  protein  structure  51  amino  acids  long  and
5802Da in weight (Schmidt et al. 1992). 
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Figure  23:  (Above)  Human  preproinsulin  molecule.  The  amino  acid
residues which construct the signal peptide are represented in green,
the A chain is represented in blue, the B chain is in red and the C chain
in orange. In order to produce insulin (below), initially the preproinsulin
is translocated from the pancreatic  β-cells  to the rough endoplasmic
reticulum causing the signal peptide to be cleaved in the process. The c-
chain is subsequently released through prohormone converstases and
carboxypeptidase E cleavage at arginine-65 and arginine -32 (Støy et al.
2007). 
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 Figure  24:  Ribbon  diagram  of  an  insulin  hexamer.  The  structure  is
composed of six insulin monomers which are held together by two zinc
ions  (depicted  as  stick  figures).  Each  monomer  is  represented  in  a
different  colour  and is  composed of  51  amino acids.  The monomers
each have a molecular mass of 5.8kDa resulting in a hexamer structure
approximately 36kDa in size.
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At  physiological  conditions,  insulin  has the  ability  to  exist  as  a  mixture  of
monomers,  dimers  and  hexamers.  Although  it  is  the  monomer  which  is
involved in glucose regulation, the predominant form is actually the 36kDa
hexamer.  The  hexamer  acts  as  a  ‘storage’  structure  composed  of  three
dimers and stabilised by two zinc ions. When in the hexameric state, insulin is
extremely stable, insoluble and resistant to conformation changes. Due to the
increased stability of this state, it is essential to dissociate the hexamers into
monomers via removal of the zinc ions in order for fibre formation to occur. It
is the resulting monomers which are able to undergo the necessary structural
changes for fibre nucleation (Figure 24).
Insulin Derived Amyloidosis
Insulin amyloidosis is rare. It occurs at insulin injection sites of diabetics in the
form  of  a  hard  nodule  (Shikama  et  al.  2010).  Its  cause  has  not  been
established although some believe it  to  be due to repeated trauma at  the
injection  site  and  increased  localisation/concentration  of  the  recombinant
protein (Lonsdale-Eccles et al. 2009). 
Localized insulin amyloid was first reported in 1983 by Störkel et al. but since
then, fewer than 100 cases have been described in literature. Due to this lack
in experimental data, the exact mechanism of insulin derived amyloidosis is
not well understood. That being said, in the year 2014 there were 52 cases of
insulin derived amyloidosis reported from one institute alone and seven from
another. This would indicate that insulin derived amyloidosis is more common
than previously  thought  and just  not  being reported  (D’Souza et  al.  2014)
(Nagase et al. 2014). 
The  underreporting  of  insulin  derived  amyloidosis  could  be  due  to  the
misdiagnosis  of  local  site  reactions.  It  is  often  found  that  the  lack  of
awareness and availability of histopathological investigations leads to insulin
derived amyloidosis being mistaken for lipohypertrophy; a condition similar to
insulin  amyloidosis  which  forms fatty  lumps  on  the  surface  of  the  skin  at
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injection  sites.  Lipohypertrophy  is  a  fairly  common  side  effect  of  insulin
injections if multiple injections are administered to the same part of the skin
over a period of time.  However, the fatty lumps are not as solid and firm as
those seen in amyloidosis. It has also been noted that lipohypertrophy lobules
generally regress after cessation of injections, whereas localized amyloidosis
does not. It is only after symptoms worsen than a histological examination for
an accurate diagnosis is performed instead (Gupta, Singla, and Singla 2015). 
In  fact,  insulin  derived  amyloidosis  can  be  diagnosed  using  both
histophathology  and  immunohistochemistry  methods.  Initially,  a  sample  of
extracellular disposition is collected and stained with Congo red. If the apple
green  birefringence  confirms  that  the  substance  is  amyloid  in  nature,  the
sample is subsequently immuno-stained with insulin antibodies to prove that
the protein involved is in fact insulin (Gupta, Singla, and Singla 2015). 
Symptoms and Treatment
Various symptoms are associated with insulin amyloidosis. The most common
being  the  presence  of  an  amyloid  mass  at  the  injection  site  which  is
responsible for poor penetration of insulin and probably contributes to insulin
resistance. Other symptoms include episodes of severe hypoglycema caused
by erratic absorption from the nodule  (Endo et al. 2010) and unpredictable
releases of insulin causing severe fluctuations in blood sugar levels. It is also
common  for  patients  to  experience  a  dramatic  gain  in  weight  due  to  an
increased  insulin  doses  prescribed  to  counteract  impaired  absorption
(Shikama et al. 2010).
Nagase et al. compared serum insulin levels before and after injections into
the amyloid site. They found that a large portion of the injected insulin did not
appear in the serum and suggested that the insulin was either being degraded
at  the  site  or  trapped.  The  latter  of  these  seems  the  more  probable
explanation  when  you  consider  that  amyloid  fibrils  recruit  new  molecules
during growth. 
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Symptoms of insulin amyloidosis can be reversed by surgically removing the
nodule. Constant changing of the injection site can also have a positive effect
however both of these solutions are temporary and nodules often reform. As
of yet a lasting treatment has not been determined.
Insulin Fibre Formation in vitro
The mechanism behind acidic insulin fibre formation in vitro has not been fully
scrutinised  however  in  1997  Brange et  al.  published  their  findings on  the
matter.   They note that  the shielding of  hydrophobic domains is  the main
driving  force for  the  partial  unfolding of  insulin  molecules into  aggregates.
Crystal  data presents  this  in  more detail.  It  shows that  the conformational
displacement of the B-chain C-terminal with exposure of non-polar, aliphatic
core  residues including  A2,  A3,  B11 and B15,  plays  a  crucial  role  in  the
fibrillation process. Further analysis of this data also suggests that this newly
exposed domain interacts with a hydrophobic surface domain formed by the
aliphatic  residues A13,  B6,  B14, B17,  and B18;  a domain normally buried
within the hexamer complex. 
Whether this is true for all insulin fibres is yet to be seen. As of yet there is not
enough published data  to  either  corroborate  or  dismiss  these discoveries.
Another  point  to  consider  is  that  the  above  results  ere  obtained in  acidic
conditions. This is not representative of the neutral pH experiments which are
to be conducted in this chapter. Therefore the information should only be used
as a guideline.
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Methods
Insulin Preparation 
Bovine insulin powder was obtained from Sigma Aldrich. 
In preparation of fibre formation, 20mg of the product was solubilised in 1ml
alkaline  buffer  containing  ethylenediaminetetraacetic  acid  (EDTA) (100mM
TRIS, 5mM EDTA, pH10). Immediately following solubilisation, the insulin was
dialysed against neutral “TE buffer” (20mM TRIS, 150 NaCl, 0.01% Na Azide,
pH8) overnight at a ratio of 1:2000, sample to dialysing buffer respectively, in
order to prevent protein deamination from occurring.
It should be noted that an alkaline buffer was chosen in favour of a neutral
one due to insulin’s low solubility at neutral  pH. Also, it  was essential  that
EDTA  be  included  so  to  sequester  the  zinc  ions  which  hold  the  insulin
hexamer together. This in turn would allow dissociation  into the monomers
which are essential to fibre formation.
Insulin Fibre Formation
A 1 ml sample of 1mg/ml dialysed insulin was prepared in a 1.5ml eppendorf
using TE buffer. The sample was continuously inverted - or “flipped” - at a
speed  of  20rpm on  a  revolving  Stuart  Rotator  SB3  for  10  days  at  room
temperature  and  the  results  were  analysed  using  the  ThT  fluorescence
method described below in ‘Insulin Fibre Analysis with Thioflavin T’. 
Example set up: 
Sample Insulin (20mg/ml) TE Buffer Final Insulin Concentration
1 50 μl 950 μl 1 mg/ml
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This protocol was repeated 3 times. Although an average was not necessary
at this point in the investigation, it was important to ensure that fibres could be
replicated to similar, if not the same amounts each time. This would allow any
future  results  to  be  comparable  to  one  another.  If  each  sample  has  the
potential  to  make  the  same  amount  of  fibres  in  the  same  conditions  the
experiment  is  fair.  If  fibre  amounts  changed  dramatically  each  time  the
protocol was carried out it would mean that further into the investigation when
SAP was involved, one would not be able to tell if differences in fibre mass
were due specifically  to  the presence of  SAP or  due to  another  unknown
factor. 
Monitoring the Effect of Insulin Concentration on Fibre 
Formation
To monitor the effect of  concentration on insulin fibre formation the above
method  -  “Insulin  Fibre  Formation”  -  was  repeated  using  varying
concentrations  of  insulin  between 0.1  and 2mg/ml.  Each 1ml  sample  was
continuously inverted at a speed of 20rpm on a revolving Stuart Rotator SB3
for 10 days at room temperature and the results were analysed using the ThT
fluorescence method described below in ‘Insulin Fibre Analysis with Thioflavin
T’.  
Example setup:
Sample Insulin (20mg/ml) TE Buffer dH20 Total Insulin Concentration
2a 100 μl 900 μl - 2 mg/ml
2b 50 μl 900 μl 50 μl 1mg/ml
2c 25 μl 900 μl 75 μl 0.5mg/ml
2d 20 μl 900 μl 80 μl 0.4 mg/ml
2e 15 μl 900 μl 85 μl 0.3 mg/ml
2f 10 μl 900 μl 90 μl 0.2 mg/ml
2g 5 μl 900 μl 95 μl 0.1 mg/ml
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Monitoring the Effect of Speed on Fibre Formation
To monitor the effect of speed on insulin fibre formation the above method
“Insulin Fibre Formation” was repeated using varying rotator speeds: 2rpm
(minimum speed of rotator),  20rpm or 40rpm (maximum speed).  Each 1ml
sample was continuously inverted at an individual speed on a revolving Stuart
Rotator  SB3 for  25 days at  room temperature.  The results  were analysed
using the ThT fluorescence method described below in ‘Insulin Fibre Analysis
with Thioflavin T’.  
Example setup:
Sample Insulin (20mg/ml) TE Buffer Rotator Speed
3a 50 μl 950 μl 2 rpm
3b 50 μl 950 μl 20 rpm
3c 50 μl 950 μl 40 rpm
SAP Preparation
Human  SAP  was  prepared  by  a  third  party  as  described  previously  by
Hawkins et al in 1991. In brief, SAP was captured from serum or malignant
effusion fluid by its  calcium dependent binding to phosphoethanolamine.  It
was  then  covalently  immobilized  by  carbodimide  coupling  to  carboxyhexyl
sepharose  and  washed  in  the  presence  of  calcium.  The  SAP  was
subsequently eluted by calcium chelation with EDTA. Trace impurities were
removed by reverse affinity chromatography absorption and gel filtration in the
absence of calcium which yielded intact, native, fully functional SAP at greater
than 99% purity and free of aggregate subunits.
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Fibre Formation with SAP Decamers 
To observe the effect of SAP decamers on fibre growth, the “Insulin Fibre
Formation”  method was repeated with  the addition of  0.2mg/ml  SAP. This
provided  a  stoichiometric  ratio  of  1:100  of  SAP  decamers  to  insulin
respectively. Each sample was continuously inverted at a speed of 20rpm on
a revolving Stuart Rotator SB3 for 10 days at room temperature. The results
were analysed using the ThT fluorescence method described below in ‘Insulin
Fibre Analysis with Thioflavin T’.  .
Example setup:
Sample Insulin (20mg/
ml)
TE
Buffer
dH20 SAP (6.66mg/
ml)
Final SAP
Concentration
4a 50 μl 920 μl 30 μl - -
4b 50 μl 920 μl - 30 μl 0.2mg/ml
In order to monitor the affect of different SAP decamer concentrations on fibre
formation the “Insulin Fibre Formation” method was repeated with the addition
of variable SAP decamer concentrations ranging from 0 to 1mg/ml. A slight
alteration was made to the protocol in this case. Samples were made up to
0.5ml instead of the normal 1ml in order to conserve insulin stocks. It was not
necessary  for  these  samples  to  be  directly  comparable  to  the  previous
experiments, only to each other. Each sample was continuously inverted at a
speed  of  20rpm on  a  revolving  Stuart  Rotator  SB3  for  10  days  at  room
temperature. The results were analysed using the ThT fluorescence method
described below:
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Insulin Concentration SAP Decamer Concentration
1 mg/ml 1 mg/ml 
1 mg/ml 0.8 mg/ml
1 mg/ml 0.6 mg/ml
1 mg/ml 0.4 mg/ml
1 mg/ml 0.3 mg/ml
1 mg/ml 0.2 mg/ml
1 mg/ml 0.1 mg/ml
1 mg/ml 0.05 mg/ml
1 mg/ml 0 
Fibre Formation with SAP Pentamers 
To perform this particular assay the SAP was diluted to 0.2mg/ml using TC
buffer. This was left to incubate for half an hour to ensure saturation of SAP
calcium pockets. Following this, 1mg/ml insulin was added and the sample
was continuously inverted at a speed of 20rpm on a revolving Stuart Rotator
SB3 for 10 days at room temperature. The results were analysed using the
ThT  fluorescence  method  described  below  in  ‘Insulin  Fibre  Analysis  with
Thioflavin T’.  
Example setup: 
Sample Insulin (20mg/
ml)
TC
Buffer
dH20 SAP (6.66mg/
ml)
Final SAP
Concentration
5a 50 μl 920 μl 30 μl - -
5b 50 μl 920 μl - 30 μl 0.2mg/ml
In order to monitor the affect of different SAP pentamer concentrations on
fibre formation the “Insulin Fibre Formation” method was repeated with the
addition of variable SAP pentamer concentrations ranging from 0 to 1mg/ml. A
slight alteration was made to the protocol in this case. Samples were made up
to 0.5ml instead of the normal 1ml in order to conserve insulin stocks. It was
not necessary for these samples to be directly comparable to the previous
experiments, only to each other.  Each sample was continuously inverted at a
speed  of  20rpm on  a  revolving  Stuart  Rotator  SB3  for  10  days  at  room
temperature. The results were analysed using the ThT fluorescence method
described below.
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Insulin Concentration SAP Concentration
1 mg/ml 1 mg/ml 
1 mg/ml 0.8 mg/ml
1 mg/ml 0.6 mg/ml
1 mg/ml 0.4 mg/ml
1 mg/ml 0.3 mg/ml
1 mg/ml 0.2 mg/ml
1 mg/ml 0.1 mg/ml
1 mg/ml 0.05 mg/ml
1 mg/ml 0 
Controls 
The high salt concentration required for stabilisation in the TC buffer was a
variable that had to be monitored. To see the effect the salt was having on
insulin  fibre formation the assay had to  be repeated in  a High Salt  buffer
(“THS Buffer” - 20mM TRIS, 600mM NaCl, 0.01% Na Azide, pH8). 1mg/ml of
insulin was continuously inverted at a speed of 20rpm on a revolving Stuart
Rotator  SB3 for 10 days at  room temperature in  the presence/absence of
0.2mg SAP. 
The THS buffer was identical to the TC buffer but lacked the calcium chloride.
If fibre behaviour in the THS assay matched that of the original TE buffer, it
could be presumed that the additional salt had no effect on fibre formation.
This would therefore suggest that all differences noted in the TC buffer assay
were due to the change in SAP conformation (or the calcium) and not the salt.
If the THS assay did not match that of the original TE assay, one would have
to presume that the salt does indeed have an affect on fibre formation. This
would mean that the conditions for SAP pentamer interactions would have to
be reviewed and altered. 
Example setup: 
Sample Insulin (20mg/ml) THS Buffer SAP (6.66mg/ml) dH20
6a 50 μl 920 μl 30 μl -
6b 50 μl 950 μl - 30 μl
It was also important to ensure that any fibres formed during the course of
these experiments were made purely of insulin. To test whether SAP has the
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ability to form fibres under these conditions 0.2mg/ml of SAP was rotated on a
revolving Stuart Rotator SB3 for 50 days at room temperature.
Sample SAP  (6.66mg/
ml)
TE
Buffer
TC
Buffer
THS
Buffer
Control a 30 μl 920 μl - -
Control b 30 μl - 920 μl -
Control c 30 μl - - 920 μl
Fibre Analysis with Thioflavin T
Thioflavin T (ThT) was used in order to confirm and quantify fibre growth. ThT
is a benzothiazole dye which, upon binding amyloid, increases in fluorescence
at a wavelength of 420nm. It binds proportionally to the channels which run
parallel to the β-sheet making it a useful quantitative method of analysis.
In preparation for analysis, a 9mM stock solution of ThT was made, wrapped
in foil and refrigerated for up to two months. On the day of measurement, the
stock  solution  was  diluted  to  500  ml  of  a  concentration  of  0.1μM.  Fibre
samples were shaken vigorously on a vortex mixer for 15 seconds and a 5μl
sample was taken and added to the diluted ThT. The mixture was incubated
at room temperature,  in the dark for 15 minutes and then measured on a
Perkin Elmer LS 55 Luminescence Spectrometer (excitation wavelength 442
nm, slit width 5nm). Please note that buffer containing ThT was used as a
base line in these measurements and subtracted from each result.
Fibre Detection using Congo Red
To perform the Congo red analysis, 3 layers of 50μl samples were individually
dried onto a glass slide and stained using Mayer's Hematoxylin.  Following
this, the slides were placed in 0.34M alcoholic sodium chloride solution for 20
minutes, drained and replaced with 3mM Congo red solution for a further 20
minutes. Finally the slides were dehydrated using ethanol and cleared with
xylene. The slides were then viewed under a microscope using polarised light.
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Structural Analysis using Transmission Electron Microscopy 
(TEM)
In preparation of TEM analysis, copper grids were covered in carbon coated
formvar  resin.  Samples  3μl  in  size  were  transferred  onto  the  grids  and
following three minutes of incubation, had the excess liquid absorbed using a
torn edge of hardened, ash-less filter paper. A 3μl measurement of 2% uranyl
acetate solution was used to stain the sample and a further three minutes of
incubation was carried out. Again, the excess solution was absorbed using
the filter paper and the samples were left  to air dry.  The slides were then
examined under the electron microscope.
Structural Analysis using Circular Dichroism 
The samples chosen to undergo CD analysis were as follows: 
Sample Insulin
(20mg/ml)
Buffer
Type
Buffer dH20 SAP
(6.66mg/ml)
Final SAP
Concentration
4a 50 μl TE 920 μl 30 μl - -
4b 50 μl TE 920 μl - 30 μl 0.2mg/ml
5a 50 μl TC 920 μl 30 μl - -
5b 50 μl TC 920 μl - 30 μl 0.2mg/ml
6a 50 μl THS 920 μl 30 μl - -
6b 50 μl THS 950 μl - 30 μl 0.2mg/ml
Sample Preparation
In order to perform CD all the samples had to be transferred to water. This
was due to the fact that the calcium chloride present in the TC buffer solutions
shows high absorbance in the far UV region and often disrupts CD results
(Kelly, Jess, and Price 2005). Water is a non chiral solution which would not
affect the results. Transference of each sample to water was achieved using
the following protocol:  
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Each fibre sample was spun in a microcentrifuge for 6 minutes at 13,000rpm
so to  separate  the  solid  fibre  mass  from the  solution.  Following  this,  the
supernatant  was  drained  from  each  and  replaced  with  water.  The  fibre
masses were “washed” via vigorous vortexing until re-suspended. The entire
process was repeated twice more to ensure complete removal of buffer, in
particular, those containing calcium chloride. 
In the cases where SAP was present, 10mM ethylene glycol tetraacetic acid
(EGTA) was also added to the first wash so to chelate the calcium and thus
unbind SAP from the fibres. The EGTA was later removed with subsequent
washes so to prevent interference with the results.
Circular Dichroism
Once  suspended  in  water  the  samples  needed  to  be  made  to  the  same
concentration so to allow comparative analysis. Unfortunately, due to the fact
that the protein to be measured via CD was in solid form, this was deemed
impractical.  Solid  protein  concentrations  can  only  be  measured  accurately
using  chemical  analysis  such  as  bicinchoninic  assays;  a  time  consuming
process.  Optical  densities,  although  not  the  most  precise  method  for
measuring  protein  concentration,  are  much  quicker  and  more  practical  to
determine so were used instead.
Each sample was diluted to the same optical density through the addition of
more or less distilled water. Following this, they were individually loaded into a
custom built rotating cell. A rotating cell was chosen instead of a stationary
one in an attempt to keep the fibres in suspension during data collection. The
difference of absorption was measured between wavelengths of 180-260 at a
slit size of 0.5mm and a path length of 0.2mm. Distilled water was used as a
base line and subtracted from each result.
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Controls 
As controls, 0.5mg/ml native insulin, 0.2mg/ml native SAP and SAP aggregate
were used. The aggregated SAP was created through the addition of a few
drops  of  37% hydrochloric  acid  to  a  0.2mg/ml  sample  of  SAP.  Once  the
precipitate had formed, it was transferred into distilled water via centrifugation,
removal of the supernatant and replacement with water. The new contents
were mixed and the diluted until the OD was identical to that of the samples. 
Bicinchoninic Acid Assay
BCA is a method used to determine the protein concentration of a solution
between the concentrations of  0.5 μg/ml  and 1.5 mg/ml.  It  incorporates all
protein present including solubilised protein and aggregated protein whether
present  as  fibres  or  amorphous  aggregate.  By  removing  the  solubilised
protein from each sample, a comparison between the BCA and ThT results
could be made. 
BCA  is  a  highly  alkali  solution  (pH  11.25)  which  contains  the  following
chemicals: bicinchoninic acid, sodium carbonate, sodium bicarbonate, sodium
tartrate and copper (II) sulphate pentahydrate. It exhibits a colour change of
green to purple proportional to protein concentration. This associated colour
change is a result of two chemical reactions. The first is named  the biuret
reaction  and  involves  the  reduction  of  the  Cu2+ ions  from the  copper  (II)
sulphate pentahydrate into Cu+.  This is done by the cysteine, tyrosine and
tryptophan side chains present in the protein and is a temperature dependent
reaction.  The result of this particular reaction occurring is the formation of a
blue/green colour. The second reaction occurs when two bicinchoninic acid
molecules chelate with  these newly formed Cu+  ions.   A purple  product  is
produced which absorbs at wavelength 562nm. The more cysteine, tyrosine
and  tryptophan  present  the  more  copper  is  reduced.  The  higher  the
concentration  of  reduced  copper  the  higher  the  amount  of  chelation  that
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occurs.  And  the  more  chelation  that  occurs  the  deeper  the  purple  colour
becomes, hence the BCA reaction being proportional to protein concentration.
(“Chemistry of Protein Assays” 2015) (Figure 25). 
The following samples were submitted to BCA analysis:
Sample Insulin
(20mg/ml)
TE Buffer dH20 SAP
(6.66mg/ml)
Final SAP
Concentration
4a 50 μl 920 μl 30 μl - -
4b 50 μl 920 μl - 30 μl 0.2mg/ml
5a 50 μl 920 μl 30 μl - -
5b 50 μl 920 μl - 30 μl 0.2mg/ml
6a 50 μl 920 μl 30 μl - -
6b 50 μl 950 μl - 30 μl 0.2mg/ml
In order to prepare the samples for BCA analysis, they were each spun on a
microcentrifuge for 10 minutes to  separate the insoluble protein aggregate
form the solubilised solution. The supernatant containing soluble insulin was
discarded  and  replaced  with  distilled  water.  Each  sample  was  vigorously
mixed on a vortex until resuspended.
To perform the bicinchoninic acid (BCA) assay, 0.5ml of a 0.74M solution of
copper (II) chloride was made and mixed with 2.5ml of BCA reagent. At this
point a green colour was observed. A 1:20 ratio of protein sample to BCA
solution was made and incubated at 37°C for 30 minutes. These were allowed
to cool to room temperature and the resulting coloured solution was measured
on a NanoDrop 3300 fluorospectrometer  at  562nm. The NanoDrop results
were converted to concentrations through use of a calibration curve and the
results were compared to their ThT equivalents. 
The  percentages  of  native,  amorphous  and  cross  β-sheet  protein  were
calculated as follows: The native protein concentrations were measured from
the  removed  supernatant  on  a  NanoDrop  3300  fluorospectrometer  at  a
wavelength of 280nm.  These figures were compared to the initial mass of
insulin used and converted into a percentage. The amorphous and cross  β-
sheet proteins were calculated via comparisons of the ThT and BCA data of
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each  sample.  A  calibration  curve  was  made  using  12  proteins  of  known
concentrations. The figures derived from this graph were then compared to
the initial mass of insulin used and converted into a percentage.
Fibre disassembly using SAP Decamers
Dialysed  insulin  was  diluted  using  TE  buffer  to  make  0.6ml  of  a  1mg/ml
solution  and  fibres  were  formed  using  the  above  method  (Insulin
Fibrillogenesis). After ten days of rotation at room temperature on a revolving
Stuart Rotator SB3 (20rpm) the fibres were removed, thoroughly mixed using
a  vortex  and  had  0.1mg of  SAP decamers  added  to  the  eppendorf.  The
eppendorf was rotated at a slower speed of 2rpm so to keep all components
in suspension for a total of 40 days. Additional aliquots of 0.1mg SAP were
added  every  10  days  and  fibre  amounts  were  measured  daily  via  ThT
measurements  on  a  spectrophotometer  as  in  the  “Fibre  analysis  with
Thioflavin T” section above. 
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 Figure 25: (Above) Diagram showing the biuret reaction –the first step
in a BCA reaction. It involves  the reduction of the Cu2+ ions from the
copper (II) sulphate pentahydrate in the BCA solution into Cu+ by the
cysteine,  tyrosine  and  tryptophan  side  chains  present.  This  is  a
temperature dependent reaction.  (Below) The second reaction involves
the chelation of a Cu+ ion by two bicinchoninic acid molecules creating a
purple product which absorbs at wavelength 562nm. The more peptide
bonds present the more copper reduced (Chemistry of Protein Assays,
2015).
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Results and Discussion
Insulin Fibre Analysis with ThT
A sample of dialysed insulin was diluted to 1mg/ml in TE buffer (pH 8) and
continuously inverted or ‘flipped’ on a rotator at a speed of 20rpm in a 1.5ml
eppendorf. This was done at room temperature for a total of 10 days. 
Within  the  first  2  days  of  inversion  -  or  ‘flipping’  -  a  white  precipitate
developed. This precipitation increased in density over the course of 3-6 days
and then appeared to remain constant for the rest of the protocol.  On the
tenth day the newly precipitated insulin sample underwent ThT analysis in
order  to determine whether  the precipitate  was cross  β-sheet in  nature or
amorphous  aggregate.  The  ThT  results  show  enhanced  fluorescence
between wavelengths 420nm and 600nm with a peak of 652 at 476.5 nm.
This provides a relatively good indication that the precipitate is cross β-sheet
in nature, however, this is not known for certain as ThT can often give false
positive results (Figure 26). 
The 10 day ‘rotator method’ was repeated using two more samples of 1mg/ml
dialysed insulin and ThT analysis was carried out. This was not to obtain an
average as an average was not necessary at this point. Instead, the repetition
of this assay was to ensure that fibres could be replicated to similar, if not
identical amounts each time. The ability to replicate fibres to a similar mass or
density is vital as it allows future results to be comparable to one another. If
each sample has the potential to make the same amount of fibres in the same
conditions the experiment is fair. If fibre amounts change dramatically each
time it would mean that further into the investigation, when SAP is involved,
one will not be able to tell if differences in fibre mass were due specifically to
the presence of SAP or due to another unknown factor. 
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Figure 26: Graph illustrating ThT fluorescence of insulin fibres made in
TE  buffer  as  measured  on  a  Perkin  Elmer  LS  55  Luminescence
Spectrometer  (excitation wavelength 442 nm, slit  width  5nm).   Fibres
were rotated for 10 days on a revolving Stuart Rotator SB3 at 20rpm at
room temperature. Fluorescence intensity peaks at 652 at a wavelength
of 476.5 nm and instrumental errors are plotted.
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Upon analysis  of  these two  extra  samples  it  was found  that  fluorescence
intensity  is  not  as  consistent  as  expected.  The ThT measurements of  the
subsequent  samples  are  similar  to  one  another  but  quite  different  to  the
original  sample.  They  exhibit  peaks  in  fluorescence  at  988  and  998  thus
providing a range of approximately 600-1000 for all  three values. This was
unexpected as each had undergone identical conditions (Figure 28). 
The fluctuations seen between samples 2 and 3 - which obtained florescence
readings of 988 and 998 - are probably a result of the dynamic nature of cross
β-sheet fibres. If fibres are constantly detaching and reforming themselves, at
any one given time one may experience more or less fluorescence compared
to another. The larger difference seen in the first sample (ThT reading 652)
however  cannot  be  explained  that  way.  Instead,  it  is  most  likely  that  this
particular reading is an anomaly.  This sample was the first attempt of a new
protocol so could quite possibly be subject to handling errors. 
The effect of rotator speeds and insulin concentration on cross β-sheet fibre
formation were tested. The results were as follows:
Changes in rotator speeds had no effect on total fibre amounts according to
the  ThT  readings.  Figure  27 shows  each  sample  reaching  a  peak  of
approximately 1000 by the end of the 25 day protocol. The different rotator
speeds, however, did have an impact on growth rates. The assays performed
at slower rotator speeds had an extended lag period compared to those at
faster speeds. Fibres grown in 2rpm conditions experienced a lag phase of
approximately 10 days where as fibres grown in 20 and 40rpm experienced
shorter lag phases of 5 and 3 days respectively. This is logical as the faster
the samples are being flipped/rotated, the higher the continuous movement of
surface tension and the higher  the internal  pressure of  the sample during
rotation. This provides more energy to break the very high surface tension
value given by water  and thus creates  more force to  denature the insulin
monomers.
116
Insulin concentration was also seen to have an affect on total fibre mass. The
more  protein  that  was  present  in  a  sample  the  higher  the  fluorescence
intensity and vice versa. The two components are directly proportional to one
another and experience a strong positive correlation of 0.897 (Figure 32). 
Alternate Fibre analysis
As previously mentioned, ThT is often considered unreliable as a diagnostic
tool as it has the propensity to bind bacteria and other tissue matter. Although
it is highly unlikely that any tissue matter would have been present in these
particular assays as samples were not extracted from ex vivo specimens, it is
entirely possible that bacteria could have contaminated them. Therefore, in
order to confirm the presence of cross β-sheet fibres the samples were submit
to alternative analytical approaches including Congo red analysis and TEM.
When submit  to  Congo red analysis,  all  samples clearly demonstrated the
apple green birefringence typical of cross β-sheets. This alongside the ThT
results provides a strong indication that the insulin had indeed formed cross β-
sheet fibres and not amorphous aggregate. Nevertheless, Congo red analysis
can often be as unreliable as ThT as a diagnostic tool but for a completely
different reason. Unlike ThT, Congo red is not structure specific and so can be
seen to bind to native proteins as well as their fibre counterparts. Although
this has not proven to be true of all  native proteins, it adds an element of
uncertainty to any results obtained by this method. Due to this, it  was still
necessary  to  perform  TEM  analysis.  Of  which,  the  resulting  images  also
confirmed the presence of cross  β-sheets.  At a magnification of x140,000,
rope-like structures approximately 7nm in diameter and of indefinite length are
clearly visible. 
In  summary,  unlike  previous studies  which  produced insulin  fibres  only  in
acidic conditions, the above method produced large amounts of cross β-sheet
insulin fibres in a pH very close to physiological conditions. This demonstrates
that insulin fibres can indeed be made in vitro at neutral pH. This was proved
using ThT, Congo red and TEM analysis.
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Figure 27:A graph showing the progression of insulin fibre growth in TE
buffer.  Fibres  were  rotated  at  room  temperature  for  25  days  on  a
revolving Stuart Rotator SB3 set at various speeds: 40rpm (light blue),
20rpm (magenta) and 2rpm (dark blue). The ThT fluorescence indicates
that rotator speeds have an impact on growth rates but not on total fibre
amounts as each sample reaches a peak of approximately 1000 by the
end of the 25 day protocol. This graph exhibits the following pattern: the
slower the rotator speed the longer the lag phase of fibre growth.  Fibres
grown in 2rpm conditions experience a lag phase of approximately 10
days where as fibres grown in 20 and 40rpm experience much shorter
lag phases of 5 and 3 days respectively. 
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Figure  28: A graph comparing ThT fluorescence of the original insulin
fibres made in TE buffer (black) with the two subsequent repetitions of
the  rotator  protocol  (maroon).  All  measurement  were  obtained  on  a
Perkin Elmer LS 55 Luminescence Spectrometer (excitation wavelength
442 nm, slit width 5nm) Fibres were rotated for 10 days on a revolving
Stuart Rotator SB3 at 20rpm at room temperature. The original  fibres
peak at a fluorescence intensity of 652 at a wavelength of 476.5 nm. The
subsequent samples exhibit peaks in fluorescence at 988 and 998. All
instrumental errors are plotted.
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The Effect of SAP Decamers on Fibre Growth
In order to monitor the effect of SAP decamers on fibre formation the “Insulin
Fibre Formation” method was repeated with the inclusion of SAP. Dialysed
insulin  was  diluted  to  1mg/ml  in  TE  buffer  and  continuously  inverted  or
‘flipped’ on a rotator at a speed of 20rpm in the presence of 0.2mg/ml SAP
decamers. Following 10 days of inversion via the rotator method, the resulting
white precipitate formed was submitted to ThT fluorescence (Figure 29). 
The ThT results show that the fibres grown in the presence of SAP decamers
at a substoichiometric ratio of 1:100 (SAP: insulin) demonstrate an average
decrease in ThT fluorescence of 54.0%.  This figure was calculated from an
average of three separate assays, each of which underwent Congo red and
TEM analysis so to confirm that the precipitate formed was cross β-sheet in
nature.  It  indicates  that  SAP,  in  its  decameric  form,  has  the  capability  of
inhibiting  fibre  growth.  Whether  it  achieves  this  through  the  depletion  of
existing fibres or through the prevention of initial fibre formation is unclear at
this point. 
Again, discrepancies in ThT fluorescence are noted between each sample.
The  samples  range  between  a  fluorescence  of  628.1  and  997.8  in  the
absence of SAP and between a range of 291.8 and 624.8 in the presence of
the SAP decamers. This provides an error margin of +14.54%, -27.91% and
+35.65%, -36.58% respectively. More specifically, sample 1 of this particular
experimental  condition  has  an  average  decrease  in  fibres  of  36.7%  and
experiments 2 and 3 have 26.1% and 70.8% respectively. This is quite a high
percentage  discrepancy;  however,  each  corresponding  pair  of  assays  (TE
fibres with and without SAP) each experienced a decrease in fibre amounts
thus  validating  these  conclusions.  Furthermore,  in  the  case  of  the  SAP
decamer assays, it is important to remember that the SAP molecule exists as
a mixture of both pentamers and decamers. The ratio between the two would
be prone to fluctuate between samples and thus explain this large range in
percentages. 
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Fluorescence /475nm
Insulin 1mg/ml SAP Experiment 1 Experiment 2 Experiment 3
TE Buffer 0 987.6 628.1 997.8
TE Buffer
0.2mg/
ml 624.8 464.4 291.8
% change in fluorescence -Helix -36.7 -26.1 -70.8 
Average % change -Helix -Helix44.5
Table  2:  A table  showing the effect  of  SAP on insulin  fibrillogenesis
made in TE buffer. Values are taken from the peak of ThT fluorescence
(475nm).  The  amount  of  fibres  decreased  with  the  addition  of  SAP
decamers: there was an average of 54% reduction in ThT fluorescence
between assays with and without SAP in TE buffer. 1mg/ml insulin was
used for each sample and 0.2mg/ml SAP in the designated samples. The
samples  range  between  a  fluorescence  of  628.1  and  997.8  in  the
absence of SAP and between a range of 291.8 and 624.8 in the presence
of the SAP decamers. This provides an error margin of +14.54%, -27.91%
and +35.65%, -36.58% respectively. More specifically, sample 1 of this
particular experimental condition has an average decrease in fibres of
36.7% and experiments 2 and 3 have 26.1% and 70.8% respectively.
When the  above assays were  repeated using various SAP concentrations
(0.1-1mg/ml)  the following results were observed: The samples grown with
higher  SAP  concentrations  experienced  a  larger  decrease  in  total  fibre
amount  whereas  those  with  smaller  concentrations  experienced  a  smaller
decrease  in  fibre  amounts.  The  two  factors  are  directly  proportional  and
exhibit  a  strong  negative  correlation  of  -0.812  (Figure  33).  These  results
clearly show that SAPs chaperoning activity is proportional to its quantity. The
more SAP molecules present the more SAP:intermediate interactions that are
occurring and the fewer fibres that are being produced. 
The  chaperoning  activity  of  SAP  decamers  was  further  confirmed  using
Congo red analysis.  In  Figure 35 images A and B represent  insulin fibres
grown in TE buffer with and without SAP decamers. As expected, image B –
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those grown in the presence of SAP decamers – demonstrate a decrease in
fibre  density  compared  to  those  grown  without.  The  decrease  in  fibres,
however, cannot be given a value in this case as the Congo red technique is
not a quantitative method. 
The mechanism on how SAP decreases fibre amounts cannot be deciphered
at this point although theories can be suggested. Perhaps SAP is detaching
intermediates from the fibre structure and binding them either reversibly or
irreversibly. This seems unlikely as crystal analysis has shown that it is the B-
face of SAP which binds to fibres via a calcium mediated interaction, not the A
face.  Not  only  is  calcium absent  in  this  particular  assay but  the B-face is
unavailable due to the interactions required to make a decamer structure.  It is
more  plausible  that  SAP is  interacting  with  the  intermediates  before  they
become part of the fibre structure or after they, themselves, detach from it.
Again the nature of the binding is unknown at this point and can be either
reversible or irreversible. 
The Effect of SAP Pentamers on Fibre Growth
In order to see the effect of SAP pentamers, the fibrillisation assay had to be
repeated in an alternate buffer which contained calcium: TC buffer. Although it
is essential to add calcium in order to ensure all SAP molecules exist in their
pentameric form, by adding calcium to the assay there is an increased risk of
SAP auto-aggregation due to the carboxylate group of glutamic acid 87 of one
SAP molecule binding to the calcium dependent ligand pocket of another. As
a way to prevent autoaggregation in the calcium buffer, supra physiological
concentrations of salt were also included as explained in chapter 1.
A  sample  of  dialysed  insulin  was  diluted  to  1mg/ml  in  TC  buffer  and
continuously  inverted  or  ‘flipped’  on  a  rotator  at  a  speed of  20rpm in  the
presence of 0.2mg/ml SAP pentamers. Following 10 days of inversion via the
122
rotator method, a white precipitate was formed in each sample submitted to
ThT fluorescence. 
It  was  found  that  fibres  grown  in  the  presence  of  SAP  pentamers  at  a
substoichiometric  ratio  of  1:100  (SAP:  insulin)  have  an  average  50.7%
increase of ThT fluorescence. This is directly opposite to what happened in
the presence of SAP decamers. These results indicate that the pentamers act
as  fibrillogenic  enhancers.  This  function  could  be  achieved  through  either
catalytic activity on fibre growth or through stabilisation of the final structure.
The  existing  literature  indicates  that  the  latter  is  the  more  plausible
explanation as SAP is known to stabilise fibres upon binding. Nonetheless,
further testing is required before the former can be dismissed. 
As expected, discrepancies in ThT fluorescence are noted between samples
of the same condition, however, each corresponding pair of assays (TC fibres
with  and  without  SAP  pentamers)  each  experienced  an  increase  in  fibre
amounts thus validating these conclusions.  The samples range between a
fluorescence of 194.2 and 311.3 in the absence of SAP and between a range
of 269.6 and 515.1 in the presence of the SAP pentamers. This provides an
error  margin  of  +17.08%,  -26.97%  and  +27.00  %,  -33.93%  respectively.
Specifically, experiment 1 had an average increase in fibres of 38.8% and
experiments 2 and 3 had increases of 65.5% and 48.0% respectively.
Fluorescence /475nm
Insulin 1mg/ml SAP Experiment 1 Experiment 2 Experiment 3
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TC Buffer 0 194.2 311.3 292.1
TC Buffer
0.2mg/
ml 269.6 515.1 432.2
% change in fluorescence -Helix 38.8 65.5 48.0
Average % change -Helix 50.8
Table  3:: A table showing the effect of SAP on insulin fibrillogenesis.
Values are taken from the peak of ThT fluorescence (475nm). 1mg/ml
insulin was used for each sample and 0.2mg/ml SAP in the designated
samples. The samples range between a fluorescence of 194.2 and 311.3
in the absence of SAP and between a range of  269.6  and  515.1  in the
presence  of  the  SAP  pentamers.  This  provides  an  error  margin  of
+17.08%,  -26.97%  and  +27.00  %,  -33.93%  respectively.  Specifically,
experiment  1  had  an  average  increase  in  fibres  of  38.8%  and
experiments 2 and 3 had increases of 65.5% and 48.0% respectively.
When the  above assays were  repeated using various SAP concentrations
(0.1-1mg/ml)  the following results were observed: The samples grown with
higher  SAP  concentrations  experienced  a  larger  increase  in  total  ThT
fluorescence  whereas  those  with  smaller  concentrations  experienced  a
smaller increase in ThT fluorescence. The two factors are directly proportional
and exhibit a strong positive correlation of 0.713. These results clearly show
that SAPs enhancing activity is proportional to its quantity.  The more SAP
molecules present the more SAP:intermediate interactions that are occurring
and the fewer fibres that are being produced (Figure 30, Figure 34). 
When  compared  to  the  fibres  grown  in  TE  buffer,  it  is  noted  that  ThT
fluorescence in these TC assays are not as high as previously seen.  The
maximum fluorescence intensity reached for TC fibres is 311 (in the absence
of SAP) which is only a third of what the TE fibres are able to achieve. Equal
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amounts of aggregate were found in both the TE and TC samples and the
same  ThT  stock  was  used  for  all.  This  implies  that  the  different  buffer
conditions are having an impact on the ThT results. 
ThT fluorescence is considered proportional for a certain type of amyloid fibre
but only under uniform conditions. By adding calcium and salt to the buffer
there is an increased risk of inhibiting ThT:fibre binding and thus diminishing
fluorescence.  That  being  said,  when  subject  to  ThT  analysis,  these  fibre
samples were diluted by a factor of x100 meaning the calcium and salt levels
would be very low overall and not likely to have affected fluorescence quite so
dramatically .  It  is more reasonable to assume that the fault  lay within the
fibres themselves or lack there of. Potentially the calcium present in the buffer
has  caused  dimerisation  of  the  insulin  monomers  and  thus  made  them
incapable of forming fibres. It is also entirely possible that the morphologies of
the  TE  and  TC  fibres  are  quite  different  having  grown  in  contrasting
conditions. This is potentially a factor which would lead to either unfair ThT
binding or even the formation of less stable fibres. 
Controls
In  order  to  clarify  the reason behind the reduced ThT fluorescence in  TC
fibres, a control assay was set up. Insulin fibres were produced in a high salt
buffer  -  THS buffer.  THS buffer  was identical  to  TC buffer  but  lacked the
calcium chloride, thus removing one of the two the additional variables. If ThT
fluorescence in  the THS assay matched those of  the original  TE buffer,  it
could be concluded that the additional salt had no effect on fibre formation
and  that  any  differences  seen  were  due  to  the  calcium  alone.  If  ThT
fluorescence of the THS assay did not match that of the original TE assay,
one would have to presume that the salt did indeed have an affect on fibre
formation. This would mean that the conditions for SAP pentamer interactions
would have to be reviewed and altered. 
ThT fluorescence of the THS buffer was capable of reaching similar peaks as
in the original TE buffer. The samples range between a fluorescence of 995.2
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and 767.5 giving an error margin of +9.48%, -15.57%. This demonstrates that
the increased salt amounts have no adverse affects on fibre growth or ThT
fluorescence. When the control THS fibres are grown in the presence of SAP
they experience an average decrease of 38.7% in fibre amounts with a range
of  377.5  and  619.1 between the three different attempts. This results in an
error margin of +17.65 and -28.25%. This is similar to the original TE assays
and confirms that in the THS buffer, SAP maintains its decameric structure
and function (Figure 31). 
  Fluorescence /475nm
Insulin 1mg/ml SAP Experiment 1 Experiment 2 Experiment 3
THS Buffer 0 995.2 767.5 964.3
THS Buffer 0.2mg/ml 619.1 377.5 582.1
% change in fluores-Helix
cence -Helix 37.8 50.8 39.6
Average % change -Helix 42.7
Table  4:  A table  showing the effect  of  SAP on insulin  fibrillogenesis
made in THS buffer. Values are taken from the peak of ThT fluorescence
(475nm).  The  amount  of  fibres  decreased  with  the  addition  of  SAP
decamers: there was an average of 42.7% reduction in ThT fluorescence
between assays with and without SAP in THS buffer. 1mg/ml insulin was
used for each sample and 0.2mg/ml SAP in the designated samples. The
samples  range  between  a  fluorescence  of  767.5  and  995.2  in the
absence of SAP and between a range of 377.5 and 619.1 in the presence
of the SAP decamers. This provides an error margin of +9.48%, -15.57%
and +17.65 and -28.25% respectively. More specifically, sample 1 of this
particular  experimental  condition  has  an  average  decrease  in  fibre
amounts  of  37.8%  and  experiments  2  and  3  have  50.8%  and  39.6%
respectively.
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TE Fibres TE Fibres with SAP decamers
Figure  29:  A  bar  graph  comparing  average  ThT  fluorescence  of  TE
insulin  fibres  grown  in  the  presence/absence  of  0.2mg/ml  SAP
decamers. Fibres were rotated for 10 days on a revolving Stuart Rotator
SB3 at  20rpm at  room temperature.  Each bar  is  an average of  three
samples and has error margins included so to show the range of those
three  samples.  The  fibres  grown  in  TE  buffer  produce  an  average
fluorescence of  657.2 where as those grown in the presence of  SAP
decamers produce an average fluorescence of 292.0. The presence of
SAP decamers causes an average reduction of 55.6% in fibre formation. 
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TC Fibres TC Fibres with SAP Pentamers
Figure 30: A bar graph comparing average ThT fluorescence of insulin
fibres grown in the presence/absence of  0.2mg/ml  SAP pentamers in
calcium  (TC)  buffer.  Fibres  were  rotated  for  10  days  on  a  revolving
Stuart  Rotator  SB3  at  20rpm  at  room  temperature.  Each  bar  is  an
average of three samples. Error margins are included to show the range
of  those  three  samples.  The  fibres  grown  in  TC  buffer  produce  an
average fluorescence of 265.9 where as those grown in the presence of
SAP decamers produce an average fluorescence of 405.3. The presence
of  SAP  decamers  causes  an  average  increase  in  fibre  formation  of
52.5%.
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THS Fibres THS Fibres with SAP Decamers
Figure 31: A bar graph comparing average ThT fluorescence of insulin
fibres grown in the presence/absence of  0.2mg/ml  SAP pentamers in
high salt (THS) buffer. Fibres were rotated for 10 days on a revolving
Stuart  Rotator  SB3  at  20rpm  at  room  temperature.  Each  bar  is  an
average of three samples and has error margins included to show the
range of those three samples. The fibres grown in THS buffer produce
an average fluorescence of 574.3 where as those grown in the presence
of  SAP  decamers  produce  an  average  fluorescence  of  347.3.  The
presence  of  SAP  decamers  causes  an  average  decrease  in  fibre
formation of 39.5%.
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Figure 32: Graph showing the correlation between insulin concentration
and  ThT  fluorescence.  A  strong  positive  correlation  of  0.897  is
observed.  This  illustrates  that  the  more  protein  present,  the  higher
amount of cross  β-sheet fibres produced and thus the higher the ThT
fluorescence. 
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Figure  33:  Graph  showing  the  correlation  between  SAP  decamer
concentration and ThT fluorescence. A strong negative correlation of -
0.812 is observed. This illustrates that the more SAP decamers present,
the  more  fibre  amounts  are  reduced  thus  the  lower  the  ThT
fluorescence. 
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Figure  34:  Graph  showing  the  correlation  between  SAP  pentamer
concentration and ThT fluorescence.  A strong positive  correlation of
0.713 is observed. This illustrates that the more SAP pentamers present,
the  more  fibre  amounts  are  increased  thus  the  higher  the  ThT
fluorescence. 
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Figure 35: Images of insulin fibres stained with Congo red.  All samples
showed the apple green birefringence typical of cross-β sheets under
polarised light.  The images were viewed using a Zenith Microlab ML-
1000M Monocular  Laboratory  Microscope 60040 at  a  magnification  of
x40for samples A, B, E, F and x100 for samples C,D. Sample contents
are as follows: A – Insulin fibres grown in TE buffer. B) – Insulin fibres
grown in TE buffer with SAP decamers. C – Insulin fibres grown in TC
buffer. D) – Insulin fibres grown in TC buffer with SAP pentamers. E) –
Insulin  fibres  grown  in  THS buffer.  F)  –  Insulin  fibres  grown  in  THS
buffer with SAP decamers. 
In the samples grown in TE buffer – A and B – a decrease in fibre density
is observed in B, the sample containing SAP decamers. In the samples
grown in TC buffer – C and D – an increase in fibre density is observed
in D, the sample containing SAP pentamers. And in the samples grown
in THS buffer –E and F – a decrease in fibre density is observed in F, the
sample containing SAP decamers There are no significant differences
seen between the images of the TE and THS samples indicating minimal
impact of the salt on the fibres. 
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This is a reassuring result. It can now be presumed that all differences with
regard to fluorescence noted within the confines of the TC buffer assays are
due to the change in SAP conformation alone and not the involvement of salt.
The  additional  calcium variable  does  not  appear  to  affect  the  relationship
between SAP pentamers  and fibres  either;  however  it  does appear  to  be
responsible for reduction of total  fibre amounts produced. This means that
direct comparisons between the TC and TE assays cannot necessarily be
made,  however,  proportional  figures  and  ratios  can  be  discussed  and
analysed. 
Another observation became apparent over time. The control fibres - those
grown in the high salt conditions of the THS buffer - were less stable than the
original TE fibres. ThT fluorescence of the THS fibres would deplete to 25% of
their original amount within 2 to 3 months whereas TE fibres would remain
stable  for  up  to  a  year  before  a similar  depletion  was observed.  It  would
appear that the salt has no observable effect on fibre growth but instead is
responsible for a lack of stability on those resulting fibres. 
That  being  stated,  THS fibres  which  were  grown in  the  presence of  SAP
‘decamers’ drastically increased in stability, withstanding up to 8 or 9 months
before  depletion.  A  similar  pattern  was  experienced  with  the  TE fibres.  It
seems that SAP is able to add stability to fibres even when in its decameric
form and  acting  as  a  chaperone.  Perhaps  in  the  decameric  form enough
conformational changes have occurred in order to allow fibre:SAP binding of a
different kind. Perhaps the edge of the decamer is interacting with the fibre
instead. The increased stability of insulin fibres grown in TE buffer with the
presence of SAP decamers compared to those grown in the same conditions
in the absence of SAP decamers would certainly suggest so. 
That being said, it is important to remember that SAP, although predominantly
decameric in this TE buffer, may also be available in its pentameric state as
SAP never exclusively exists as decamers according to Thompson  et al. in
2002. It  is a mixture. The most logical conclusion, therefore, would be that
when  in  its  “decameric”  state,  it  is  the  predominant  decameric  molecules
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which  are  acting  as  chaperones,  refolding  available  monomers  and  the
subsidiary pentameric molecules are binding to the fibres present in solution
and increasing their stability. 
SAP Control
When submit to the same inversion conditions as the prepared insulin, lone
SAP - at concentration 0.2mg/ml - did not form fibres or any other form of
amorphous aggregate; it remained soluble in solution. This demonstrates that
SAP concentration and function does not diminish during the course of the
rotator assay and it should not interfere with ThT fluorescence or any other
analytical methods for cross β-sheets.
The Role of SAP in Fibrillogenesis
Thus far from this chapter the following conclusions can be made: In the case
of insulin, SAP appears to have a dual role in fibrillogenesis; it can enhance or
reduce fibre formation depending on its conformation. When in its decameric
state SAP inhibits fibre formation and decreases total fibre mass. When in its
pentameric state SAP acts as a fibrillogenic stabiliser or enhancer. This dual
behaviour of SAP is consistent and is not affected by environmental factors
such as rotator speeds, concentration changes or high salt  concentrations.
SAP alone, when submitted to the same conditions as the prepared insulin,
does  not  form amorphous aggregate  nor  cross-β  sheets;  it  remains  in  its
solubilised  state  as  confirmed  by  ThT fluorescence.  This  confirms  that  all
cross β-sheet fibres are purely insulin in origin.
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SAP State Available
face
Role in
fibrillogenesis
Decamer A-face Molecular
chaperone
Pentamer B-face Fibrillogenic
catalyst/enhancer
A table to illustrate the roles of each SAP conformer.
The  existing  literature  has  already  demonstrated  increased  fibre  stability
through  SAP  binding,  and  so  provides  one  explanation  as  to  why  fibre
amounts increase in the presence of SAP pentamers. The increased stability
would encourage the rope-like structures to extend and therefore increase the
amount  of  fibre  present  in  the  solution.   The behaviour  of  the  decamers,
however, is less clear. Is the diminishing function carried out through partial
binding of unfolded species or through the depletion of existing fibres? The
former would seem more feasible due to a number of reasons: Firstly, during
growth, a high number of  partially unfolded intermediates are available for
decamer interaction. Secondly, cross  β-sheet fibres are extremely stable so
detachment  of  monomers  from  the  core  via  the  decamers  seems  wholly
unlikely. Finally, when in its decameric form, the binding (B) side of SAP is
involved  in  an  interaction  with  another  SAP  molecule  so  is  not  actually
available for fibre interaction via its binding (B) face. That being said, alternate
interactions via the edge of the decamer cannot be ruled out.
When  comparing  SAP  decamers  to  existing  chaperones  quite  a  few
similarities are observed. The decamer exists as a large cylindrical structure
formed  of  two  rings  of  oligomers.  This  description  is  similar  to  that  of
chaperonins.  Although  not  as  big  as  the  GroEL  chaperonin,  for  example,
250kDa rather than 798kDa, the SAP decamer also has a hollow chamber
which passes through its centre. The larger GroEL structure often deals with
proteins up to 60kDa in size. Being much smaller than GroEL, it is doubtful
that SAP would be able to interact with proteins up to this size. However, in
this case, it is the insulin protein which is involved. Insulin is only 6kDa so
could  quite  easily  enter  one  of  the  SAP rings,  bind  to  the  inner  wall  via
135
hydrophobic  interactions  providing  enough  conformational  changes  to
encourage protein folding. Not only is it entirely possible that SAP is indeed
some form of chaperonin but it is able to act as so even without the need of
ATP. 
Fibre Comparison using Congo Red
As with the ThT results, the effect of SAP on fibres can be distinguished using
Congo red images. The following samples underwent Congo red analysis and
were compared in Figure 35: 
- Insulin fibres grown in TE buffer
- Insulin fibres grown in TE buffer with the addition of 0.2mg/ml SAP
decamers
- Insulin grown in TC buffer
- Insulin  grown  in  TC  buffer  with  the  addition  of  0.2mg/ml  SAP
pentamers
- Insulin grown in THS buffer
- Insulin  grown  in  THS  buffer  with  the  addition  of  0.2mg/ml  SAP
decamers
All samples showed the apple green birefringence typical of cross-β sheets
under polarised light. The images were viewed using a Zenith Microlab ML-
1000M Monocular  Laboratory Microscope 60040 at  a magnification of  x40
except for those grown in TC buffer with and without SAP. This was due to the
fact  that  these  particular  samples  had  less  clustering  of  apple  green
birefringence. A higher magnification of x100 was required for comparison to
the previous samples. 
Image A and B represent insulin fibres grown in TE buffer without and with
SAP decamers  respectively.  As  expected,  image  B  –  those  grown  in  the
presence  of  SAP  decamers  –  demonstrate  a  decrease  in  fibre  density
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compared  to  those  grown  without.  This  further  confirms  the  chaperoning
activity of the decamer molecule. The decrease in fibres cannot be given a
value in this case as the Congo red technique is not a quantitative method.
Images C and D represent fibres grown in TC buffer without and with SAP
pentamers  respectively.  Here,  an  increase in  fibre  density  is  witnessed in
image D – those grown in the presence of the SAP pentamers thus confirming
their activity as an enhancer and stabiliser. Finally, images E and F represent
insulin  fibres  grown  in  THS fibres  without  and  with  the  presence  of  SAP
decamers respectively. Again, a decrease in fibre density is seen in F; those
grown  in  the  presence  of  SAP  decamers.  This  result  confirms  that  the
chaperoning  activity  of  the  SAP decamers  is  not  altered  by  the  high  salt
conditions.
No significant differences are seen between the images of the TE and THS
samples.  This  clarifies  that  the  high  salt  concentrations  do  not  have  a
substantial impact on the amount or density of fibres made. These results,
alongside the ThT results, provide a strong indication that all  samples had
indeed formed fibres and not  amorphous aggregate.  However,  neither  the
ThT  or  Congo  red  techniques  provide  enough  information  regarding  the
structure of the samples in order to confirm this. Also, having grown in varying
conditions it seemed unlikely that the morphologies of each sample would be
completely identical even though they originated from the same stock solution
of insulin. Structural work was required.
Fibre Comparison using Transmission Electron Microscopy 
(TEM)
Initial  structural  analysis  was  carried  out  using  transmission  electron
microscopy (TEM). Although the specific cross β-sheets fold cannot be seen
using TEM due to magnification limitations, the typical rope like structure can
be distinguished. The visualisation of rope like structures in TEM images not
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only confirms the presence of the cross β-sheet structure specific to amyloid
but also provides a comparable image with regards to structure. 
The following samples were analysed using TEM and compared ():
- Insulin fibres grown in TE buffer
- Insulin fibres grown in TE buffer with the addition of 0.2mg/ml SAP
decamers
- Insulin grown in TC buffer
- Insulin  grown  in  TC  buffer  with  the  addition  of  0.2mg/ml  SAP
pentamers
- Insulin grown in THS buffer
- Insulin  grown  in  THS  buffer  with  the  addition  of  0.2mg/ml  SAP
decamers
The TEM images of fibres grown in the TE buffer exhibited morphology typical
of  cross-β  sheet  fibres.  At  140,000x  magnification,  rope-like  structures
approximately 7nm in diameter and of indefinite length are clearly visible. A
similar result  is  also seen in  the TE fibres grown in the presence of  SAP
decamers. Very little difference is seen between the two. This would indicate
that the decamers, although involved in growth rates and total fibre amounts,
have no (or very little) influence on fibre structure and morphology. This would
also indicate that the decamers are not physically bound to the fibres when in
their  decameric  state.  SAP decamers have a depth of  70Å or 7nm and a
diameter of 100 Å or 10nm. If it were true that the decamers were bound to
the fibres, there would be a large increase in diameter of the fibre structures.
This further  suggests the theory that  the SAP interacts with the fibre in a
mechanism similar to a chaperonin molecule.
Contrastingly, the fibres grown in the calcium containing (TC) buffer are rather
different. Those grown in the absence of SAP have a slate-like morphology.
They are much wider in diameter than previously seen - 30nm rather than the
expected 10nm – and also much shorter growing to only 100nm in length. The
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presence of salt or calcium ions in the buffer has undoubtedly had a marked
effect on fibre structure and would explain the instability noted on these fibres.
Remarkably, the fibres grown in the TC buffer in the presence of 0.2mg/ml
SAP pentamers have developed a structure much like the typical rope-like
morphology with a wider diameter of 15-20nm and a length of up to 500nm.
These results suggest that the SAP pentamers are playing an active role in
fibre  assembly.  Upon  binding,  they  appear  to  direct  and  encourage  the
formation of a more stable formation however they are unable to completely
counteract  the  effect  that  either  the  salt  or  the  calcium is  having  on  the
structure.
These increases in diameter could be due to one of two reasons. The first
being  the  SAP  pentamers  are  bound  to  the  fibres.  Although  completely
plausible, stacks of SAP cannot be distinguished in either of these images so
is  likely  not  the  case.  Alternatively  one  could  suggest  that  the  increased
diameter in both the TC images is a result of the insulin monomers interacting
differently  with  one  another  in  order  to  create  the  fibres.  Cross  β-sheet
formation occurs when, in this case, the insulin molecule partially unfolds and
interacts  with  another  of  its  kind.  Perhaps  when  subject  to  different
environmental conditions, the monomers unfold in a different place or to a
different degree. In turn, this would cause the monomers to interact differently
upon  cross  β-sheet  formation  and  cause  smaller  or  larger  side  bulks
depending on the degree of unfolding. The more unstable the environment,
the larger the degree of unfolding and thus the wider the fibre will be when
stacked.  The  more  stable  the  environment,  the  smaller  the  degree  of
unfolding and thus the thinner the fibre will be.
The control  fibres,  i.e. the fibres made in THS buffer closely resemble the
typical  rope-like  structures  as  seen  in  the  TE  buffer.  The  fibres  are
approximately 7nm in diameter and are of indefinite length. This establishes
that it is the calcium which causes the dramatic change of morphology to the
‘slate’ pattern and not the high salt conditions. However, a distinct difference
is  noted between the  TE and THS fibres.  The THS fibres  appear  slightly
fragmented and have a ‘sickly’  quality to them. This suggests that the salt
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does have a slight impact on fibre structure which explains why these fibres
are less stable than the TE fibres. THS fibres grown in the presence of 0.2mg/
ml  SAP  lack  this  ‘sickly’  quality,  further  demonstrating  SAPs  stabilising
qualities.  SAPs  fibrillogenic  involvement  is  clearly  structural  as  well  as
mechanical. 
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Figure  36:  TEM  images  of  insulin  fibres.  Images  were
obtained using a Philips (FEI) CM120 TEM microscope at
a magnification of  140,000x.  A)  TE fibres grown in the
absence  of  SAP.  Typical  rope-like  structures
approximately 7nm in diameter  and of  indefinite  length
are  seen.  B)  TE fibres  grown in  the  presence  of  SAP.
Here, the rope-like structures are approximately 8.5nm in
diameter and of indefinite length. C) TC fibres grown  in
the  absence  of SAP have  a  different  morphology  than
expected.  They  have  a  slate-like  morphology  30nm  in
diameter and approximately 100nm in length. D) The TC
fibres  grown  in  the  presence of  SAP  pentamers  were
again the typical rope-like morphology but were slightly
wider  and  shorter  than  expected.  15-20nm in  diameter
and  approximately  500nm  in  length.  E)  The  high  salt
conditions created ‘Sickly’ THS fibres in the absence of
SAP.  F)  700,000x magnification of  THS fibres grown in
the presence of SAP decamers show fibres have reverted
back  to  the  typical  rope-like  structures  approximately
7nm  in  diameter.  SAP  pentamers  can  be  seen  in  the
background and attached to the fibres in this image.
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Due to the higher magnification of the THS fibres grown with SAP images, the
SAP  structure  can  also  be  seen.  The  distinctive  disc  shaped  structure  is
scattered in the background of the image but also appears to be stacked on the
amyloid fibres. This illustrates that SAP does indeed have interactions with the
fibres themselves and not just with the amyloid prone intermediates. It should
be noted that the staked SAP structures appear to be in the pentameric form.
To explain this one must remember that SAP never exists solely as a decamer
but instead as a mixture of decamers and pentamers. This lack of evidence
regarding  decamer  binding  to  fibres  would  suggest  that  it  is  indeed  the
pentamers  which  bind  to  the  fibres  and  in  doing  so  increase  stability  and
enhance growth, however, the decamers carry out their chaperoning activity in
solution, separate from the fibres. 
Considering there is a far greater number of non-bound decamers than bound
pentamers  it  would  explain  why  when  added  as  a  ‘decamer’  i.e.  a  mixed
solution, the decameric activity is the dominant form. Although the pentamer is
present, its low numbers are unable to maintain or exceed the rate of reaction
of  the  decamer  activity.  Whether  there  is  a  condition  which  allows  pure
decamers to form is yet to be seen but this seems unlikely for two reasons. The
first being SAPs tendency to exist exclusively as decamers in the serum under
conditions which would normally promote decamer formation. Clearly this is the
favoured formation whether due to stability or binding ability. Secondly, due to
the apparent reversible nature of the decamer interactions it would be unlikely
that  reasonable  conditions  could  be  found  to  encourage  full  saturation  of
decamer binding. even if such conditions could be found, they would not hold
any sense of resemblance to in vivo conditions and would never be able to be
replicated in the body so is irrelevant to these particular experiments.
Fibre Comparison using Circular Dichroism 
The  following  samples  were  processed  using  CD  and  compared:
- Insulin fibres grown in TE buffer
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- Insulin  fibres  grown  in  TE  buffer  with  the  addition  of  0.2mg/ml  SAP
decamers
- Insulin grown in TC buffer
- Insulin grown in TC buffer with the addition of 0.2mg/ml SAP pentamers
- Insulin grown in THS buffer
- Insulin grown in THS buffer with the addition of 0.2mg/ml SAP decamers
- Native insulin (before and after dialysis)
- Native SAP
- Aggregated SAP
In the cases where SAP was involved, SAP was removed from the solution
using  EGTA and washed away.  Although EGTA was not  necessary  for  the
removal  of  decamers  from  solution  as  they,  unlike  the  pentamers,  do  not
experience metal specific binding to the fibres, it was decided that all samples
should be submitted to the same preparatory conditions in order to ensure a fair
test. Each sample was transferred to water, a non chiral solution which would
not affect the CD results, and diluted to the same optical density. It was chosen
to  dilute  the  fibres  to  the  same  optical  density  rather  than  the  same
concentration due to the  impracticalities of measuring the concentration of a
solid. CD measurements were obtained at Diamond Light Source, Oxfordshire ,
on beamline 23 (B23). Each sample was measured a total of three times in
order to obtain an average. 
As expected, the native insulin samples demonstrate curves typical of alpha
helices (Figure 37). The typical peak and double depression are seen in both
spectra  with  little  difference  seen  between  the  dialysed  and  non-dialysed
samples. The x axis interception point occurs at wavelength 203nm for both
where as the wave amplitudes differ slightly at +34 and -16mdeg for the non-
dialysed sample and +32 and -14mdeg for the dialysed sample. As explained in
the introduction, insulin is a predominantly helical structure composed of two
chains.  The  shorter  A  chain  contains  an  N-terminal  helix  linked to  an  anti-
parallel C-terminal helix and the longer B chain has a central helical segment.
This explains why a helical spectrum is produced. In contrast to this, SAP is
formed predominantly of ß-sheets, ß-turns and some unknown structures. The
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CD data of native SAP illustrates this by producing a curve typical of β-strands.
The single peak and depression typical of ß-structures is observed with the shift
of the x axis interception point to the right compared to that of the helices. The x
axis interception point for native SAP occurs at 207nm with amplitude peaking
at  +26  and  -13mdeg.  When  made  into  amorphous  aggregate  through  the
addition of a few drops of 37% hydrochloric acid, the spectra changes. A very
low and broad peak and depression close to the base line is produced. It has a
shifted x axis interception point of 204nm. This shows that some level of  β-
strand  has  been  retained  in  SAP  in  acidic  conditions  but  the  majority  of
secondary structure has been lost.
Upon submitting the different fibre samples to CD, various observations were
noted (Figure 38, Figure 39). First and foremost, each fibre spectra produced a
curve typical of  β-strands. This shows that the rotator assays had caused the
insulin samples to undergo a huge conformational change from predominantly
α-helices to predominantly  β-sheets.  However,  each of the produced curves
intercepted the x axis at a different point. These unique interception points imply
that each fibre is cross β-sheet in nature but slightly unique in morphology. This
is in agreement with the TEM results. The CD spectra of the fibre samples have
all shifted slightly towards the right hand side of the graph compared to native
insulin. Interception points of the x axis are no longer at 203nm but rather at
unique points of 217nm (TE fibres), 210nm (TE fibres + SAP decamers), 221nm
(TC fibres), 213nm (TC fibres + SAP pentamers) 208 (THS fibres) and 211
(THS fibres  +.  SAP decamers).  Had  all  fibres  contained  the  same  ratio  of
secondary structure  i.e. if their morphology were identical, the spectra would
intersect the x axis at the same point regardless of concentration as per the two
native insulin spectra.
The unusual result from the CD data is that each fibre curve is of a different
amplitude compared to its’ peers. There is a range of +2 to +25mdeg in the
positive peak and -2 to -16mdeg in the negative depression with the TE fibres
having  the  highest  amplitude  and  the  TC  fibres  having  the  lowest.  The
amplitude of a curve or spectra is representative of the protein concentration of
the  sample  submitted  to  CD  analysis.  Taking  into  consideration  that  each
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sample was diluted to the same optical  density,  it  is  logical  to  expect  each
sample to have the same concentration of protein thus the same amount of
cross β-sheets and equal amplitude. This is clearly not the case. 
The amplitude differences of each curve indicate that the amount, or mass, of
cross  β-sheets in each sample is different.  Yet,  each sample had the same
optical density when undergoing CD analysis. This can only be explained one
way. There is more than one component present in each sample. This extra
component or components are having an effect on fibre concentration. It is safe
to say that native insulin is not responsible for this impact on the results as it
was completely removed during sample preparation. Even if it were present, it
is logical that each sample would have a proportional amount of native insulin
thus making any affect it had on the spectra a uniform effect.  
It is possible that SAP is having an effect on the results. Each fibre, CD sample
subsequently underwent SDS-PAGE electrophoresis. The results show a faint
band at a molecular weight of approximately 25kDa in each of the samples
which originally contained SAP; the equivalent of a single SAP domain. Clearly
the EGTA was unable to fully detach SAP form the fibres. It is indeed possible
that  the  SAP  could  have  had  some  influence  on  the  CD  spectra  causing
anomalous results to arise. However, regardless of this being true of not, this
would not  explain  the difference in  magnitudes between the samples which
didn’t contain any SAP to begin with. It cannot be the SAP which is having this
drastic effect on amplitude. Something else must be causing this phenomenon.
Another factor is causing the optical densities to remain constant while the β-
sheet concentrations vary (Figure 40).
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Figure 37: Control CD spectrum showing insulin and SAP in their native
forms. Measurements were taken at Diamond Light Source, Oxfordshire,
on  beamline  23  (B23)  –  soft  condensed  matter.  Both  native  insulin
samples – before (dark green) and after (blue) dialysis - produced spectra
typical of  α-helices crossing the x-axis uniformly at 202nm. Native SAP
(bright green) produced spectra typical of β-sheets with an x-intercept of
207nm.  Aggregated  SAP  (purple)  produced  spectra  of  no  defined
structure. 
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 Figure  38:Average CD results of TE and TC insulin fibres grown in the
presence and absence of SAP. TE fibres are represented in dark green,
TE fibres + SAP are represented in blue, TC fibres are represented in dark
purple,  TE  fibres  +  SAP  are  represented  in  bright  green  and  TTR
aggregate  is  represented  in  pink.  Each  spectra  is  an  average  of  ten
measurements and was taken at Diamond Light Source, Oxfordshire, on
beamline 23 (B23) – soft condensed matter. All insulin fibres produced
spectra  typical  of  β-sheets.  The  differences  in  amplification  are  due
simply to differences in fibre concentrations. However, the differences in
x-axis  interception  would  indicate  that  the  structure  of  each  fibre  is
different. X-axis interception ranges from 210-222 nm. Those fibres grown
in the presence of SAP have higher amplification and x- axis interception
shifted to the left of the graph. 
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 Figure 39: Average CD results of THS fibres with/without SAP decamers.
THS fibres are represented in green and THS fibres + SAP decamers are
in blue. Each spectra is an average of ten measurements and was taken
at  Diamond  Light  Source,  Oxfordshire,  on  beamline  23  (B23)  –  soft
condensed matter. Although on a small scale, the curves are still typical
of β-sheets with interception at 208 and 211nm.
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Figure 40: Electrophoresis gel showing of the six samples submitted to
CD analysis  following  EGTA washes  and  transference  to  water.  The
contents of each lane are as follows: 1) Pre-stained molecular marker –
weights are labelled 2) Blank 3) TE fibres 4) TE fibres + SAP decamers 5)
TC fibres 6) TC fibres + SAP pentamers 7) THS fibres 8) THS fibres +
SAP decamers. The presence of faint bands at 25kDa in lanes 4, 6 and 8
indicate that SAP was still  attached to fibres even after washing with
EGTA.
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Optical density is the measurement of how much a refractive medium retards
transmitted  rays  of  light.  It  takes into  account  the  mass or  density  of  the
medium but not the composition.  The only logical explanation for this strange
occurrence is that all the fibre samples did indeed contain the same amount of
precipitate within as measured by the optical density but that the precipitate
was not purely cross β-sheets. This suggests that each precipitate consisted
of at least two insoluble substances. One of these is cross β-sheets and the
second must be amorphous aggregate. 
As shown in Figure 37 with the aggregated SAP, amorphous aggregate does
not produce a peak on the CD spectra as it lacks secondary structure. The
presence of amorphous aggregate in a cross β-sheet fibre sample shouldn’t
alter results in a drastic way although it is possible that it could cause the x
axis  interception  to  shift  slightly.   However  the  presence  of  amorphous
aggregate  would  defiantly  cause  discrepancies  to  occur  between
concentration of cross  β-sheet fibres and the optical  density  of  the overall
sample. Each sample may have the same amount of aggregate mass but a
different  cross  β-sheet:  amorphous  aggregate  ratio.  It  is  not  possible  to
separate the two as both are white solids with similar densities and made of
the  same  protein.  However,  seeing  as  the  presence  of  the  amorphous
aggregate  is  not  affecting  the  CD  results  this  is  not  something  to  be
concerned about.  That  being said,  this  observation presents  a new set  of
questions. Why is amorphous aggregate formed? How much is formed? Does
this vary between the fibres grown in different conditions? 
Further scrutiny of all the CD results was achieved using the programme ‘CD
Apps’.  This  programme – which was developed at  Diamond Light  source,
beamline B23 – takes the spectra produced from CD analysis and converts
the resulting curves into unique numerical values. These values represent the
ratio  of  α-helices  and  β-strands  present  in  a  particular  sample  as  a
percentage. By using this programme one can see the secondary structure
composition in ore detail.
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Each of the fibre sample spectra was submitted to this programme alongside
native insulin as a comparison and the results are represented in the table
below: 
Secondary
Structure
Native
Insulin
TE
Fibres
TE Fibres
+  SAP
Decamers
TC
Fibres
TC Fibres
+ SAP
Pentamers
THS
Fibres
THS
Fibres +
SAP
Decamers
Alpha Helix 15.6% 0.3% 19.7% 0% 0.1% 0.1% 0.1%
Distorted
Alpha Helix
14.3% 6.3% 15.9% 4.5% 4.0% 3.7% 4.0%
Alpha Helix
(both
types)
29.9% 6.6% 35.6% 4.5% 4.1% 3.8% 4.1%
Beta Strand 15.6% 25.3% 22.4% 26.7% 30.1% 28.6% 28.7%
Distorted
Beta Strand
8.2% 14.6% 11.5% 13.7% 14.4% 14.0% 13.9%
Beta Strand
(both
types)
23.8% 39.9% 33.9% 40.4% 44.5% 42.6% 42.6%
Unordered 46.3% 53.5% 30.5% 55.1% 51.4% 53.6% 53.3%
 Table  5:  A  table  comparing  the  secondary  structures  of  each  fibre
sample calculated using the ‘CD Apps’ programme available at Diamond
Light Source, beamline B23.
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When  looking  at  the  native  sample  you  can  see  that  insulin  is  normally
constructed of 29.9% -helices, of this, almost half (14.3%) are distorted.  Aɑ-
further 23.8% of the structure is made of β-strands (8.2% distorted) whist the
remaining 46.3% represents turns  and unordered structures.  To put  these
numbers  into  perspective,  SAP,  a  predominantly  β-  stranded  structure,
consists  of  21.8%  -helices  (6%  distorted),  30.1%  β-  strands  (11.4%ɑ-
distorted)  and  the  remaining  48.1%  is  turns  and  unordered  structures.
Alternatively the aggregated SAP– achieved by exposing SAP to hydrochloric
acid  solution  –  contains  10% -helices  with  90% dedicated  to  unorderedɑ-
structures. 
From  these  results  it  would  appear  that  a  protein  must  consist  of
approximately  30% of  either  helices  or  strands  in  order  to  be  considered
predominantly of that form. Insulin is constructed of 29.9% -helices and SAPɑ-
is 30.1% β- strands. Whether these secondary structures are distorted or not
appear to have no effect on the secondary structure itself but most likely will
alter the packing of the tertiary structure. 
In a typical aggregated structure, i.e. in the amorphous state, a protein is able
to maintain some form of secondary structure but the majority is unordered
such as with the aggregated SAP mentioned above. This is not the case,
however,  when  dealing  with  cross  β-sheet  aggregation.  Cross  β-sheet
structures do have a secondary structure. Each of the fibres samples under
the scrutiny of the CD Apps programme have decreased in -helix percentageɑ-
with the exception of the TE fibres + SAP decamers. The drop from 29.9% to
6.6% (TE fibres), 4.5% (TC fibres) 4.1% (TC + SAP pentamers) 3.8% (THS
fibres) and 4.1% (THS fibres + SAP decamers) in each of the samples clearly
shows that the primary secondary structure is lost. The variety on the degree
of loss can be explained by the variation of the conditions to with the samples
were  submit  to  originally.  Oddly,  the  percentage  of  -helices  in  TE fibresɑ-
grown in the addition of SAP decamers has increased to 35.7% however, as
with the other samples, the percentage of β-strands has also increased. The
percentage  has  doubled  to  39.9%  (TE  fibres),  33.8%  (TE  fibres  +  SAP
decamers),  40.4% (TC fibres)  44.5% (TC fibres + SAP pentamers)  42.6%
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(THS fibres) and 42.6% (THS fibres +SAP decamers) with up to ¾ of these
being  ordered.  Although  the  TE  fibres  were  able  to  maintain  (and  even
increase)  their  helical  structure,  the  β-sheet  conformation  has  a  higher
percentage so is dominant. If anything, this result shows how little the insulin
needs to unfold before this drastic change in conformation occurs in optimum
conditions. 
Fibre Comparison using Bicinchoninic Acid Assay (BCA)
Fibres grown in the following six conditions were processed using the BCA
assay and compared. Four different samples per condition were analysed in
order to obtain an average:
- Insulin fibres grown in TE buffer
- Insulin fibres grown in TE buffer with the addition of 0.2mg/ml SAP
decamers
- Insulin grown in TC buffer
- Insulin  grown  in  TC  buffer  with  the  addition  of  0.2mg/ml  SAP
pentamers
- Insulin grown in THS buffer
- Insulin  grown  in  THS  buffer  with  the  addition  of  0.2mg/ml  SAP
decamers
BCA is a method used to determine the protein concentration of a solution
between the concentrations 0.5 μg/ml to 1.5 mg/ml. It incorporates all protein
present including solubilised protein and aggregated protein whether present
as fibres or amorphous aggregate. By removing the solubilised protein from
each sample, a comparison between the BCA and ThT results could be made
and  an  indication  of  the  fibre:amorphous  aggregate  proportions  could  be
determined. 
TE  fibres  grown  in  the  absence  of  SAP had  a  direct  positive  correlation
between protein precipitation and ThT signal – i.e. the more protein used the
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more fibre that was made. Of which, approximately 80% of the insulin was
made into cross β-sheets, 16% was amorphous aggregate and the remaining
4% continued as  native insulin  or  soluble  intermediates.  However,  the TE
fibres grown in the presence of SAP decamers did not follow this pattern.
They  had  a  lower  ThT  signal  yet  contained  almost  equal  amounts  of
precipitate as their SAP free counterparts. Only 20% of the insulin became
cross  β-sheet  whereas  62%  became  amorphous  aggregate  with  the
remaining 18% continuing as either native insulin or soluble intermediates.
This  suggests  that  the  SAP  decamers  promote  amorphous  aggregate
formation.  Alternatively  it  would be sensible  to  suggest  that  the decamers
promote refolding of unfolded aggregates (Figure 41). 
The samples grown in TC buffer, like their TE equivalents, also experienced
direct  correlation  between  protein  precipitation  and  ThT  signal;  the  more
protein, the more fibre that was made. Approximately 21% of the insulin was
made into cross β-sheets, 69% was amorphous aggregate and the remaining
10%  continued  as  native  insulin  or  soluble  intermediates.  These  lower
amounts are most likely due to the presence of calcium and salt in the buffer
creating a less stable fibre structure. Again, those grown in the presence of
SAP  -  in  this  case  SAP  pentamers  –  produced  different  results.  Those
samples  grown  in  the  presence  of  SAP  pentamers  exhibited  higher  ThT
signals  yet  contained  less  overall  precipitate  compared  to  their  control
equivalents. Approximately 41% of the insulin was made into cross β-sheets,
57% was amorphous aggregate and the remaining 2% continued as native
insulin or soluble intermediates. This supports the theory that SAP pentamers
are promoting the formation of amyloid fibres.  
Perhaps SAP is the regulator of a reversible pathway between cross β-sheet
fibres and amorphous aggregate (Figure 42). The decamers would therefore
be responsible for shifting equilibrium towards amorphous aggregate whereas
the pentamers are responsible for shifting equilibrium towards cross β-sheets.
In fact, it is even more plausible to suggest that the role of SAP is to maintain
equilibrium between cross β-sheet fibres and the native structures as the body
has no use for amorphous aggregate (further discussions below). 
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Figure  41:  A  bar  graph  comparing  composition  of  the  insulin
precipitates  made  from  different  rotator  conditions.  Amorphous
aggregate  is  represented  in  purple  and  cross  β-sheet  fibres  are
represented in  blue.  The precipitates were processed using the BCA
assay and compared to their ThT fluorescence signal in order to obtain
the  following  figures.  Four  different  samples  per  condition  were
analysed in order to obtain an average. In TE fibres approximately 80%
of the insulin was made into cross β-sheets, 16% amorphous aggregate
and  the  remaining  4%  continued  as  native  insulin  or  soluble
intermediates. TE fibres grown in the presence of SAP decamers had
20%  become  cross  β-sheet,  62%  amorphous  aggregate  and  18%
continuing as either native insulin or soluble intermediates. TC buffer
fibres produced 21% cross  β-sheets,  69% amorphous  aggregate  and
10% as native insulin or soluble intermediates. TC fibres grown in the
presence  of  SAP  pentamers  produced  41%  cross  β-sheets,  57%
amorphous aggregate and 2% continued as native insulin  or  soluble
intermediates.  THS  fibres  produced  73%  cross  β-sheets,  22%,
amorphous aggregate and 5% continued as native insulin  or  soluble
intermediates.  THS  fibres  grown  in  the  presence  of  SAP  decamers
yielded  37%  cross  β-sheets,  48%  amorphous  aggregate  with  15%
continuing as either native insulin or soluble intermediates.
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Figure  42:  Diagram  representing  the  theory  of  SAP  controlling
equilibrium between fibre and amorphous aggregate. The decamers are
responsible for shifting equilibrium towards amorphous aggregate and
the pentamers are responsible for shifting equilibrium towards cross β-
sheets. It may be possible that amyloidosis is just the result of improper
regulation of this reversible reaction.
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The control THS fibres experienced a similar result to the TE fibres. Those
grown  in  the  absence  of  SAP  had  a  direct  correlation  between  protein
precipitation and ThT signal with approximately 73% of the insulin was made
into cross  β-sheets, 22% was amorphous aggregate and the remaining 5%
continued as native insulin or soluble intermediates. Again, as before, those
fibres grown in the presence of SAP decamers did not follow this pattern.
They  had  a  lower  ThT  signal  yet  contained  almost  equal  amounts  of
precipitate as their SAP free counterparts. Only 37% of the insulin became
cross β-sheet, 48% amorphous aggregate with the remaining 15% continuing
as either  native  insulin  or  soluble  intermediates.  These results  are  almost
identical to the TE fibres indicating that it is the calcium and not the high salt
concentration which is the main effecter of fibre formation in the TC assays. 
Fibre Disassembly  
Upon the addition of 0.2mg/ml SAP decamers to pre-formed insulin fibres,
ThT fluorescence shows that fibre amounts decrease to approximately 50% of
their original mass over a period of 3-4 days. Following this initial decline, fibril
concentrations  will  rise  again  although  original  fibre  amounts  are  not
recovered. It has already been established in this chapter that SAP decamers
appear to behave in a fashion similar to chaperonins. They prevent elongation
of the fibres by binding to the soluble intermediates and possibly aiding in
their refolding into the native state.
Continuing with this concept, one could argue that the reason fibre amounts
cease decreasing after the initial 3-4 days is due to saturation of all the SAP
molecules.  Had  the  interactions  between  decamer  and  intermediate  been
irreversible then one would expect fibre amounts to remain at equilibrium near
this lower fibre mass. The subsequent  increase in fibre amounts suggests,
instead, that the interactions are indeed reversible and that when released
back into the solution the protein is able to reassemble itself onto the fibre
structure. Whether the protein has gone through the process of re-folding then
unfolding again, however, cannot be established as of yet.
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The addition of further 0.2mg aliquots of SAP at 5 day intervals again sees a
decrease in fluorescence after each addition but as previously experienced,
fibre amounts eventually increase even when SAP is in excess. This would
suggest that refolding of the insulin into its native state is not occurring. The
reason for this is likely to be the lack of ATP and co-chaperones in these
simplistic  in  vitro conditions.  SAP  is  unable  to  undergo  the  appropriate
conformational  changes  necessary  to  assist  in  intermediate  folding.
Alternatively, it is possible that refolding is occurring but the pre-existing fibres
are catalysing new fibre growth.
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Conclusions
Neutral insulin fibres are successfully made  in vitro when dialysed stock is
subject to continuous inversions on a revolving Stuart Rotator SB3 at room
temperature for 10 days. This is confirmed through ThT fluorescence, Congo
red birefringence, TEM imagery and CD analysis. 
The presence of SAP in these assays, at least in the case of insulin, can have
one of two effects depending on its conformation. When in its decameric state,
SAP  has  the  ability  to  reduce  total  fibre  mass.  Alternatively,  when  in  its
pentameric state SAP has the ability to increase total fibre mass. This would
imply that SAP (at least in the case of insulin) is capable of acting as both a
molecular  chaperone and a fibrillogenic enhancer;  it  has a dual  role.  This
behaviour of SAP is consistent and is directly proportional to its concentration.
When  submit  to  structural  techniques  such  as  TEM and  CD,  it  becomes
apparent that the cross β-sheet fibre morphology can vary depending on the
conditions in which it was developed. The most stable form is the typical rope-
like structure approximately 7-10nm in width and of indefinite length produced
in TE buffer conditions. The less stable ‘sickly’ and ‘slate like’ morphologies
are experienced in conditions of high salt and calcium respectively. It is not
clear as to how salt and calcium disrupt fibre formation but one can assume
that they become integrated into the fibre structure and thus disrupt optimum
binding of the insulin molecules. Upon inclusion of SAP to these conditions,
the  more  stable  rope-like  morphology is  resumed.  This  emphasises SAPs
involvement in fibre stability.
In addition to these results, another relevant fact was discovered. Cross β-
sheet  fibres are not  the sole product  of  in  vitro  fibrillogenesis.  Amorphous
aggregate is also produced. The amount of amorphous aggregate produced
again varies between samples of different conditions however a pattern can
be  determined.  When  SAP  is  not  involved,  there  is  a  direct  correlation
between  protein  concentration  and  cross  β-sheet  fibre  production.
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Approximately  80%  of  the  protein  is  converted  to  fibres  and  16%  into
amorphous aggregate (although his  figure is  considerably  lower in the TC
fibres - 21% ad 69% respectively due to the interference of calcium). Upon the
inclusion  of  SAP decamers  there  is  an  increase  in  amorphous  aggregate
production and a decrease in cross  β-sheet fibre production. This suggests
that either  the SAP decamers promote amorphous aggregate formation or
they promote refolding of unfolded aggregates. The latter is unsuccessful in
simplistic in vitro conditions, presumably, because of the lack of ATP and co-
chaperones. Upon the inclusion of SAP pentamers the reverse is seen. There
is a decrease in amorphous aggregate production and an increase in cross β-
sheet  fibre  production  supporting  the  theory  that  SAP  pentamers  are
promoting the formation of amyloid fibres.  
Perhaps SAP is the regulator of a reversible pathway between cross β-sheet
fibres and amorphous aggregate; it  maintains equilibrium between the two.
The  decamers  are  responsible  for  shifting  equilibrium towards  amorphous
aggregate and the pentamers are responsible for shifting equilibrium towards
cross β-sheets. The formation of amyloid diseases may simply be the result of
improper regulation of this reversible reaction. 
It is plausible that the cross β-sheet formation is a temporary storage solution
created  in  the  situation  where  an  excess  of  unfolded  intermediates  are
present in the serum. By encouraging fibre formation instead of amorphous
aggregate  formation  or  soluble  oligomerisation,  SAP  may  be  preventing
damage to the host. One must remember that in small quantities, cross  β-
sheet folding is not harmful. Only when present in large quantities do cross β-
sheet  fibres  become  problematic  as  they  prevent  organ  function  due  to
stiffening of the tissue. In comparison, soluble oligomers have been known to
be toxic e.g. Aβ oligomers in Alzheimer’s disease 
In fact, it is even reasonable to suggest that the role of SAP is to maintain
equilibrium between cross β-sheet fibres and the native protein. The body has
no use for amorphous aggregate so would not wish to produce it deliberately.
One could argue against this by highlighting the fact that vast amounts of
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amorphous  aggregates  were  produced  in  these  in  vitro  experiments,  not
native  protein.   Although  this  is  true,  amorphous  aggregate  was  regularly
produced in these in vitro experiments, this was likely to be the product of the
absence of ATP and co-chaperones. Had these been present, the native fold
may indeed have been reconstituted upon interaction with SAP decamers. 
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Chapter 3
Alternate Fibre Analysis
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Transthyretin (TTR) Fibre Analysis
Chapter Aims
Following  the  success  of  the  experiments  involving  insulin  fibres,  it  was
decided to carry out similar assays on fibres made form other proteins. This
was to ensure that the dual  behaviour of  SAP was in fact  universal  to all
proteins  and  not  just  unique  to  insulin.  By  carrying  out  the  above  on  a
minimum of two more proteins it may be possible for a general ‘rule’ on SAP
behaviour to be established. 
Again, it was vital that all fibre assays be performed at neutral pH rather than
the  acidic  conditions  normally  implemented  for  fibre  formation  due  to  the
inclusion of SAP. This was not only to prevent alterations in SAP structure and
function,  but  to  make  sure  that  any  results  obtained  could  be  directly
compared those obtained in chapter 2. 
In  order  to  monitor  SAPs  behaviour  with  respect  to  another  protein  the
following steps were proposed:
 Produce alternate protein fibres in vitro at neutral pH using the rotator
method established in chapter 2 
 Expose one set of fibres to SAP pentamers during growth.
 Expose another set of fibres to SAP decamers during growth.
 Leave  one  final  set  to  grow  without  SAP  interference  to  act  as  a
control.
 Use dyes, electron microscopy and other analytical techniques in order
to observe the effect of SAP on fibril formation and morphology.
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Transthyretin Structure and Function
The second protein chosen for SAP analysis was transthyretin (TTR). TTR -
formerly known as prealbumin - is another protein known to form fibres in vitro
but, as with insulin, only under acidic conditions. 
TTR is responsible for binding and transporting thyroxine and retinol (vitamin
A)  around  the  body  and  has  gained  its  name  in  doing  so  -
transports thyroxine and retinol.  In  fact,  TTR functions in  conjunction with
two other  thyroid  hormone-binding proteins in  the serum: thyroxine-binding
globulin and albumin. Of these, thyroxine-binding globulin is present at the
lowest concentration but has the highest affinity. Albumin is the reverse and is
present at the highest concentration of the three but has the lowest affinity.
Unlike albumin, which has a half-life of approximately 20 days, the turnover
rate for TTR is rapid with a half-life of only 2–3 days. It is produced in the liver,
secreted into the serum and finally catabolized in the kidneys. It  has been
noted that small quantities of TTR are also synthesised in the choroid plexus
and retinal pigment epithelium and is secreted into the cerebrospinal fluid and
eye respectively (Murrell et al. 1992). 
In the serum TTR exists predominantly as a homotetramer with each of its
four  identical  monomers  being  127  residues  in  length.  Each  monomer  is
structured into eight beta strands (A-H) and folded into a β-sandwich. When
scrutinised  further,  one  can  see  that  the  sandwich  consists  of  two,  four
stranded beta sheets (CBEF and DAGH) and is held together by loops and a
nine residue -helix connecting strands E and F ɑ- (Figure 43). 
In order for the homotetramer to form, initially two monomers must interact
with  one  another.  They  bind  via  hydrophobic  interactions  which  occur
between  the  two  F  and  H  strands  of  neighboring  monomers.  The  final
tetramer structure is 55kDa in size, is very stable, and is produced when two
of these dimers interact face to face (Ciszak, Cody, and Luft 1992). 
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 Figure  43:  Ribbon  diagram  of  the  stable  TTR  homotetramer.  Each
monomer  is  approximately  14kDa  in  mass  and  is  represented  in  a
different colour.
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Transthyretin Amyloidosis
Transthyretin  amyloidosis  (ATTR)  is  a  term  used  to  describe  a  group  of
autosomal, dominant diseases caused by mutated TTR. With the exception of
senile  systemic  amyloidosis  (SSA)  -  which  develops  from  wild  type  TTR
accumulation - all ATTR mutations are inherited, however, they are not found
equally worldwide. Instead they are found in clusters within Portugal, Japan
and northern Sweden with a gene frequency of 1.5% (Zaros et al. 2008) (M.
Olsson et al. 2014). It must also be noted that although present in the body
from birth, the symptoms of mutated TTR do not occur until the 3rd, 4th or 5th
decade of a patients life. This is because the variant TTR requires several
decades  to  build-up  in  mass  before  it  becomes  problematic  (Planté-
Bordeneuve and Said 2011) (Pettersson and Konttinen 2010). 
As  with  insulin,  TTR  fibre  formation  requires  the  disassociation  of  the
homotetramer into monomers – this is the rate limiting step. Upon completion
of  this,  the  monomers  are  able  to  undergo  the  significant  conformational
changes required for amyloid fibre formation  (Hammarström et al. 2003). Wild
type TTR is usually an extremely stable structure, however, when a mutation
is present the stability of the TTR homotetramer is compromised leading to
the  dissociation  of  the  quaternary  structure.  Sometimes  only  a  single
monomer of the quaternary structure carries a mutation where as in other
occasions two, three or even all four monomers may carry it. 
Mutations  in  TTR are  relatively  rare  affecting  only  1  in  100,000  cases  of
amyloid, however, TTR mutations must not be treated lightly as they induce a
wide  set  of  symptoms  and  are  fatal  (Planté-Bordeneuve  and  Said  2011)
(Pettersson and Konttinen 2010). 
ATTR is a form of systemic amyloidosis. This means that symptoms are not
limited to  a single organ but  instead affect  various organs simultaneously.
These include the heart, kidneys, gastro intestinal tract, peripheral autonomic
nerves, connective tissue of the carpal ligament and the eyes. The reason
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that such a vast array of conditions are experienced with TTR amyloidosis is
due to the fact that ATTR is caused by point mutagenesis which is not limited
to a single specific point.  Alterations can occur at  various points  along its
sequence. 
The TTR gene is located on chromosome 18q12.1. More than 120 mutations
have been found on this gene, nearly all  of which are amyloidogenic. This
includes single mutations, compound heterozygotes and deletions.  These all
lead to a collection of different symptoms which are uniquely categorised into
different categories of ATTR. The first and most common of these is when
valine at  residue 30 is  replaced by a methionine forming something more
commonly  referred  to  as  familial  amyloid  polyneuropathy (FAP)  (Coelho
1996).  Alternatively,  familial  amyloid  cardiomyopathy (FAC)  is  the  name
chosen when valine 122 is replaced by isoleucine (Jacobson et al. 1997) and
other  examples  include  Familial  euthyroid  hyperthyroxinemia  and  Senile
systemic amyloidosis (SSA). 
The most common mutation, Val30Met a.k.a. FAP, is responsible for 85% of
ATTR cases. It is known to affect the peripheral autonomic nerves, connective
tissue of the carpal ligament, heart, kidneys, gastrointestinal tract and eyes.
(Tantau, Laszlo, and Laszlo 2015). In FAP, initially it is only the lower limbs
that  are  affected  but  over  time  this  spreads  to  the  thighs,  upper  limbs,
forearms  and  fingers  as  the  anterior  trunk  is  involved.  Symptoms  include
discomfort,  numbness  and  spontaneous  pain;  similar  to  carpal  tunnel
syndrome (Ando et al. 2013). A large number of patients with TTR-FAP are
often mis-diagnosed with carpal  tunnel syndrome and only when a lack of
improvement is noticed following carpel tunnel syndrome surgery does correct
diagnosis occur (Planté-Bordeneuve and Said 2011).
ATTR is notorious as it  frequently affects the heart and is often fatal  as a
result  of  this.  To date,  a total  of  14 TTR mutations have been associated
specifically with cardiac-predominant familial disease. Nine of these develop
an exclusive cardiac phenotype whereas five TTR mutations (Gly30, Arg53,
Ser64, His69, Cys114) have also been associated with the nervous system,
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manifesting  as  dementia  or  cerebral  haemorrhage  (Tantau,  Laszlo,  and
Laszlo 2015).
Examples  of  mutations  involved  in  cardiac  amyloidosis  are  Val122Ile,
Thr60Ala,  Ile68Leu,  Leu111Met  and  Ser77Tyr.  The  Val122IIe  mutation  in
particular  is  associated  with  a  late-onset  amyloid  cardiomyopathy
characterized by progressive severe heart failure  (Moreira et al. 2010). The
consequences  of  these  mutations  include  increased  thickness  of  both
ventricular walls and the interventricular and atrial septums. Deposition of the
amyloid  on  the  heart  and  specifically  in  the  electrical  conduction  system
ultimately  results  in  unpredictable  arrhythmia  episodes  and/or  severe
conduction disorders. These include high degree atrioventricular blocks with
faintness, or even sudden death (Banypersad et al. 2012) (Falk 2005).
Diagnosis and Treatment of ATTR
Diagnosis of both cardiac and neurodegenerative related ATTR is difficult due
to the vast array of symptoms. In fact, diagnosis of any form of TTR related
amyloidosis is difficult to diagnose due to the extensive collection of diseases
related to this particular protein. Be that as it may, a few methods are being
used in clinics today. 
The  first  non-invasive  test  of  choice  for  cardiac  amyloidosis  diagnosis  is
echocardiography,  or  more  simply  put,  a  sonogram  of  the  heart.  The
increased ventricular wall  thickness and diastolic dysfunction is one of the
earliest echocardiographic found abnormalities. Another test frequently used
is  cardiac  MRI.  This  provides  important  information  by  illustrating  the
restrictive  cardiomyopathy  and  wall  hyperechogenicity  (O’Hara  and  Falk
2003). Finally, Congo red staining can be used alongside iodine123 labelled
SAP and TTR gene sequencing as a way to establish TTR amyloidosis.
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Following ATTR diagnosis the life expectancy for patients is approximately 10
years following symptom onset. To help prolong this, liver transplantation has
become the standard treatment form especially in the case of patients with
FAP. Transplantation replaces the variant TTR gene with the wild type gene in
the liver and causes variant TTR serum concentration to decrease reaching
almost zero. However, following transplantation the rate of survival at 5 years
is only 59% for non Val30Met patients and 82% for Val30Met patients (Nelson
et al. 2013). The disease may progress particularly in patients with mutations
which are non-Val30Met. This is as a result of the deposition of wild-type TTR
fibrils on pre-existing amyloid matrix. Combined heart and liver transplant is
therefore proposed on highly selected patients. 
Recently a new method has been developed to help control FAP in particular.
Tafamidis  and  diflunisal  are  two  drugs  that  are  undergoing  clinical
development worldwide. Tafamidis is a novel TTR stabilizer and diflunisal is a
nonsteroidal anti-inflammatory drug that can stabilize TTR tetramers. Suhr et
al. conducted  an  18  month  trial  which  evaluated  the  status  of  TTR-FAP
patients treated with tafmidis. They used the patients BMI as a way to monitor
overall health and improvement. Following the 18 months they observed that
the BMI improved in the tafamidis group and worsened in the placebo group.
The placebo group was subsequently treated with tafmidis and their BMIs also
increased  (Suhr  et  al.  2014).  The  drug  generally  caused  no  harm to  the
patients  and  little  progression  was  observed  in  amyloid  cardiomyopathy
during the course of treatment. However, these drugs do have gastrointestinal
side effects and vaginal and urinary tract infections may appear.
TTR Fibre Formation in Vitro
Wild  type  TTR  has  shown  to  be  extremely  resistant  to  aggregation  at
physiological  pH  due  to  the  tetramer  being  extremely  stable  in  these
conditions  (Bourgault  et  al.  2011);  the  binding  of  a  single  ligand  alone  is
enough  to  completely  prevent  amyloidosis.  Various  lab  groups  have
demonstrated this in vitro. They have shown that in addition to thyroxine and
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retinol,  TTR has the ability  to  bind numerous other  small  molecules in  its
thyroxine  binding  sites.  These  include  many  natural  products  (such
as resveratrol), drugs (Tafamidis or Vyndaqel, diflunisal, flufenamic acid), and
toxicants (polychlorinated biphenyl - PCB). Upon binding of these molecules,
TTR is  stabilised  and  unable  to  form  amyloid  fibres  (Razavi  et  al.  2003)
(Adamski-Werner et al. 2004) (Purkey et al. 2004) (Baures et al. 1999).
Studies using acidic conditions have shown that a lower pH can be used to
facilitate homotetramer dissociation, however there have been cases where
pH’s  as  low  as  4.6  have  still  not  induced  alterations  in  TTR  structure.
Significant structural changes are only noted when pH is lowered to 4 or less.
Further to this,  in 1992  Colon and Kelly  found that the optimum range for
producing TTR fibres is between pH 3.6 and 4.8. Above this range the stability
of the homotetramer is too strong and below this  the rate of fibril formation
decreases markedly. 
During their investigations Colon and Kelly also discovered some information
regarding  the  structure  of  their  TTR  fibres.  Using  Far  and  Near-UV  CD
methods they were able to demonstrate that under acidic conditions TTR has
the ability to retain the majority of  its tertiary form, even when part  of  the
cross-β sheet.  In  doing so they provided further evidence that  only  partial
denaturation  is  required  in  order  for  fibres  to  form  rather  than  complete
unfolding.  Some years  later  the  cause of  the  unfolding  was presented by
another  group.  In  2008  Palaninathan et  al.  discovered  that  under  acidic
conditions the EF helix (residues 75-90), the adjacent EF loop and part of the
beta-strands become unstructured allowing TTR fibres to form. 
Unfortunately,  in  order  for  any  TTR  results  to  be  comparable  to  those
produced with insulin in chapter 2 it was essential that fibres be created at
neutral pH, not acidic pH, preferably using the rotator method. Due to the high
stability of wild type TTR at physiological pH (and even at acidic pH!) it was
deemed unlikely that fibres would form using this method and any attempt to
do so would be futile. However, as a way to combat this, it was decided to use
less stable, mutant variants.
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L55P  and  S52P are  two  different  TTR  variants  known  to  dissociate  into
monomers under physiological conditions at 37°C as shown by Lashuel et al.
in 1999. In the L55P variants a proline residue has replaced the wild type
leucine at position 55 whereas in the S52P proline residue has replaced the
wild type serine at position 52. These mutations cause destabilisation of the
D-strand on the outer edge of the tetramer and result in the formation of a
disordered loop. The disordering of this loop facilitates tetramer dissociation
and  thus  provides  monomers  capable  of  unfolding  into  amyloid  prone
intermediates.  
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Methods
TTR Preparation 
Two different TTR mutants were used during the course of experimentation:
L55P and S52P. Each mutant was expressed and purified by a predecessor
of the Crystallography Lab at the Royal Free Hospital. Stock solutions were
stored in 25mM TRIS, 300mM NaCl buffer solution at a temperature of 4°C.
TTR Fibre Formation 
L55P and S52P TTR stocks were diluted to 1ml samples of 1mg/ml. This was
achieved  using  TE  buffer  in  a  1.5ml  eppendorf.  The  samples  were
continuously inverted – or “flipped” - at a speed of 20rpm on a revolving Stuart
Rotator SB3 for 10 days at room temperature as per the protocol for making
insulin fibres described in chapter 2. 
Sample TTR (5 mg/ml) TE Buffer dH2O Total TTR Concentration
1a 20 μl 800 μl 180 μl 0.1 mg/ml
To monitor the effect of protein concentration of fibre formation, TTR stocks
were diluted to 1ml samples of various concentrations ranging from 0.1mg/ml
-  1mg/ml.  This  was  achieved  using  TE  buffer  in  a  1.5ml  eppendorf.  The
samples were continuously inverted – or “flipped” - at a speed of 20rpm on a
revolving Stuart  Rotator  SB3 for  30 days at  room temperature as per  the
protocol for making insulin fibres described in chapter 2. This protocol was
repeated for both the L55P and S52P variants.
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Set up:
Sample TTR (5 mg/ml) TE Buffer dH2O Total TTR Concentration
1b 20 μl 800 μl 180 μl 0.1 mg/ml
1c 40 μl 800 μl 160 μl 0.2 mg/ml
1d 100 μl 800 μl 100 μl 0.5 mg/ml
1e  200 μl 800 μl - 1mg/ml
Fibre Formation with SAP decamers
To observe the effect of SAP decamers on TTR fibre growth, the “TTR Fibre
Formation”  method was repeated with  the addition of  0.2mg/ml  SAP. This
provided a stoichiometric ratio of 1:10 of SAP decamers to TTR respectively.
Each sample was continuously inverted at a speed of 20rpm on a revolving
Stuart  Rotator  SB3  for  30  days  at  room  temperature.  This  protocol  was
repeated for both the L55P and S52P variants. 
Sample TTR (5
mg/ml)
TE
Buffer
SAP
(6.66mg/ml)
dH2O Total TTR
Concentration
2a 20 μl 770 μl - 210 μl 0.1 mg/ml
2b 20 μl 770 μl 30 μl 180 μl 0.1 mg/ml
2c 40 μl 770 μl - 190 μl 0.2 mg/ml
2d 40 μl 770 μl 30 μl 160 μl 0.2 mg/ml
2e 100 μl 770 μl - 130 μl 0.5 mg/ml
2f 100 μl 770 μl 30 μl 100 μl 0.5 mg/ml
2g  200 μl 770 μl - 30 μl 1mg/ml
2h  200 μl 770 μl 30 μl - 1mg/ml
Fibre Formation with SAP Pentamers
To perform this particular assay the SAP was diluted to 0.2mg/ml using TC
buffer. This was left to incubate for half an hour to ensure saturation of SAP
calcium pockets. Following this, various concentrations of TTR were added
and  the  samples  were  continuously  inverted  at  a  speed  of  20rpm  on  a
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revolving Stuart Rotator SB3 for 30 days at room temperature. This protocol
was repeated for both the L55P and S52P variants.
Sample TTR (5
mg/ml)
TC
Buffer
SAP
(6.66mg/ml)
dH2O Total TTR
Concentration
3a 20 μl 770 μl - 210 μl 0.1 mg/ml
3b 20 μl 770 μl 30 μl 180 μl 0.1 mg/ml
3c 40 μl 770 μl - 190 μl 0.2 mg/ml
3d 40 μl 770 μl 30 μl 160 μl 0.2 mg/ml
3e 100 μl 770 μl - 130 μl 0.5 mg/ml
3f 100 μl 770 μl 30 μl 100 μl 0.5 mg/ml
3g  200 μl 770 μl - 30 μl 1mg/ml
3h  200 μl 770 μl 30 μl - 1mg/ml
Control
To see  the  effect  the  salt  was  having  on  TTR fibre  formation  the  rotator
assays  were  repeated  in  a  High  Salt  buffer  (“THS Buffer”  -  20mM TRIS,
600mM  NaCl,  0.01%  Na  Azide,  pH8).  A  range  of  TTR  concentrations
spanning 0.1-1mg/ml of were continuously inverted at a speed of 20rpm on a
revolving Stuart Rotator SB3 for 30 days at room temperature in the presence
and absence of 0.2mg SAP. This protocol was repeated for both the L55P
and S52P variants.
Sample TTR (5
mg/ml)
THS
Buffer
SAP
(6.66mg/ml)
dH2O Total TTR
Concentration
4a 20 μl 770 μl - 210 μl 0.1 mg/ml
4b 20 μl 770 μl 30 μl 180 μl 0.1 mg/ml
4c 40 μl 770 μl - 190 μl 0.2 mg/ml
4d 40 μl 770 μl 30 μl 160 μl 0.2 mg/ml
4e 100 μl 770 μl - 130 μl 0.5 mg/ml
4f 100 μl 770 μl 30 μl 100 μl 0.5 mg/ml
4g  200 μl 770 μl - 30 μl 1mg/ml
4h  200 μl 770 μl 30 μl - 1mg/ml
TTR Fibre Analysis using ThT
Please refer to the ‘Fibre Analysis using ThT’ section in chapter 2.
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Fibre Detection using Congo red 
Please refer to the ‘Fibre Detection using Congo red’ section in chapter 2.
Fibre Analysis using Circular Dichroism
Please refer to the ‘Fibre Analysis using Circular Dichroism’ section in chapter
2.
Fibre Formation in Alternate Conditions
Fibre Formation via Seeding 
Each variant of TTR was “seeded” in an attempt to catalyse fibre growth. This
was attempted two ways:
The first way involved repetition of the “TTR Fibre Formation” method with an
additional 30 μl (0.03mg) of either pre-aggregated TTR or insulin added to the
new assay. This mixture was subsequently rotated for 10days at 20rpm on a
revolving Stuart Rotator SB3. 
The  second  method  involved  using  sodium  acetate  buffer  at  pH5  and  6
(50mM  sodium  acetate,  100mM  potassium  chloride)  as  taken  form  the
Takahiro Tajiri (2002) protocol. Here, 0.2mg/ml off TTR was incubated in this
buffer for 10 days at 37°. This, again, was attempted with and without 30 μl
(0.03mg) TTR aggregate and Insulin fibre “seeds”
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Fibre Formation – Tajiri Protocol (Takahiro Tajiri 2002)
Each variant  of  TTR was diluted to  the  following range of  concentrations:
0.1mg/ml, 0.2mg/ml, 0.5mg/ml and 1mg/ml. This was achieved using sodium
acetate buffer (50mM sodium acetate, 100mM potassium chloride, pH5) and
incubated at 37°C for 10 days. This was later repeated at pH 6 and 7 with and
without the addition of 0.2mg/ml SAP
Sample TTR (5 mg/
ml)
Takahiro
Buffer
SAP (6.66mg/
ml)
dH2O Total TTR
Concentration
5a 20 μl 770 μl - 210 μl 0.1mg/ml
5b 20 μl 770 μl 30 μl 180 μl 0.1 mg/ml
5c 40 μl 770 μl - 190 μl 0.2 mg/ml
5d 40 μl 770 μl 30 μl 160 μl 0.2 mg/ml
5e 100 μl 770 μl - 130 μl 0.5 mg/ml
5f 100 μl 770 μl 30 μl 100 μl 0.5 mg/ml
5g  200 μl 770 μl - 30 μl 1 mg/ml
5h  200 μl 770 μl 30 μl - 1 mg/ml
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Fibre Formation – Kugimiya Protocol (Kugimiya et al. 2011)
A total  of 1.75mg/ml of each TTR strain was incubated at 37°C in sodium
acetate buffer for  5 days in the dark (20 mM sodium acetate and 100 mM
NaCl at pH 3.0). SAP was not added to this assay due to the highly acidic
conditions which would likely alter its structure and function.
Sample TTR (17.5
mg/ml)
PBS Buffer Total TTR
Concentration
6a 100 μl 1400 μl 1.2mg/ml
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Results and Discussion
TTR Fibrillogenesis (Rotator method)
L55P and S52P TTR stocks were diluted to concentrations of 0.2mg/ml and
made up  to  1ml  using  TE buffer  (pH 8).  The  samples  were  continuously
inverted – or “flipped” - at a speed of 20rpm on a revolving Stuart Rotator SB3
for  10  days  at  room  temperature  and  the  results  analysed  via  ThT
fluorescence.
Within  the  first  3  or  4  days of  inversion,  as  per  the  insulin  assays,  white
precipitates developed in both the L55P and S52P TTR variant samples. This
precipitation  increased  in  density  over  the  course  of  2-3  days  and  then
appeared to remain constant for the rest of the protocol. The total amount of
precipitant  produced was  considerably  lower  to  what  had previously  been
seen.  Only approximately  1/6 of  precipitate was produced compared to the
insulin assays. On the tenth day the TTR samples underwent ThT analysis in
order  to determine whether  the precipitate  was cross  β-sheet in  nature or
amorphous aggregate. Unfortunately, in the case of TTR, neither the L55P
nor the S52P variant showed enhanced fluorescence between wavelengths
420nm and 600nm on a spectrophotometer.  This suggests that the rotator
method  had  only  produced  amorphous  aggregate  and  not  cross  β-sheet
fibres. This was verified using Congo red analysis. Here the samples showed
no apple green birefringence under polarised light.
This  was  an  unexpected  result.  The  rotator  method  had  proven  to  be
overwhelmingly successful in the case of the protein insulin. It may be true
that wild type TTR is extremely resistant to aggregation at physiological pH
due to tetramer stability, however, both mutants (L55P and S52P) are known
for their high tendency to dissociate into monomers in vitro as discovered by
Lashuel et al.
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Further investigation of the literature suggested various explanations as to
why cross β-sheets had not been produced.  Lashuel explains that high TTR
concentrations can restrict fibre formation. Lashuel also indicates that aged
L55P TTR, in particular, has a tendency to form soluble aggregates which can
interfere with  experiments.   Upon discovery of these facts,  all  TTR stocks
were treated as suggested in this paper. They were subject to centrifugation
at 50,000 rpm followed by filtration through a 0.2μm membrane so to remove
the vast majority of soluble aggregates. Following this treatment the rotator
protocol was repeated with a few alterations in an attempt to encourage fibre
growth.  These  alterations  included  sample  concentration,  rotator  speeds,
temperature, protocol duration, buffer conditions and SAP incorporation.
Samples  of  each  variant  were  diluted  to  varying  protein  concentrations
ranging from 0.1-1mg/mg. This was done in all three buffer types previously
used for insulin fibre formation - TE buffer, TC buffer and THS buffer – in the
presence  and  absence  of  SAP.  These  were  all  submitted  to  the  rotator
method using various speeds of 2-30 rpm, (the minimum and maximum speed
respectively) for a longer duration of one month. Replicas of these assays
were also subject to incubation at 37°C with/without agitation.  Sadly, none of
these methods produced cross  β-sheet fibres. All samples developed white
precipitates but all were amorphous in nature according to ThT and Congo
red analysis. 
Structural analysis using the CD technique supported these findings (Figure
38). The spectrum shows a curve of TTR aggregate compared to its insulin
fibre counterparts. This particular TTR sample demonstrated in the spectrum
was produced from the inversion of 0.2mg/ml L55P TTR in TE buffer for one
month  -  The  other  samples  from  both  variants  produced  almost  identical
curves but were excluded from the graph for  display purposes. The curve
produced was typical of neither  α-helices nor β-strands. This was true of all
samples produced from both TTR variants. They each produced a very broad
curve just above the base line with no x axis interception point. This indicates
that the aggregates formed using the TTR variants contained no secondary
structure and was indeed amorphous in nature.
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What  this  suggests  is  that  the  conditions  used on the  TTR variants  were
sufficient to allow denaturation of the TTR molecules but not optimal to allow
cross  β-sheet  formation.  Perhaps  the  TTR  molecules  were  not  in  their
monomeric form when aggregation occurred thus would not  assemble into
cross β-sheets. Alternatively it is possible that cross β-sheet fibres were being
made  in  conjunction  with  amorphous  aggregate  but  just  at  very  low
concentrations.  The insulin  assays from chapter  2 clearly  demonstrate the
ability of proteins to make both cross β-sheet fibres and amorphous aggregate
simultaneously. They have also shown that the ratio of fibres and aggregate
varies depending on the conditions in which they were made. It  is entirely
possible that TTR, being a different protein to insulin, would behave differently
in these assay conditions and thus produce a different ratio of cross β-sheet
fibres to amorphous aggregate. It  is  possible that cross  β-sheet fibres  are
present in the assays but just in very small quantities.  
Upon further scrutiny of the TTR results using the ThT method, it was noticed
that  a  negligible  ‘blip’  of  ThT  fluorescence  can  be  seen. The
spectrophotometer  shows  enhanced  fluorescence  between  wavelengths
420nm and 600nm with a peak of approximately 2 at 476.5nm (Figure 44). At
first this reading was considered anomalous due to its small size, however,
every sample produced this ‘blip’ where as native TTR did not.  Although this
was a very small, but promising, development, the presence of cross β-sheet
fibres still had to be confirmed using an alternative method so to confirm this
was not a false positive result.
When  magnified  to  x1600  on  a  Zenith  Microlab  ML-1000M  Monocular
Laboratory  Microscope  60040,  the  Congo  red  slides  of  each  TTR  assay
confirmed very small  amounts of fibres. All  samples showed specks of the
apple green birefringence typical of cross-β sheets under polarised light. This
would  suggest  that,  in  very  small  amounts,  TTR cross  β-sheet  fibres  are
indeed being formed using the rotator method at neutral pH in all three buffer
types. This is true of both mutants and can be replicated (Figure 45). 
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Figure 44: (Above) A bar graph comparing average ThT fluorescence of
neutral TTR fibres created in  TE buffer  and TC buffer  via the rotator
method alongside acidic TTR fibres created via the Tajiri and Kugimiya
protocol.  Each bar  is  an average of  three samples  and experimental
error  bars  are  displayed.  The  fibres  grown  in  TE  buffer  reached  an
average peak in fluorescence of 3.8 where as those grown in TC buffer
produce  an  average  of  1.6.  Those  grown  in  via  the  Tajiri  and  the
Kugimiya protocols produced fluorescence intensities of 12.0 and 4.6
respectively. (Below) A graph comparing the aforementioned TTR fibres
with TE insulin  fibres grown using the rotator  method at  neutral  pH.
Insulin fibres reach an average fluorescence intensity of 871.2.
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Figure 45: A photograph of TTR fibres stained with Congo red grown in
TE buffer via the rotator method.  The image was viewed using a Zenith
Microlab  ML-1000M  Monocular  Laboratory  Microscope  60040  at  a
magnification of  x1000.  The sample shows traces of  the apple  green
birefringence typical of cross-β sheets under polarised light. 
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Unfortunately, due to the miniscule amounts of fibre it is difficult to compare
TTR results to those previously obtained by insulin. Also, the different effect (if
any) of SAP pentamers and decamers on each mutant is not distinguishable.
Due to this, alternate methods of forming TTR fibres had to be carried out.
Fibre Formation via Seeding
‘Seeding’ was another method used to attempt TTR fibre formation. “Seeding”
is a method that is able to catalyse fibre growth. It involves the addition of pre-
formed fibre  nuclei  to  a  solution  of  soluble  protein.  In  doing  so,  the  time
consuming lag phase often seen in fibre growth is eliminated and rapid fibre
formation is achieved.
Seeding is normally performed between variants of the same protein therefore
it  was  attempted  to  ‘seed’  fresh  TTR assays  with  30  μl  (0.03mg)  of  pre-
aggregated TTR. The specks of apple green birefringence and increased ThT
fluorescence  demonstrated  that  cross  β-sheet  nuclei  had  indeed  formed.
These nuclei have the ability to catalyse cross β-sheet growth  in vitro.  After
rotation for 10 days with the ‘seed’ however there was no improvement on
fibre  amounts.  Again,  a  white  precipitate  was  formed  but  it  was  mostly
amorphous aggregate in nature. This result is most likely due to the fact that
in the pre-formed TTR fibres, the cross β-sheets were in such small quantities
that there was no guarantee that  they would be present in the 30 μl sample
added to the fresh assay. It would be more beneficial to separate the small
amount  of  TTR  fibres  from  the  amorphous  aggregate  and  then  seed,
however, it  is impossible to separate the two substances. Both amorphous
aggregate and cross  β-sheet fibres are white solids.  They each have very
similar, if not identical, densities and are made of the same protein. 
Attempts were made to seed the TTR variants using insulin fibres. It has been
shown in literature that cross-species seeding is possible,  however,  this is
usually only successful when both proteins have significant tertiary structural
similarity  as explained by Ma and Nussinov in 2012. The structure of insulin
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has already been described in chapter 2 as being a predominantly helical
structure where as TTR exists mostly as β-sheets. This indicates that the two
are not compatible with regards to seeding as was demonstrated. This was
verified when TTR failed to produce  cross  β-sheet fibres upon seeding with
insulin fibres.
Fibre Formation in Alternate Conditions 
Another method implemented in an attempt to increase TTR fibre amounts
was with the use of  acidic buffers.  This  was not  an ideal  experiment with
regards to this investigation due to two reasons: The first being that acidic
conditions are not necessarily representative of the conditions experienced
within  the  body.  The second is  that  the  acidic  conditions  could  affect  the
interaction of SAP with fibres due to the occurrence of SAP denaturation. It
was  chosen,  however,  to  attempt  acidic  fibre  formation  regardless  so  to
ensure  that  TTR fibre  formation  was possible  to  the  same extent  as  with
insulin. 
Tajiri  et al.  had found success in forming TTR fibres using sodium acetate
buffer  in 2002.  An attempt was made to  replicate this.  Each sample went
cloudy after three days and was scrutinised using ThT upon completion of the
protocol.  Again,  initially  it  appeared  that  this  method  had  also  been
unsuccessful.  Under  further  scrutiny,  however,  minuscule  amounts  of  fibre
were  detected  using  ThT.  Approximately  3  times  more  TTR  fibre  was
experienced with this protocol than with the rotator method at neutral pH. A
ThT peak reading of 12  ±28.2% was achieved. The Kujimiya protocol from
2011 yielded similar success. A peak reading of 5  ±28.2% was achieved –
similar to the neutral rotator method in TE buffer. From figure you can see that
of all these methods the TC rotator fibres produced the smallest amount of
fibres at on 1.65. However, these results are so small and the instrumental
error margins so large in comparison that this observation is not justified. Also,
when compared to the insulin fibre fluorescence in figure all the TTR results
become negligible. 
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Conclusion
Although wild type TTR is notorious for resisting monomerisation even at very
low  pH,  the  L55P  and  S52P  variants  are  not.  Therefore,  the  difficulty
experienced in obtaining fibres in this chapter was unexpected. 
It  is  not  completely  clear  as  to  where  the  fault  lay  in  these  particular
experiments.  It  is  true  that  the  variant  TTR  samples  used  during
experimentation were a year old,  however proper measures were taken to
ensure removal of  obstructive, solubilised components.  Perhaps it  was the
storage of  the TTR variants which  led to  the  lack of  results.  It  may have
proven to be more successful to freeze the stocks at lower concentrations in
order to prevent oligomerisation form occurring. 
When looking at the pre-existing literature one will notice that the many of the
papers illustrating TTR fibres made in vitro have done so using ThT analytical
methods  alone.  The  unreliability  of  this  method  has  already  been  stated
various  times  in  chapters  1  and  2.  ThT  is  known  to  undergo  enhanced
fluorescence following non–specific binding to bacteria, connective tissue and
genetic material such as DNA and RNA. Perhaps a percentage of these ‘TTR
fibres’ found in literature are not cross  β-sheet fibres at all. False positives
could have occurred and there is not enough evidence to dictate otherwise.
Not all the papers have used alternative methods to verify the presence of the
cross β-sheets so this is entirely plausible.
Also, when looking at fluorescence intensity it is important to remember that
the  numbers  obtained  from  each  spectrophotometer machine  cannot  be
directly  compared  to  those  of  another  machine.  The  resulting  intensity
numbers  are  determined  by  the  software,  the  detector  systems,  the
electronics and filtering,  etc  of  the machine in  question thus making them
unique and of no units. This could explain why when carrying out the acidic
protocols on the two TTR variants – the protocols known to produce TTR fibre
as confirmed in the literature – only a very small ThT peak was observed. It is
possible that TTR cross β-sheet fibre amounts obtained in this chapter were
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the  same  as  in  the  literature  but  the  different  spectrophotometers  are
generating different numbers. Perhaps insulin produces such a vast amount
of fibres that it is making the TTR results appear insignificant in comparison. 
Another reason for taking extreme care when comparing fibres from different
papers is that a number of factors are known to affect fluorescence intensity;
factors which scientists are not always considerate of or aware of. Different
environmental conditions, the specific protein involved, fibril morphology, ThT
concentration, pH, and ionic strength can all have an affect on fluorescence.
There is no consistency within the literature regarding ThT concentration or
environmental conditions in which the TTR ‘fibres’ were formed. This means
that pre-existing literature regarding TTR fibres cannot be compared to one
another  let  alone  to  the  results  obtained  here.  Only  by  attempting
fibrillogenesis with an alternate protein can matters be clarified.
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Amyloid Beta (Aβ) Fibre Analysis
Amyloid Beta (Aβ) Structure and Function
Amyloid Beta (Aβ) was the final protein chosen to undergo fibre analysis with
SAP. It was chosen due to the fact that it is a natively unfolded protein. By
existing  in  such  a  form,  any  issues  regarding  monomerisation  of  stable
quaternary structures are eliminated. This in turn should make amyloid prone
intermediates easy to obtain. 
Aβ  derives  from  the  cleavage  of  amyloid  precursor  protein  (APP),  a
transmembrane protein  expressed at  high  concentrations  in  the  brain  and
neuron synapses of the nervous system. In order to produce Aβ from APP,
the  APP  molecule  is  cleaved  in  its  transmembrane  region  by  secretase
enzymes β and .ɣ.  It should be noted that cleavage via the β- and γ-secretases
can be promiscuous and often results in several isoforms of Aβ fragments
being produced,  some of  which  are more amyloidogenic  than others.  The
protein chain can range between 30 and 51 residues in length with the most
common isoforms being Aβ40 and Aβ42 (F. Olsson et al. 2014) 
At present, the physiological role of Aβ is unknown but various theories have
been presented. Tabaton et al. believe Aβ to be involved in the activation of
kinase enzymes, in particular, the ones responsible for its own production; β
and γ secretase enzymes. They noticed that Aβ, when in high concentrations,
has the ability to behave as an extracellular signalling peptide. It  begins a
cascade which regulates both β– and γ–secretase activity,  thus regulating
both steps of its own cleavage from the Aβ precursor protein. This in turn
creates more Aβ and begins a positive loop effect on Aβ production (Tabaton
et al. 2010).  Alternatively, multiple studies have shown Aβ to protect neurons
either  by shielding them against oxidative stress,  or  through the regulation
of cholesterol transport  (Zou et al.  2002) (Yao and Papadopoulos 2002). All
the same, a number of animal studies have demonstrated that physiological
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function is not disrupted in the absence of Aβ, implying that its role can be
considered negligible (Luo et al. 2003). 
Aβ Amyloid Development
Under  normal  conditions,  there  is  equilibrium between the  production  and
elimination of Aβ that maintains Aβ at constant levels. This is referred to as
the  steady  state  (Shankar  and  Walsh  2009).  However,  in  aging  and
excitotoxicity, the steady sate is disrupted leading to an accumulation of Aβ
and senile plaque formation. 
An  example  of  the  steady  state  being  disrupted  can  be  explained  in
conjunction  with  β-Site  APP-cleaving  enzyme  1  (BACE1)  -  the  major  β-
secretase in the brain - and γ-secretase. Upon cleavage of APP by BACE1, a
neurotoxic form of  Aβ is created in  the form of  the C99 fragment.  This  is
further cleaved by γ-secretase to produce the final Aβ chain  (Cheng et al.
2011). Aβ amyloid often occurs when the regulation of the proteolytic function
of γ-secretase is compromised resulting in high concentrations of neurotoxic
C99 chains. This often happens when the multi-subunit γ-secretase complex
is compromised. γ-secretase is made up of  four core proteins: presenilin 1
(PSEN1) and 2 (PSEN2), nicastrin and   anterior pharynx-defective 1 (APH-1).
Mutations in any of these four result in the increased ratio of Aβ in early-onset
forms of Alzheimer’s disease (Ridge, Ebbert, and Kauwe 2013). 
Another  way  in  which  Aβ  imbalance  can  be  caused  is  through  improper
clearance of the protein from the brain. Clearance can happen in a number of
different  ways.  These  include  with  P-glycoprotein  and  with  low-density
lipoprotein  receptor-related  protein  1  (LRP1).  In  2005  Cirroto  et  al.
demonstrated  that  removal  of  P-glycoprotein  enhanced   deposition  in  the
brain of an Alzheimer’s disease mouse model  (Cirrito et al. 2005) and more
recently  in  2013  Kanekiyo  et  al. showed  an  increase  of  amyloid  plaque
deposition in the cortex in LRP1 knock out mice (Kanekiyo et al. 2013).
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A final  way in which Aβ clearance can be regulated is through the use of
degrading peptidase enzymes,  in  particular,  neprilysin  enzyme and  insulin
degrading enzyme. Studies have shown that neprilysin knockout mice have
increased  levels  of  Aβ  peptides  in  the  brain.  Moreover,  the  activity  of
neprilysin is reduced in the cortex and hippocampus of Alzheimer’s patients
(Caccamo et  al.  2005).  In  the  case  of  insulin  degrading  enzyme,  genetic
studies  have  shown  that  insulin-degrading  enzyme  gene  variations  are
associated with the clinical symptoms of Alzheimers disease (W. Q. Qiu and
Folstein 2006).
Alzheimer’s Disease
Although  often  associated  with  Alzheimer’s,  Aβ  is  not  the  sole  protein
responsible  for  this  particular  disease.  It  is  found  in  conjunction  with
intracellular  neurofibrillary  tangles  containing  tau  protein.  Intracellular
neurofibrillary  tau  tangles  are  similar  to  amyloid  plaques  in  that  they  are
formed from cross β-sheet fibres, however, they remain as such and do not
associate  with  extracellular  matrix  proteins  and  proteoglycans.  Another
difference  between  the  Aβ  plaques  and  the  tau  tangles  is  their  site  of
deposition.  Aβ  plaques  are  found  between  brain  nerve  cells  (neurons)
whereas tau tangles are found within the neurons themselves (Butterfield and
Boyd-Kimball  2004) (Ittner  et  al.  2010).   The  accumulation  of  these  two
proteins  causes  damage in  the  neurons  resulting  in  mental  and  cognitive
deficits such as impaired memory, intellect and personality disorder (Khatami
2012). Collectively, Alzhemer’s disease related problems reduce quality of life,
cause  physical  disability  and  ultimately  decrease  life  expectancy  (C.  Qiu,
Kivipelto, and von Strauss 2009) (Figure 46).
Alzheimer’s  disease  is  considered  to  be  the  most  widespread
neurodegenerative  disorder  in  the  world.  It  is  responsible  for  75%  of  all
dementia cases and affects approximately 35.6 million people. This number is
believed to be increasing in correlation to population aging and it is estimated
that 106.8 million people will be affected by 2050 (Nordberg 2008). 
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Figure  46:  (Left)  Comparison  of  normal  neurons  with  those  disrupted  with  plaques  and  neurofibrillary  tangles.  The
amyloid plaques are located between the neurons and are composed of  Aβ fibrils,  extracellular  matrix  proteins and
proteoglycans.  The  tangles  are  made  from  tau  fibril  alone  and  are  located  within  the  neuron  themselves.  (Right)
Comparison of normal brains with those mildly and severely disrupted from Alzheimer’s (Bright Focus,  2015).
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Alzheimer’s  disease  can  be  either  inherited  (familial)  or  spontaneous
(sporadic).  The familial  version arises due to  mutations within  the amyloid
precursor protein (APP) gene whereas the sporadic version occurs when an
extra copy of the APP gene is produced. Aβ amyloidosis can also be caused
by defects in its regulatory enzymes as explained above  (Nunomura et al.
2006). 
Another point to consider is that in their aggregated form, Aβ peptides are
able to induce neurotoxicity (Moreira et al. 2010). Neurotoxicity refers to tox-
icity in the nervous system. It  occurs when exposure to natural or artificial
toxic substances (neurotoxins) alters the normal activity of the nervous system
in such a way as to cause damage to nervous tissue. Aβ aggregates induce
this by provoking nitric oxide formation and an influx of calcium ions.  This dis-
rupts synaptic functions and can eventually lead to the formation of peroxyni-
trite radicals and cell death (Kihara and Shimohama 2004). Unfortunately the
precise mechanism of this is still unknown. Interestingly, the accumulation of
soluble Aβ oligomers (nonfibrillar),  has the same neurotoxic effects  (Hardy
and Selkoe 2002). This indicates that neurotoxicity is induced through high
concentrations of Aβ rather than by the cross β-sheet structure itself.
Treatment
Various  drug  treatments  have  been  used  over  the  years  for  Alzheimers
disease  including  cholinesterase  inhibitors,  memantine  and
anti-depression/anxiety  drugs.  These treatments  do  not  slow  or  stop  the
progression of the disease, but they may help with the symptoms for a time.
The  reason  for  this  is  that  none  of  these  treatments  act  on  the  plaques
themselves but instead reduce the effect of the chemical changes occurring in
the  body.  For  example,  the  cholinesterase  drug  acts  as
an acetylcholinesterase  inhibitor  thereby  inhibiting  the acetylcholinesterase
enzyme from  breaking  down acetylcholine,  Acetylcholine  is  the
neurotransmitter released by motor neurons of the nervous system in order to
activate  muscles.  By  increasing  both  the  level  and  duration  of  action  of
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the neurotransmitter acetylcholine  a  patient  is  able  to  maintain  a  greater
amount of muscular control. Moreover, memantine is a blocker of N-methyl-D-
aspartate receptors (NMDA receptors). The NMDA receptors are a glutamate
receptor and  an ion  channel protein found in the  nerve  cells.  It  is  activated
when glutamate and glycine bind to it, and when activated it allows positively
charged ions to flow through the cell membrane. The NMDA receptor is very
important for controlling synaptic plasticity and memory function.
Due to the inability to slow the progression of the disease, remarkable efforts
have been made to find diagnostic markers which predict the disease earlier.
Neuroimaging methods such as magnetic resonance imaging and positron
emission  tomography  have  been  developed  to  enable  researchers  to
diagnose Alzheimer’s disease in its early stages (Graham 2011). Also, several
biomarkers, which are crucial in detecting pathological features of AD, have
been found in cerebrospinal fluid (CSF) and can be assessed (Dubois et al.
2007). 
Although there is a great amount of literature on ex vivo samples of Aβ fibres
and its relation to Alzheimers disease, the literature on  in vitro Aβ fibres is
lacking.  Nevertheless,  it  was  discovered that  Lomakin et  al.  were  able  to
produce Aβ fibres in 1996 using 0.1M HCl. The fibres were produced using
Aβ1-40  at  room  temperature.  They  were  measured  using  lasers  and  light
scattering techniques alongside CD measurements.  Unfortunately, the exact
conditions used to create these fibres - pH, agitation etc - are not detailed in
this paper making the results difficult to compare with fibre works from other
proteins. 
Aβ Preparation; Recombinant Protein Expression
Unlike insulin, Aβ is an expensive protein to obtain from manufactures. The
price of 50mg of Insulin is equivalent to only 1mg of Aβ thus not providing
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much freedom for experimental trial and error. Due to this, it was decided to
express and purify Aβ ‘in house’. 
Considering the size and complexity of protein molecules, chemical synthesis
is  not  a  practical  approach  for  ‘in  house’  protein  manufacturing.  Instead,
molecular biologists have developed a way in which to prompt living cells into
producing functional proteins from genetic (DNA) templates. This process is
referred to as recombinant protein expression. 
Recombinant protein expression is the process of synthesising large amounts
of  a  specific protein from DNA into which the gene sequence that codes for
the protein has been artificially introduced into a host organism.  DNA, unlike
protein, is relatively simple to construct  in vitro  as it is only composed of 4
nucleotides  instead  of  20  amino  acids.  The  development  of  recombinant
protein techniques has revolutionised biochemistry. Before, huge quantities of
animal and plant tissue were needed to purify small amounts of protein. This
was not only wasteful and a time consuming process, but also did not always
guarantee high yields of protein sample.  The ability to express and purify
proteins in large quantities allows for its biochemical characterization, its use
in industrial processes and the development of commercial goods.
At the theoretical level, the steps needed for obtaining a recombinant protein
are  quite  straightforward.  You  take  your  gene  of  interest,  clone  it  in  an
expression vector, transform it into the host of choice, then induce, purify and
characterise. However, in practice, things can often go wrong. It is relatively
common to witness poor growth of the host, the formation of inclusion bodies,
protein  inactivity,  and  even  not  obtaining  any  protein  at  all  (Rosano  and
Ceccarelli 2014). Choosing the host cell in which protein production will take
place is the most important step as it will initiate the outline of the process and
define the technology needed. 
The  process  of  protein  expression  can  be  accomplished  using  either
prokaryotic or eukaryotic cells including bacteria, yeast, filamentous fungi, and
unicellular  algae.  Each  of  these  cells  has  its  own set  of  advantages  and
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disadvantages. For example, prokaryotic systems such as bacteria are easy
to  culture,  quick  to  grow and  produce high  yields  of  recombinant  protein.
Unfortunately,  many  eukaryotic  proteins  produced  in  prokaryotic  cells  are
inactive as the bacteria are unable to perform post translational modifications
required  for  protein  folding.  This  often  results  in  the  protein  becoming  an
insoluble inclusion body which can be difficult to recover without the use of
strong denaturants. On the other hand, eukaryotic systems will often produce
fully functional proteins however the cells take much longer to grow, the yield
is lower and production is costly compared to the prokaryotic counterparts
(Andersen and Krummen 2002).
Escherichia coli (E.coli) bacterium is one of the organisms of choice for the
production of recombinant proteins. Its use as a cell factory is well-established
and it has become the most popular expression platform. The advantages of
using E.coli as  the  host  organism  are  well  known.  Transformation  with
exogenous DNA is fast and easy,  plasmid transformation of E. coli can be
performed in as little as 5 min and rich complex media can be made from
readily  available  and  inexpensive  components.  E.coli has  unparalleled  fast
growth kinetics and it achieves high cell density cultures easily.  E.coli cells
have  a  doubling  time  of  only  20  minutes  when  in  glucose-salts  media  in
optimal  environmental  conditions  meaning that  a  culture  inoculated with  a
1/100 dilution of a saturated starter culture may reach stationary phase in only
a few hours(Sezonov, Joseleau-Petit, and D’Ari 2007). However, it should be
noted that the expression of a recombinant protein may impart a metabolic
burden on the microorganism, causing a considerable decrease in generation
time (E. Bentley et al. 1990).
The  second  most  important  step  in  recombinant  protein  expression  is
choosing your expression vector.  An expression vector is a plasmid or virus
used to introduce the specific protein gene into the chosen target host cell.
Examples  of  expression  vectors  include  the  pET  ,  pUC,  pBAD  and  pQE
series. In fact, there is an enormous catalogue of available expression vectors
in  use  today.  They  are  a  result  of  multiple  combinations  of  replicons,
promoters, selection markers, multiple cloning sites, and fusion protein/fusion
194
protein  removal  strategies.  In  order  to  make  an  informed  decision  when
choosing an appropriate expression vector, one must evaluate each feature
according to one’s individual needs:
Replicons
Replicons – the first feature – are a region of DNA or RNA that replicate from
a single  origin  of  replication.  Genetic  elements  which  undergo  replication,
such  as  plasmids,  always contain  a  replicon and  its  associated  cis-acting
control  elements.  It  is  essential  to  have some form of  control  on  plasmid
replication as a high plasmid number may impose a metabolic burden that
decreases the bacterial growth rate and may produce plasmid instability. This
would cause the number of healthy organisms for protein synthesis to fall and
would  result  in  a  decrease  in  production  yields  (E.  Bentley  et  al.  1990).
Commonly used vectors such as the pET series possess the pMB1 origin, a
derivative of Co1E1 which allows 15-60 copies per cell. Alternatively, the pUC
vector  series  contains  a  mutated  form  of  the  pMB1  origin  which  allows
between 500 and 700 copies per cell (Bolivar et al. 1977) (Minton 1984).
Promoters
Promoters – the second feature - are DNA sequences located in the 5' region
adjacent  to  the  transcriptional  start  site.  RNA  polymerase  and
accessory proteins (transcription  factors)  bind  to  the promoter to  initiate
production of an mRNA transcript.  The T7 promoter system present in the
pET vectors is extremely popular for recombinant protein expression. In this
system, the gene of interest is cloned behind a promoter recognized by the
phage T7 RNA polymerase. This highly active polymerase should be provided
in another plasmid or, most commonly, it is placed in the bacterial genome in
a  prophage  (λDE3) encoding for the T7 RNAP under the transcriptionalDE3)  encoding  for  the  T7  RNAP  under  the  transcriptional
control of a lacUV5 or  lacO  promoter.  Thus, the system can be induced by
lactose or its non-hydrolyzable analog isopropyl β-D-1-thiogalactopyranoside
(IPTG).  (Studier  and  Moffatt  1986).  T7  lysozyme  binds  to  T7  RNAP and
inhibits transcription initiation from the T7 promoter (Stano and Patel, 2004).
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After  induction,  the  amount  of  T7 RNAP produced  surpasses the  level  of
polymerase  that  T7  lysozyme  can  inhibit.  The  “free”  T7  RNAP  can  thus
engage  in  transcription  of  the  recombinant  gene  (Dubendorff  and  Studier
1991).
Selection markers
The selection markers are responsible for deterring the growth of plasmid-free
cells.  In the E.coli system, antibiotic resistance genes are habitually used for
this  purpose.  Resistance  to  ampicillin  is  provided  by  the bla gene  in  the
plasmid whose product is a periplasmic enzyme that inactivates the β-lactam
ring of β-lactam antibiotics. During recombinant protein expression, ampicillin
is added to the culture. Those cells which have incorporated the antibiotic
resistant plasmid exhibit a continuous secretion of β-lactamase. Over time this
degrades the antibiotics and within  a couple of  hours,  ampicillin  is  almost
depleted.  Those  cells  which  have  not  incorporated  antibiotic  resistant
plasmids do not have the ability to inactivate the β-lactam ring of β-lactam
antibiotics and are killed (Korpimäki, Kurittu, and Karp 2003).
Affinity Tags
It  is  crucial  when  expressing  a  recombinant  protein  to  have  a  means  of
purifying it  from the  E. coli cellular milieu.  It  can be found that  purifying a
protein via such characteristics as size and charge, although effective, can
often lead to multiple rounds of purification due to the likelihood of another
protein in the milieu having similar properties. Each round of purification is a
time consuming task and can lead to delays in actual experimentation of the
protein.  However,  more  recently  scientists  have  found  that  fusion  of  the
recombinant protein with a stretch of amino acids can be used to allow single
step purification. 
The first affinity tags used were large proteins utilized almost exclusively for
protein  expression  and  purification  in E.coli.  Examples  of  these  include
staphylococcal  protein  A;  a  polypeptide  280  residues  long  which  can  be
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purified using its affinity to IgG Sepharose, and lacZ, a peptide 1024 residues
long which can be purified using its affinity to immobilized p-amino-phenyl-β-
D-thio-galactosidase (APTG).  Both of these affinity tags were successful with
respect  to  single  step  affinity  purification,  however,  their  large  peptide
sequence often caused problems within  the  process of  protein  expression
itself.   Their  large  sizes  influenced  the  proteolytic  stability,  increased  the
solubility  and/or  expression  of  the  heterologous  proteins  and  occasionally
resulted in denaturation and loss of activity of the fusion protein (Kimple, Brill,
and Pasker 2013). 
Since this time, advances in recovery technique have improved the ability to
isolate Protein A and lacZ and their associated protein complexes without any
complications in protein expression and activity. This allows for the continued
use  of  these  affinity  tags  today.  However,  many  other  affinity  tags  have
recently been developed which improve on the two original designs. These
include  the  polyhistidine  (His)  tag,  maltose  binding  protein,  Calmodulin
Binding Peptide and Streptavidin/Biotin-based tags. Each of these is isolated
through their affinity for metal, amylose, calmodulom and avidin respectively.
They are all small peptide tags which make them less likely to interfere with
protein folding however this can still happen on occasion. They can be tagged
on either the N- or C- terminal end of the protein although it is preferable to
place them on the latter if a signal peptide is present on the N-terminus. Also,
if the three dimensional structure of the protein is known, it is wise to place the
affinity tag on the end which is solvent accessible instead of the end which is
buried so to minimise the affect it has on tertiary structure. Ultimately it is best
to remove the tag in enzyme digestion processes following purification so not
to  interfere  with  the  protein  activity  and  structure  (Rosano  and  Ceccarelli
2014). 
Of these more modern affinity tags, the his-tag is the most widely used. His-
tags  were  first  used  in  single  step  protein  purification  in  1991  to  purify
recombinant  galactose  dehydrogenase  by  immobilized  metal  affinity
chromatography (Lilius et al. 1991). They are small peptide sequences usually
consisting of 6 histidine residues although they can be anything between 2
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and 10 residues.  His-tags  exhibit  strong affinity  to  transition metal  ions in
particular with cobalt,  copper,  nickel,  zinc, calcium and iron ions and form
strong co-ordination bonds with each although nickel is the most commonly
used. 
Affinity Chromatography
Affinity  chromatography  is  the  technique  used  to  separate  affinity  tagged
recombinant proteins from mixtures through specific ligand binding. This is
achieved  through use  of  a  column containing  immobilised versions of  the
ligand specific to the tag. In the cases where his-tags are used, an affinity
column containing nickel is typically chosen. Here, when a mixed solution is
passed through the  column only  those with  an  attached his-tag  will  show
binding  affinity  towards the  nickel  in  the  column and bind.  The  remaining
protein  will  simply  pass  through  the  column and  be  eluted.  Following  the
elution of the unwanted material, the bound, his-tagged protein is recovered
using imidazole. Imidazole is an organic compound with the formula C3N2H4.
When solubilised in water imidazole has a higher affinity to nickel than the his-
tag and displaces it allowing the elution of the recombinant protein.
Following the purification of a recombinant protein it is always vital to confirm
its purity and identity before any subsequent experimentation. The purity of a
protein  is  typically  confirmed  using  something  called  SDS PAGE (sodium
dodecyl sulfate polyacrylamide)  electrophoresis and the identity of a protein
by a technique called Western Blotting.
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Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis
(SDS PAGE) Electrophoresis 
SDS PAGE electrophoresis is a process which separates protein mixtures via
their electrophoretic mobility; a quality that is affected by length, conformation
and charge of  a  protein.  In  order  to  eliminate  two of  those variables,  the
protein samples are heated with sodium dodecyl sulphate (SDS). SDS is an
anionic denaturant which breaks down protein structures into their monomeric
state. Heating with SDS linearises proteins and binds to them giving an even
distribution of charge per unit mass; i.e. the longer the protein, the more SDS
that  will  bind  and  the  higher  the  negative  charge.  When  carrying  out
electrophoresis, the protein samples must be pipetted into an acrylamide gel
and an electric field must be applied. When this happens the proteins, which
are negatively charged due to the SDS, are attracted to the positively charged
anode and begin to migrate through the gel. The bigger proteins, although
having a greater charge, are unable to travel through the tightly packed matrix
of the gel so do not migrate as far as the smaller proteins.  
Western Blott
The identity  of  a  recombinant  protein  is  confirmed using  Western blotting.
Western  Blotting  is  a  technique  which  identifies  a  specific  protein  from a
mixture through the use of antibodies specific to it (Tahrin Mahmood 2012). 
The first stage – separation of the proteins - is carried out through the use of
SDS  PAGE  electrophoresis  as  explained  above.  Samples  are  denatured,
coated in negative charge and then subject to an electric current.  Smaller
proteins, although not as negatively charged, travel faster through the porous
gel towards the positively charged anode. Larger proteins, due to their size,
are unable to travel efficiently through the gel thus proteins are separated via
their molecular weight. 
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Immediately following protein separation, step two is performed: transference
onto a solid membrane. There are a variety of methods that can be used for
this  process,  including  diffusion  transfer,  heat-accelerated  convectional
transfer and vacuum blotting transfer. However, due to its speed and transfer
efficiency,  the electrophoretic  transfer  method is  the most  commonly used
today.  Here,  the  proteins  are  ‘pulled’  out  of  the  acrylamide  gel  onto  a
membrane using a current that runs perpendicular to the gel. In doing so, the
separated proteins are able to maintain their organisation during the transfer.
Transfer  efficiency  varies  greatly  amongst  proteins  as  each  has  a  unique
ability to migrate out of the gel and bind to the membrane. The efficiency of
transfer  depends  on  factors  such  as  the  gel  composition,  field  strength,
transfer time, complete contact of the gel with the membrane and composition
of the proteins (Overview of Western Blotting, 2017).
The use of a membrane is essential in order to make the proteins accessible
for  antibody  binding. It can  be made  from  either
nitrocellulose or polyvinylidene difluoride (PVDF) as both materials have non-
specific  binding  properties.  This  characteristic  allows  all  proteins  to  bind
equally  well  to  them  through  hydrophobic  and  charged  interactions.
Unfortunately,  the  antibodies  used  in  the  final  step  of  western  blotting  –
antibody staining – are proteins themselves so would bind non-specifically to
the  entire  surface  of  the  membrane.  As  a  way  of  preventing  this,  the
membrane is soaked in a dilute solution of protein, usually 3-5% non-fat milk,
plus 0.1% of Tween 20 detergent in a process called ‘blocking’. Blocking is an
inexpensive  method  of  attaching  protein  to  the  remaining  space  on  the
membrane. Thus, when the antibody is finally added, it will  only bind to its
specific protein – the target protein (Jensen 2012). 
The antibodies used in western blotting are modified. They are linked to a
reporter  enzyme  such  as  alkaline  phosphatase or horseradish  peroxidase
which,  when  exposed  to  an  appropriate  substrate,  produces  a  colour.  At
present both specificity and colour can be achieved using a single antibody,
however, these roles were originally split between two: primary and secondary
antibodies. The primary antibodies were specific to the target protein making
200
theirs a specific choice for the target protein. In general, primary antibodies
were not directly detectable so tagged secondary antibodies would have to
bind to  the primary for  detection purposes.  Antibodies are able to  bind to
another  of  its  kind  i.e. bovine  originated  antibodies  bind  to  other  bovine
antibodies. Therefore, in this case, the secondary antibody would have to be
anti-bovine.  This  ‘same-species’  quality  means  that  the  same  secondary
antibodies can be used for various western blotts regardless of the protein
involved. Although successful, the two step staining method is susceptible to
non-specific binding and involves additional incubation steps compared to the
single step method. Having both the specificity and the reporter enzyme on
the  same  antibody,  although  more  costly,  reduces  experimental  time  and
reduces the amount of reagents necessary (Jensen 2012) (Tahrin Mahmood
2012).
Visualisation  of  the  target  protein  occurs  upon  the  incubation  of  the
membrane  with  a  substrate  that  reacts  with  the  reporter  enzyme  e.g.
peroxidase. This converts the soluble dye into an insoluble form of a different
colour.  It  precipitates  next  to  the  enzyme  and  in  doing  so  stains  the
membrane. The membrane can then be compared to the original SDS PAGE
gel  and  the  identity  of  the  target  protein  can  be  calculated  through  its
molecular weight. Alternatively, fluorescently tagged antibodies can be used
as well  as chemiluminescent  substrates.  The resulting  light  output  can be
measured by a fluorescence imaging system or a film/ charge-coupled device
(CCD) camera respectively.
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Methods
Aβ Expression 
The  gene  for  Aβ42  was  cloned  and  inserted  into  a  pET15b  vector  by  a
predecessor of the ‘Crystallography’ lab at the Royal Free Hospital, Hampstead
Heath.  The  pET15b  vector  sequence  is  5708  base  pairs  long  and  contains
ampicillin resistance. Additional features of this vector include a T7 promoter at
residues 463-479, T7 transcription start site at residue 452, His-Tag coding
sequence  (362  –  380),  Multiple  cloning  sites  (Nde1-BamH1)  (319-335),  T7
terminator (213-259), Lac1 coding sequence (866-1945), pBR322origin (3882)
and a bla coding sequence at residues 4643-5500 (Figure 47). 
A 1µl measurement of Aβ42  genes was used to transform 40µL of BL21 (DE3)
competent E.coli cells containing chloramphenicol resistance. This was achieved
through incubation of the genes and cells for half an hour on ice. They were then
heat shocked for 45 seconds at 42˚C and later recovered on ice for a further 10
seconds. Following transformation the cells were plated onto luria broth (LB) agar
plates  containing  ampicillin  and  chloramphenicol  antibiotics  and  incubated
overnight at 37˚C. 
Successful colony growth occurred in the  E.coli  cells which had incorporated a
vector and thus contained resistance to both antibiotics. A colony was picked at
random  and  transferred  to  50ml  of  antibody  containing  LB  for  overnight
incubation  with  120rpm shaking  at  37˚C.  The  following  day,  1ml  of  the  new
bacterial  growth  was  pipetted  into  1  litre  of  autoclaved  Overnight  express
Medium (contents on ‘Buffer  Solutions’  page)  and incubated overnight  a final
time at 37˚C whilst shaking at 120rpm. 
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 Figure  47: Simplified diagram of a pET15b vector. The vector sequence
carries an N-terminal His-Tag followed by a thrombin site and three cloning
sites. pET15b is 5708 base pairs long and contains ampicillin resistance. It
has  a  5’  sequencing  1  primer  of  T7Fwd  of  sequence
5'd[TAATACGACTCACTATAGGG]3'. The pET15b vector landmarks are as
follows:
T7 promoter 463-479
T7 transcription start 452
His-Tag coding sequence 362 - 380
Multiple cloning sites (Nde1-BamH1) 319-335
T7 terminator 213-259
Lac1 coding sequence 866-1945
pBR322origin 3882
bla coding sequence 4643-5500
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Aβ Purification
 
Upon completion of bacterial growth the cells were lysed on ice with sonication.
Four rounds of sonication were carried out on a Branson Sonifier Cell Disruptor
2000. Each round included three, 75 seconds pulses with 30 second pauses in
between.  Between  each  round  the  sample  was  subject  to  spinning  via
centrifugation  at  15,000  rpm,  4˚C  for  10  minutes.  Following  each  spin,  the
supernatant was discarded so to remove unwanted cellular components such as
the nucleus, mitochondria and other cell waste, whilst the remaining pellet was
re-suspended in purification buffer.  Following the final  spin  the pellet  was re-
suspended in  20ml  8M urea so to  solubilise the Aβ42  inclusion bodies.  Once
solubilised, the sample was diluted to 2M urea at which point the sample was
ready for purification via affinity chromatography. 
A 1ml HiTrap nickel column was used for recombinant Aβ42 purification. Initially,
the column was equilibrated using 4ml of sample buffer. Following this, the mixed
sample was passed through twice to ensure his-tag-nickel-ion binding and the
remaining, unwanted, protein was eluted and discarded. The application of 4ml
low strength imidazole (50mM) removed any low-specific nickel binding protein
and  300mM imidazole  was  later  used  to  detach  the  remaining  Aβ  from  the
column.
The  purity  of  the  product  was  tested  on  a  pre-manufactured  Novex™
WedgeWell™ 4-20% Tris-Glycine gradient gel  run in 1x running buffer at  25-
30mA for up to 2 hours. Once removed from the casket, the gel was stained for
40 minutes in coomassie and left to de-stain overnight in de-stain buffer. (Buffer
contents on ‘Buffer Solutions’ page) 
Western Blotting 
For the purpose of the western blott it was decided to use 16% acrylamide gels
instead of the normal 12% due to the small size of the protein involved. On the
original 12% gels it was noted that the smaller molecules would “run off” the gel if
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left  under  current  for  too  long.  Contrastingly  the  bands  would  be  difficult  to
distinguish if not left for long enough. By using a gel with a larger percentage of
acrylamide, the proteins were presented with a denser environment, slowing their
progression and allowing a more defined gel.  A common problem with  these
denser  gels,  however,  was the  increased running time and increased risk  of
damaging the gel from the necessity of higher currents.
The  contents  of  the  ‘purified  Aβ’  sample  were  separated  through  gel
electrophoresis simultaneously on two separate gels. One of these was used for
membrane transference whilst the other was coomassie stained so to be used as
a visual  comparison later.  The gel which was transferred to the nitrocellulose
membrane was done so immediately after electrophoresis through the use of a
perpendicular current.  The electric field caused the negatively charged proteins
to  move  towards  the  anode  onto  the  membrane  whilst  maintaining  the
organisation they had on the gel. The transfer was run at 100V for 1.5-2hours on
ice creating a mirror image of my gel. 
Once  transferred, the  membrane  was  blocked  with  5% milk  in  Tris  Buffered
Saline  Tween (TBS-Tween).  Blocking  was performed for  one hour.  Following
blocking,  an  antibody  specific  to  His-tags  was  added.  The  antibody  also
contained the enzyme  horseradish peroxidase (HRP) which, when stained with
acetate  buffer,  AEC  chromogen  and  hydrogen  peroxide  at  a  ratio  of  2:1:1
respectively, became a red colour.  Following an hour long antibody incubation,
all  solutions were washed off and the membrane was stained with the above
mixture. 
Aβ Preparation
Aβ elutions  from  each  expression  attempt  (table?)  were  combined  and
concentrated to make a stock of approximately 1.5ml of 3.41mg/ml solution. This
stock was dialysed overnight against neutral “TE buffer” (20mM TRIS, 150 NaCl,
0.01% Na Azide, pH8) at a ratio of 1:2000 sample to dialysing buffer respectively,
in  order  to  remove  the  urea  from the  solution.  The  presence of  urea in  the
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fibrillisation assays containing SAP would have had an effect on the structure of
the SAP and thus altered the results. The urea was no longer necessary as the
oligomers had been solubilised and removal of the denaturant should allow the
Aβ to revert back to its natively unfolded form.  
Aβ Fibrillogenesis
The  rotator  method  as  described  in  chapter  2 was  carried  out  using  the
expressed  Aβ42.  The protocol  was carried out exactly with the exception of a
lower  protein concentration  (0.3mg/ml)  due  to  limited  stocks  of  Aβ42.  Having
already  performed  fibrillogenesis  with  insulin  at  lower  concentrations  it  was
known that fibre mass is still able to form in these conditions and that its ThT
fluorescence is proportional to the amount of protein initially added. 
In order to set up the fibrillisation assays, the  Aβ stock was diluted to a 1ml
sample  of  0.3mg/ml.  It  was  chosen  to  continue  using  the  1ml  sample  size
standard  to  maintain  the  same  surface  area  during  tumbling  and  thus  not
introduce a new variable to the experiment which could affect results. This was
achieved using TE buffer in a 1.5ml eppendorf. The samples were continuously
inverted – or “flipped” - at a speed of 20rpm on a revolving Stuart Rotator SB3 for
10  days  at  room  temperature  as  per  the  protocol  fro  making  Insulin  fibres
described in chapter 2. This time, a variety of concentrations was not set up due
to the limited stock amounts. It had already been seen that at least, in the case of
insulin,  that  fibre  masses  were  proportional  to  protein  concentration.  That
assumption was applied to these assays also.
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Fibre Formation with SAP decamers
In order to observe the effect of SAP decamers on Aβ fibre growth, the rotator
method was repeated with the addition of 0.06mg/ml SAP. This maintained the
stoichiometric ratio 1:100 of SAP decamers to  Aβ respectively, as carried out
with  the insulin  fibres.  Each sample was continuously  inverted at  a speed of
20rpm on a revolving Stuart Rotator SB3 for 10 days at room temperature. This
protocol was repeated for both the L55P and S52P variants. 
Sample Aβ (3.41 mg/ml) TE Buffer SAP (6.66mg/ml) dH2O Final Aβ
Concentration
1a 88 μl 903 μl -  9 μl 0.3 mg/ml
1b 88 μl 903 μl 9 μl  - 0.3 mg/ml
Fibre Formation with SAP Pentamers
To perform this particular assay the SAP was diluted to 0.06mg/ml using TC
buffer.  This was left  to incubate for half  an hour to ensure saturation of SAP
calcium pockets. Following this, 0.3mg of Aβ was added and the samples were
continuously inverted at a speed of 20rpm on a revolving Stuart Rotator SB3 for
10 days at room temperature. 
Sample Aβ (3.41 mg/ml) TC Buffer SAP (6.66mg/ml) dH2O Final Aβ
Concentration
2a 88 μl 903 μl -  9 μl 0.3 mg/ml
2b 88 μl 903 μl 9 μl  - 0.3 mg/ml
Control
To see the effect the salt was having on Aβ fibre formation the assay had to be
repeated in a High Salt buffer (“THS Buffer” - 20mM TRIS, 600mM NaCl, 0.01%
Na Azide, pH8). A concentration of 0.3mg/ml Aβ was continuously inverted at a
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speed  of  20rpm  on  a  revolving  Stuart  Rotator  SB3  for  10  days  at  room
temperature in the presence and absence of 0.06mg SAP. 
Sample Aβ (3.41
mg/ml)
THS
Buffer
SAP
(6.66mg/ml)
dH2O Final Aβ
Concentration
3a 88 μl 903 μl -  9 μl 0.3 mg/ml
3b 88 μl 903 μl 9 μl  - 0.3 mg/ml
Aβ Fibre Analysis using ThT
Please refer to the ‘Fibre Analysis using ThT’ section in chapter 2.
Fibre Detection using Congo red 
Please refer to the ‘Fibre Detection using Congo red’ section in chapter 2.
Fibre Analysis using Circular Dichroism
Please refer to the ‘Fibre Analysis using Circular Dichroism’ section in chapter 2.
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Results and Discussion
Protein Expression and Purification
The Aβ42 clone was expressed in BL21 (DE3) competent E.coli cells then cultured
and purified  as  per  the  methods described above.  Throughout  the  course of
protein expression the progression of the purification process and the purity of
the  final  product  was  analysed  via  SDS-PAGE  electrophoresis  on  a  pre-
manufactured  Novex™  WedgeWell™  4-20%  Tris-Glycine  gradient  gel.  The
contents of each lane is as follows: Lane 1) Pre-stained molecular marker, 2)
Sample of lysed cells, 3-6) Sample after first, second, third and forth round of
centrifugation  and  7)  Purified  protein  following  elution  from  a  nickel  column
(Figure 48). 
Upon analysis of the protein expression gel one can see that lanes 2 – 6, which
represent the sample during the sonication process, each contain multiple bands.
These represent the vast array of bacterial protein content as is expected during
this part of the purification process. Lane 7 of this gel represents the sample after
submission to affinity chromatography. This lane contains a single, well defined
band  at  approximately  36kDa  as  well  as  various  very  faint  bands  at
approximately 39, 47, 52, 80 and 84 kDa. 
The contents  of  lane 7 draw attention to  two matters.  The first  concerns the
molecular weight of the strong band and the second concerns the presence of
other bands in that lane. 
With regards to  the first  issue,  one can see that the molecular weight of  the
strong band, 36 kDa, is not representative of Aβ42  which has a molecular weight
of only 6kDa. This suggests that Aβ42 is not present in the sample. Perhaps it was
lost or discarded at some point during the purification process or perhaps it was
run off the gel due to excessive electrophoresis times. The latter of these seems
most likely as molecular weights lower that 20kDa cannot be seen. 
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Figure 48: Electrophoresis gel showing the progression of Aβ purification
in a Novex™ WedgeWell™ 4-20% Tris-Glycine gradient gel.  A total of
10μl was added to each lane except in the case of the marker where only
5μl  was  added  for  preservation  purposes.  During  preparation,  samples
were diluted to 1mg/ml using laemmli  buffer containing  sodium dodecyl
sulfate (SDS) and boiled in order to enforce monomerisation and uptake of
negative charge. Electrophoresis was carried out for 1 hour 20 minutes at
25 mA. The contents of each well are as follows: 1) Pre-stained molecular
marker.  2)  Sample  of  lysed  cells.  3)  Sample  after  first  round  of
centrifugation. 4) Sample after second round of centrifugation. 5) Sample
after  third  round  of  centrifugation.  6)  Sample  after  last  round  of
centrifugation. 7) Purified protein following elution from a nickel column. 
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With regards to the second issue, the presence of multiple bands in a purified
lane indicates that the protein is not pure in content. The presence of additional
bands could be a result of sample contamination from either human error or non-
specific nickel binding. It is entirely possible that the nickel column had lost its
specificity.  This  is  a  common  problem  following  multiple  uses  of  the  same
column. Another explanation could that the Aβ42 had indeed not been expressed
and that  the bands in the gel  represented other proteins with mild affinity for
nickel binding.
Ideally, in order to test all these theories, the entire protein expression protocol
would need to be repeated. However, this is a very long and wasteful process so
instead  it  was  decided  to  use  a  much  quicker  method  first,  SDS-PAGE
electrophoresis.  By producing another gel, one run for a shorter period of time,
one would get an indication as to whether any Aβ42 is present in the sample at all.
The brightness of the band would then provide an indication as to whether affinity
binding had occurred or not. As a way to resolve the apparent impurity of the
sample, a round of affinity chromatography would need to be carried out first with
a new nickel column.
Upon producing this  gel,  however,  the  exact  same results  were  observed.  A
strong band was present at  approximately 36kDa alongside various very faint
bands at approximately 39, 47, 52, 80 and 84 kDa. This lead to the following
conclusions: Plasmid transformation had indeed been successful. The antibiotic
resistance exhibited by the bacterial cells proves this. His-tag affinity had also
been successful.  The presence of a strong band in lane 7 demonstrates this.
What is not known is the identity of the protein that had been expressed. 
Considering that the vector used during this protocol was created by an unknown
predecessor, it as decided to submit the clone through DNA sequencing in order
to verify its contents.  The result of the DNA sequencing of the Aβ42 vector was
translated via the translation tool available on the ExPasy website and compared
with the Aβ42  sequence available on the ncbi website (PDB code 2MXU_L). The
5’3’ open reading frame 2 illustrated that Aβ42  protein was indeed present and
that  it  did  contain  the  His-tag  required  for  nickel  binding  and  single  step
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purification. This indicated that the SDS PAGE gel anomalies were a result of
protocol negligence alone (Figure 49).
Further reading of the literature, however, led to the discovery that Aβ is prone to
aggregation  and  oligomer  formation  when  expressed  in  bacterial  cells  as
experienced by  Lesné et al. in 2006. The oligomers are complexes made from
multiple Aβ monomer units and are usually exhibited as structures made up of
multiples of three. They cannot be separated by either urea or SDS meaning they
would appear on a SDS-PAGE gel as multiple sized bands instead of as a single
monomerised unit. For example, a single Aβ monomer has the molecular weight
of approximately 6kDa so oligomers composed of 3, 6, 9 etc monomers would
exhibit  weights  of  approximately  18,  36  and  54kDa  respectively  on  an  SDS
electrophoresis gel.  This is in  agreement with  Figure 48. The strong band at
36kDa would indicate that the oligomer approximately 36kDa in size - the one
containing 6 Aβ monomers - is the most prominent form. 
When looking at the fainter bands in this gel one will notice that the molecular
masses of these bands do not necessarily add up precisely to units of 15kDa,
this  can be explained by  the  fact  that  the  oligomers  are not  linear;  they are
globular. Globular proteins experience a retarded migration through acrylamide
gels  due  to  their  bulk  in  size.  The  larger  the  protein,  the  more  difficulty  it
experiences when travelling through the gel matrix. The protein marker used in
lane 1 consists of linear proteins. These do not experience the same restrictions
upon travelling down an acrylamide gel as globular proteins so therefore travel at
a  faster  rate.  This  means  that  the  size  markers  demonstrated  at  particular
distances in lane 1 are not necessarily representative of the molecular weights of
the globular proteins present in lane 7.
This oligomerisation phenomenon could be the result of a number of reasons.
The introduction  of  a  foreign  gene  into E.coli,  can cause  the  spatio-temporal
control  of  its  expression  to  be  lost.  The  newly  synthesized  recombinant
polypeptide is being expressed in the microenvironment of E. coli,  which may
differ from that of the original source in terms of pH, osmolarity, redox potential,
cofactors, and folding mechanisms thus encouraging aggregation of some sort.
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One  must  also  take  into  account  that  in  high  level  expression,  hydrophobic
stretches in the polypeptide are present at high concentrations and available for
interaction with similar regions. Prokaryotic chaperones do not always have the
capability to fold eukaryotic proteins into their native state. Even if they do, they
are not present at a high enough concentration to fold this excess number of
recombinant protein molecules. All of these factors lead to protein instability and
aggregation (Hartley and Kane 1988).
Verification of the presence of Aβ in the ‘purified’ sample was carried out using
Western blotting in conjunction with his-tag specific antibodies. This was done
alongside proteins lacking any his-tags so to act as a control. The contents of
each gel are a follows: 1) Purified Aβ with his-tag attached. 2) Albumin. 3) TTR.
4) SDS PAGE/Western Blott Marker. 
When looking at the results of the Western blott various things can be observed.
Firstly,  the  high  acrylamide  percentage  prevents  the  protein  samples  from
travelling through the gel  in a neat and clear manner.  This is true even after
being submit to a current for two hours at a time. Unfortunately this could not be
helped due to the small size of the protein in question. A higher percentage gel
had to be used to ensure that there was no chance the Aβ42 would run off the gel.
Although the gel could have been left to run longer in an attempt to separate the
bands, by doing so there was an increased risk of damaging the gel (Figure 50). 
When comparing the Western blott with its SDS-PAGE counterpart one can see
that the contents of lane 1 – purified Aβ - resulted in positive identification of his-
tags where as lanes 2 and 3 – albumin and TTR respectively - did not. This
proves  that  the  recombinant  Aβ protein  had  successfully  been  integrated,
expressed  and  purified  from  E.coli  cells.  The  crucial  observation  is  that  the
western blott caused red bands to appear not on a single band but on each of the
anomalous bands seen in the sample. This confirms the theory that the Aβ was
indeed pure and simply forming oligomers. 
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Figure 49: Translated sequence of the pET15b vector. Start codons leading
to  possible  proteins  are  represented  in  grey  and  the  Aβ  sequence  is
highlighted in blue. The Aβ sequence has a molecular weight of 6.81kDa
(including the methionine and his-tag) as calculated using the ‘Compute pI/
Mw’ programme on the ExPASy website (https://www.expasy.org/).
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Figure  50:  Comparative  electrophoresis  (left)  and  western  blott  (right)
results. The contents of each lane are as follows: 1) Purified Aβ with his-
tag attached. 2) Albumin. 3) TTR. 4) Western Blott Marker. Proteins were
run on home made 16% acrylamide gels at 25mV for 1 hour 45 minutes. The
transfer to the nitrocellulose membrane was run at 100V for 1.5 hours on
ice. Once transferred, the membrane was blocked with 5% milk and an anti-
his tag antibody containing the enzyme horseradish peroxidase (HRP) was
used. 
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Following  this  revelation,  multiple  rounds  of  expression  and  purification  were
carried out. In order to encourage monomer formation, the purified solutions were
re-submit to 8M urea and shaken overnight at 50rpm. The finishing products of
each attempt were combined to produce 1.2ml of  stock solution measuring a
concentration of 5.2mg/ml.
A table of Aβ recombination attempts. Aβ concentrations were determined
through  use  of  a  nano  drop  spectrophotometer  set  at  a  wavelength  of
280nm. Units were converted using the Beer Lambert Law. The finishing
products  of  each  attempt  were  combined  to  produce  1.2ml  of  stock
solution measuring a concentration of 5.2mg/ml.
Aβ Fibrillogenesis
Again,  in  order  to  allow for  fair  comparison,  the  rotator  method described in
Chapter 2 was used as a way in which to encourage  Aβ fibre formation.  The
protocol  was  carried  out  exactly  but  with  the  exception  of  a  lower  protein
concentration  (0.3mg/ml).  This  was  due  to  the  limited  supply  of  Aβ  stocks.
Having already performed fibrillogenesis with insulin at lower concentrations it
was known that fibre mass is still able to form in these conditions and that fibre
mass and its corresponding ThT fluorescence is proportional to the amount of
protein initially added. 
Aβ
Recombination
Number Final Aβ volume (μl)l)
Final Aβ
concentratio
n (mg/ml)
Total  Aβ
content (mg)
1 200 2.22 0.44
2 200 0.50 0.10
3 200 2.44 0.49
4 200 3.41 0.68
5 200 3.36 0.67
6 100 9.76 0.97
7 100 10.23 1.02
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Attempting to create fibres from the  Aβ stock proved to be much more difficult
than creating the stock itself. Unlike the previous two proteins, the rotator method
did not cause precipitation to occur at in the Aβ assays. Neither cross β-sheets or
amorphous aggregate were produced. When tested with ThT fluorescence a flat
line was produced directly on the base line. 
This difficulty in obtaining Aβ fibres is believed to be a result of Aβs tendency to
form soluble oligomers in environments lacking high concentrations of denaturant
(i.e urea). Lashuel  et al.  have already demonstrated that soluble oligomers can
affect fibre formation in TTR. It is logical that the same theory can be used for all
proteins. The fact that Aβ did not even form a precipitate is likely due to the fact
that these assays were done at a lower concentration. 
Although it would be possible to make Aβ fibres in conditions of high denaturant
or  strong,  the  results  would  be  rendered  useless  with  regards  to  these
experiments. The original reason behind making fibres was to see the affect of
SAP pentamers and decamers on their growth.  By creating fibres in conditions
of  high  denaturants,  it  would  become impossible  to  observe  this  relationship
between Aβ and SAP as the denaturant would have an affect on SAP itself. Even
proteins with properties of high stability such as SAP will experience some form
of structural change in those extreme conditions and thus prevent the pentamers
and decamers from carrying out their roles efficiently. This is turn would disallow
any comparison with the insulin results obtained in chapter 2. A similar statement
could also be said of  any attempt to  make  Aβ in  acidic  conditions.  Although
success would more likely be obtained, the acidic conditions would also have an
affect on the interaction of SAP with fibres due to SAP denaturation. Not only is
this non-representative of inducible conditions of the body but it would also make
any result obtained non-comparable to those from the insulin experiments which
were done at neutral pH.
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Conclusion
The tendency of Aβ to form either soluble or insoluble oligomers is a very
common  problem  experienced  in  Aβ  expression.  In  fact,  Prokaryotic
expression and purification of any highly amyloidogenic peptides such as Aβ
have all proven difficult due to their small size, their tendency to aggregate
and the toxicity of the formed aggregates. The repeated difficulty in obtaining
functional Aβ protein explains the high cost when purchasing this product form
manufacturers.  Phenomenal efforts have been carried out in an attempt to
make the  recombinant  proteins  more  competent  and  fit  for  use.  Of  these
attempts, the use of protein fusions has been the most successful. 
Fusions protect the Aβ from proteolysis and enhance its solubility (Sørensen
and Mortensen 2005). The expression of Aβ42 fused to segments of a surface
protein from the malaria parasite Plasmodium falciparum (Döbeli et al. 1995),
maltose binding protein (Hortschansky et al. 2005), ubiquitin (Lee et al. 2005),
GroES-ubiquitin (Shahnawaz, Thapa, and Park 2007), trigger factor-ubiquitin
(Thapa et al.  2008), and hen egg white lysozyme  (Nagata-Uchiyama et al.
2007) have all been reported. Although each of these has proven successful
in obtaining a more solubilised version of the protein, in order to then remove
this undesirable tag, specific proteolysis is an inevitable additional purification
step in all of these cases. The proteolytic cleavage reaction is cost-intensive,
requires time-consuming optimisation and necessitates post-reaction clean-
up, which further reduces the attainable yield. 
Although a lack of  experimental  success was experienced with  two of the
three proteins, I believe enough progress was made with insulin to provide
grounds for  further  testing.  The overall  aims of  the  thesis  so  far  were  as
follows:
- To clarify whether cross β-sheet fibres can be made in vitro at neutral
pH as so to replicate physiological conditions. 
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- To establish whether,  in  these physiological  conditions,  SAP has to
ability to exhibit  both pro-fibrillogenic and anti-fibrillogenic activities as
Hamazaki and Janciauskiene debated.
- If  so,  to  determine  whether  these  two  roles  are  each  specific  to  a
particular face on SAP or to a particular configuration.
- Suggest whether therapeutic strategies using the SAP decamer would
be against the fibres would be possible. 
Thus far these experiments have proven that it is indeed possible to make
cross β-sheet fibres at neutral pH. This was shown very clearly using insulin
and not so clearly with TTR or Aβ. What TTR has shown is that the capability
to form fibres is present, but that the optimum conditions to produce a high
yield  have  not  been  discovered.  The  TTR  assays  also  highlighted  the
importance  of  analysing  literature  figures  with  caution  so  to  avoid  making
incorrect  conclusions  regarding  fluorescence  form  differently  calibrated
machinery.
These experiments have also proved that, at least in the case of insulin, SAP
does indeed have the capability of exhibiting both pro-fibrillogenic and anti-
fibrillogenic activities and not just one or the other as argued by  Hamazaki
and  Janciauskiene.  These  activities  are  dependent  on  the  conformation
exhibited by SAP at the time. When in its decameric form, SAP acts as a
fibrillogenic  stabiliser  and  enhancer.  In  its  decameric  form,  however,  it
behaves in a manner similar to a chaperone. 
Unfortunately, this theory cannot be verified based on the results from a single
protein alone. Other amyloid proteins will need to be assessed. It is possible
that Aβ and TTR were not the best choices for SAP analysis and alternatives
should be used instead. Aβ is infamous not only for its cost but for its difficulty
in being produced using recombinant technology. It often forms oligomers and
insoluble aggregates which interfere with experimental techniques. TTR also
has the propensity to form soluble aggregates. In addition to this, TTR is a
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highly stable protein known to resist  unfolding when the wild type is in its
native state. Although amyloid prone variants can be used as a way to combat
this,  they  may  not  necessarily  be  as  adept  to  forming  amyloid  prone
intermediates as other, less stable, proteins. 
Perhaps  in vitro fibre formation is not as easily obtained as it would appear
especially when attempted at near neutral pH. It may be possible that in the
case of some proteins, other components are required in order to allow the
cross β-sheet to form, without which, fibre assembly is restricted.  The lack of
extracellular matrix proteins and proteoglycans could hinder a proteins ability
to form cross  β-sheet fibres thus resulting in the amorphous aggregate that
was seen in the TTR cases. Another possibility is that not all proteins have the
potential to form amyloid due to their size or chemical composition. Proteins of
only  30-40  residues  may  not  be  large  enough  to  form  the  cross  β-sheet
structure and thus explain the behaviour of Aβ. 
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Chapter 4
X-HelixRay Crystallography
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X-HelixRay Crystallography
An Introduction to SAP Structural analysis  
Having performed various experiments with respect to the behaviour of SAP,
it became prudent to perform structural analysis on the molecule as well. SAP
is a critical  component  of  all  amyloid  deposits  in vivo and a key factor  in
preventing  its  removal  from  the  body.  By  understanding  the  mechanism
through which SAP interacts with fibres or other key proteins in the serum,
one could possibly devise a way in which to control or reduce fibre stability
and growth. 
As previously discussed, SAP exhibits an anti-opsinin role,  i.e. it blocks the
immune  system  from  interacting  with  amyloid  deposits  and  prevents  an
immune response against it. Recent developments by GlaxoSmithKline have
led to the production of antibodies which are specific to SAP. These anti-SAP
antibodies have the ability to detach SAP from amyloid deposits and thus
leave  the  deposits  exposed  to  the  host’s  immune  system.  The  exact
mechanism behind this is not fully understood however clinical  trials have
shown that following the removal of the deposit bound SAP from the body,
deposits are dissociated and fibre mass is reduced. 
Although these results appear promising, more work needs to be carried out
in order to guarantee safety and effectiveness of the treatment. These trials
have shown to decrease fibre mass but they have yet to be successful  in
complete amyloid eradication. This means that surgery is still an eventuality
as there is the potential for fibre re-assembly, redevelopment of symptoms
and further progression of the disease. 
The first step in trying to improve this situation is by solving the structure of
the  SAP:antibody  complex.  The  most  efficient  way  in  which  to  do  this  is
through use of x-ray crystallographic techniques. This is a technique which
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uses x-rays as a way in which to determine atomic structure of a protein. To
this date, a structure of the SAP:antibody complex has not been published. It
is not known how or where they bind. This limits the understanding scientists
have on the interactions between the two molecules and how detachment
from in vivo  fibres actually occurs. By solving the structure of this complex,
the mechanism behind SAP:antibody binding could be distinguished and thus
methods could be developed to optimise this interaction. This would allow for
more efficient removal of SAP from the deposits, lead to the optimisation of
the  treatment  and  thus  allow  for  higher  success  rates  and  lower  fatality
numbers to be obtained. 
The Concept of X-HelixRay Crystallography
For the purpose of  chapter  4 and 5 all  structural  analysis  was performed
using x-ray crystallography. X-ray crystallography is a valuable experimental
technique which can be used to determine the three-dimensional structure of
proteins. It  provides the atomic detail  necessary for understanding protein-
ligand interactions, allosteric mechanisms and facilitating drug design. 
In  order  to  perform  x-ray  crystallography  one  must  place  a  pure  protein
sample in the path of an x-ray beam. Upon doing so, a diffraction pattern is
produced in the form of dark spots  (Figure 51,  Figure 52). The dispersion
and  intensity  of  each  spot  is  measured  by  a  detector,  transmitted  to  a
computer,  and  through  this,  a  graphical  three-dimensional  image  of  the
molecule is reconstructed  (Wlodawer, Minor, Dauter, & Jaskolski, 2008). X-
ray  beams  are  specifically  chosen  for  this  level  of  analysis  as  their
wavelengths are close in size to the atoms in a protein. The similarity in size
guarantees that the two will interact and cause diffraction.
Unfortunately, diffraction from a single molecule does not provide sufficient
information for measurement thus there is a need for amplification. This is
achieved  through  conversion  of  the  pure  protein  sample  into  a  crystal.
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Crystals form when the smallest asymmetric sections of a crystal (unit cells)
spontaneously assemble into a crystal nucleus. Following this, more unit cells
attach to the nucleus to generate an ordered crystalline lattice. Each unit cell
packs in identical orientation – similar to the packing of identical boxes in a
warehouse  –  which  is  essential  to  prevent  canceling  out  of  waves  upon
diffraction.
X-ray crystallography has grown dramatically in the last 40 years. In 1975
only 78 crystal structures had been published in the Protein Data Band (PDB)
whereas  now  there  are  more  than  100,000.  More  structures  are  being
published every week than there were per year in 1975. This exponential rate
in  publishing  is  due  to  the  advances  in  computer  technologies,  the
development of more intense x-rays sources and the invention of recombinant
molecular biology (Hendrickson, 2000). 
Although a  useful  technique,  x-ray  crystallography has various challenges
which need to be overcome before structure determination can occur. Firstly,
the  desired  protein  must  be  successfully  expressed  and  purified.  Once
achieved, protein crystals must be grown to an adequate quality and size.
This  is  not  always  possible  or  necessarily  representative  of  the  protein’s
natural state.  Finally,  diffraction must occur at a high enough resolution in
order to reveal atomic detail. Each of these steps is incredibly time consuming
and can require great amounts of trial and error (G Wagner, S G Hyberts, &
Havel, 1992).
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Figure 51: Above – A cartoon representation of a crystal lattice and its
constituents  (arrows  represent  protein).  Note  that  a  unit  cell  is  the
smallest asymmetric section of a crystal.  The lattice is formed when
identical unit cells assemble spontaneously. Below - A cartoon diagram
to demonstrate  x-ray diffraction of  a  protein  crystal  lattice.  An x-ray
wave is generated using one of 3 methods: x-ray tubes, rotating anodes
or particle storage rings. The generated wave is focused using a lead
screen and upon contact with the protein crystal, diffract, generating a
pattern of spots.
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Figure  52: A diffraction pattern of a SAP:Fab crystal at a resolution of
4Å collected at Diamond Light Source Synchrotron, Oxfordshire (more
details in Chapter 5). The centre of the film is referred to as the origin
and is assigned the coordinates (h,k,l) = (0,0,0). The dark circle seen at
3Å is referred to as the water ring and is caused by the diffraction of ice
which is created during the freezing process. 
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Protein Crystallisation
The  first  step  carried  out  during  x-ray  crystallography  experiments  is
crystallisation of the desired protein. Crystallisation is a difficult  process to
achieve due to the challenges presented by solubilised proteins. Firstly, it is
difficult to obtain the high protein concentrations necessary for crystallisation
to  occur.  Secondly,  it  is  common  for  contaminants  to  taint  samples  and
thirdly,  proteins  can  be  extremely  sensitive  to  temperature,  pH  and  ionic
strength. This makes them likely to denature when put through the screening
process.  Any  changes  to  their  environment,  even  very  small  ones,  could
render a protein unsuitable for crystallisation. It is also important to note that
every protein is unique in its physiochemical characteristics. This individuality
makes optimum crystallisation conditions almost impossible to predict. As a
result  of  this,  finding the conditions which make good quality crystals of a
particular protein can take months or even years to decipher (Smyth & Martin,
2000) ().
In order for crystal growth to occur, non-destructive environmental conditions
are required; preferably in the form of physiological conditions. Unfortunately,
most proteins  are  still  soluble  at  physiological  conditions.  In  order  to
overcome this, proteins call for an increase in solute concentration. This can
be  achieved  by  using  either  salt  or  precipitants.  Each  of  these  is  non-
disruptive and allow crystal  growth.  Once formed,  the protein  crystals  are
extremely soft, fragile and sensitive to environmental variations. This is due to
the fact that they are made of 50-70% solvent and are held together through
weak hydrogen bonds, salt bridges and Van der Waals interactions (Smyth &
Martin, 2000).
Crystallisation  is  a  form of  supersaturation  which  is  often  described  as  a
controlled precipitation of protein. If precipitation is not controlled, the protein
will leave the solution to form an amorphous precipitate which cannot be used
for crystallography.  The first stage involved in this controlled precipitation is
nucleation. Nucleation involves the formation of well  organised aggregates
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until a stable nucleus is achieved. This is a rate limiting step and is the cause
of the lag phase typically seen in crystal  growth curves (sigmoidal).  Upon
completion of nucleation the growth stage can commence. Here, additional
protein molecules are added onto the stable nuclei forming a crystal lattice
until limited by external factors such as contaminants, the depletion of protein
molecules and the development of growth defects (Ducruix & Giegé, 1992).
It is common to use a phase diagram to provide a visual representation of
crystal growth  (Figure 54). The solubility curve separates regions which do
and do not permit supersaturation  (Asherie,  2004). Naturally, in the region
which does not allow supersaturation, the protein remains in solution and are
therefore useless for x-ray crystallography. The region which does promote
supersaturation can allow crystal growth but does not guarantee it. In fact,
this  supersaturation  region  can  actually  be  divided  into  three  categories:
precipitation, nucleation and metastate. The precipitation region represents
conditions  in  which  only  amorphous  aggregate  is  formed  where  as  the
nucleation  region  promotes  spontaneous  nuclei  formation  and  therefore
crystal  growth.  The  metastable  region,  however,  represents  conditions  in
which the growth of stable nuclei  is promoted but the original formation of
those nuclei is inhibited. The metastable region is therefore idyllic for crystal
‘seeding’  which  is  a  name  used  to  describe  when  pre-formed  nuclei  are
added  to  a  solution  of  protein  monomers.  (McPherson,  1990).  Most
crystallographers consider it ideal for crystallisation to occur at the borderline
between the metastable and nucleation regions. This permits fewer but bigger
crystals to form. 
In crystallography it is crucial that the protein sample is pure. Contaminants
result  in  non uniform molecules being incorporated into  the crystal  lattice,
causing defects and limiting crystal growth. The pH of the solution is equally
important as pH affects the solubility of proteins. Protein solubility is at its
lowest just before its pI - the pH at which a protein has no net charge. Also,
proteins in low ionic strength solutions exhibit increased interaction between
molecules as they attempt to balance their electrostatic charges. Of course,
lowering the pH can cause additional problems with protein solubility however
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this can be counterbalanced through the addition of salt. The salt acts as a
competitor for water molecules and thus lowers protein solubility in a process
called “salting out” (Rhodes, 2012).  
The addition of precipitants has a similar dehydrating affect to that of salt.
Precipitants reduce the dielectric constant of solutions and increase molecular
interactions  by  increasing  the  strength  of  electrostatic  forces  between
molecules.  Popular  precipitants  include  polyethylene  glycol  (PEG),
ammonium sulfate  and  2-Methyl-2,4-pentane-di-ol  (MPD)  (Ladd &  Palmer,
2014). 
Proteins  with  flexible  regions  in  their  structure  (e.g.  enzymes)  cannot  be
crystallised in their entirety due to their inability to exhibit the uniform structure
necessary for crystal lattices. Fortunately, crystallographers have found two
distinct approaches to overcome this. The first of these is fragmentation. This
involves the cleavage of the desired protein and individual crystallisation of
each  fragment.  The  second  approach  is  called  co-crystallisation.  Here  a
super-saturating concentration of substrate, inhibitor or coenzyme specific to
the protein is added to the protein solution. The stable complex is separated
from  the  excess  components  using  chromatography  methods  and  then
crystallised (Ladd & Palmer, 2014).
Vapour Diffusion
There are various methods in which to form crystals, the most common being
vapour  diffusion.  In  vapour  diffusion,  a  droplet  containing  purified  protein,
buffer and precipitant is equilibrated with a large reservoir containing similar
buffers and precipitants but at  higher concentrations.  As the two solutions
equilibrate the concentration of protein and precipitate in the droplet increase.
If the appropriate conditions have been used a crystal will form in the drop.
The  reason  vapour  diffusion  is  one  of  the  more  popular  choices  when
attempting crystallisation is because it allows for gentle and gradual changes
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in  the  concentrations.  This  allows  large and well-ordered  crystals  to  form
(Chayen, 1998). 
There are two ways in which to perform vapour diffusion: the hanging drop
method or the sitting drop method. The hanging drop method involves the
suspension  of  the  droplet  on  a  siliconised  cover  slip  above  a  reservoir
whereas the  sitting  drop method  involves  the  placing  of  the  droplet  on  a
pedestal separate from the reservoir  (Dessau & Modis, 2011). The hanging
drop technique was used predominantly throughout chapter 4 and 5. In this
technique,  a  drop  of  pure  protein  is  usually  mixed  with  equal  volume  of
crystallisation solution on a siliconised cover slip. This makes the precipitant
50% of the concentration required for crystallisation. The cover slip is placed
over a well containing 1ml of the crystallisation solution (drop facing inwards)
and sealed with grease so that a closed system is formed. The concentration
in the drop is less than that in the well causing vapour diffusion to occur until
equilibrium  is  reached.  If  the  correct  conditions  have  been  chosen,
supersaturation should occur (Ducruix & Giegé, 1992) (Figure 56).
Robots  can  be  used  to  set  up  a  large  number  of  crystallisation  screens
simultaneously. They use the same systems as above but are able to carry
out the steps quickly, with a large number of replicates and without human
error.  Robots  are  very  beneficial  as  they  require  only  a  small  amount  of
protein which allows conservation of protein stocks. Also, the smaller volumes
result  in quicker crystallisation  (Zhu et al.,  2014). When making crystals –
especially  when  working  with  proteins  which  have  never  before  been
crystallised - it is common to use a robot alongside a commercial screen as a
preliminary step.   In doing so, one is provided with a quick and easy method
to determine possible “hits” for crystal growth.  Commercial screens use a
grid system which varies in reagents, pH, precipitant and salt concentrations.
There are multiple manufacturers who produce trays containing 96 pre-made
well  solutions.  Each of  the  solutions  is  different  allowing a  wide range of
conditions to be tested in one manoeuvre.  Unfortunately, due to the small
volumes used, the crystals made from these commercial screens are usually
too small for diffraction. Subsequently, the ‘hit’ conditions must be replicated
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by a crystallographer on a manual grid. The manual grids can be used to
create pH and precipitant gradients around the ‘hit’ as a way to optimise the
conditions. It is also common to make changes in protein concentration and
temperature in order to achieve optimisation. 
Crystal Harvesting
Originally, crystals were harvested by transferring them into a glass capillary
tube. A drop of crystallisation buffer was added to keep the crystal hydrated
and then the capillary was sealed at both ends, mounted onto a goniometer
head  and  shot  with  x-rays.  This  method  has  both  advantages  and
disadvantages. The advantage of this method is that the crystals are kept in
their native well  solutions. This prevents them from cracking or drying out.
However, the disadvantage is that when shot with x-rays, the crystals which
are harvested in this manner are often subject to radiation damage. 
Crystallographers  have  recently  discovered  the  benefit  of  harvesting  and
freezing the crystals. The crystals are collected or ‘scooped up’ in loops made
from plastic or nylon and frozen.  When frozen, crystals experience reduced
radiation  damage  from  x-rays  due  to  their  increased  durability.  The  free
radicals produced during diffraction have a slower diffusion rate and slower
mobility in the crystals limiting radiation damage (Elspeth Garman, 2003).
Although  there  are  clear  advantages  from  freezing  crystals,  initially  this
proved difficult  for  crystallographers. They found that the production of ice
crystals damaged the lattice and affected results (E. F. Garman & Schneider,
1997). Ice has its own diffraction pattern which can mask the one generated
from  the  protein  structure.  Nowadays  crystals  are  flash  frozen  in  liquid
nitrogen in the presence of an ice preventing cryoprotectant. This prevents
the formation of ice whilst still protecting the crystals from radiation damage.
As necessary as cryoprotectants are, they produce their own set of problems.
They can cause crystals to crack if  an inappropriate one is used or if  the
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change in solution occurs too quickly. Identifying the correct cryoprotectant
requires trial and error which is not ideal as crystals are difficult  to obtain.
Cryoprotectants  are  usually  a  solution  of  sugar or polyol  e.g. glycerol  and
dimethyl  sulfoxide  (DMSO).  They  work  by  forming hydrogen  bonds with
biological molecules causing the displacement of water molecules. Hydrogen
bonds are necessary for proteins to maintain their native state in solution. By
displacing  the  water  molecules,  the  cryoprotectant  allows  the  protein  to
maintain  those hydrogen bonds when frozen without  incorporating  excess
water (Drenth, 2013).
Data Collection / X-Helixray Exposure 
During  data  collection,  the  crystal  containing  loop  is  mounted  onto  the
goniometer  where  it  is  continuously  exposed to  a  stream of  nitrogen gas
(temp. 100K) to prevent thawing  (Drenth, 2013). The goniometer accurately
positions the loop within  the x-ray  beam with  the  aid  of  a  camera and a
computer. This accuracy is essential as both the crystal and the beam are
extremely small and are required to be within 25μm of accuracy. There are
various  types  of  goniometer  with  the  most  common  being  the  kappa
goniometer.  The kappa goniometer  provides 3  angles  of  rotation  (omega,
kappa and phi). The omega (ω) angle rotates about an axis perpendicular to) angle rotates about an axis perpendicular to
the beam. The kappa (κ) angle, which is an axis approximately 50° to the ω) angle, which is an axis approximately 50° to the ω) angle rotates about an axis perpendicular to
axis, allows convenient mounting of the crystal and the phi (φ) angle rotates
around the loop/capillary axis. When the κ) angle, which is an axis approximately 50° to the ω angle is zero, the ω) angle rotates about an axis perpendicular to and φ axes
are aligned (Figure 55).
When a crystal is exposed to an x-ray beam it causes the beam to diffract and
scatter into a pattern of spots/reflections. The pattern and intensity of each
spot is noted by a detector and recorded on a computer. A single picture is
not  enough to  represent  the  entire  Fourier  transform therefore  the  crystal
must be rotated step-by-step through 45-180° (depending on the symmetry of
the  crystal)  with  images taken throughout  in  order  to  collect  enough data
(Rhodes, 2012). 
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Figure  53:  Examples  of  two  SAP  crystallisation  attempts  using  the
following conditions: 0.1M MgAc, 0.1M MES, 8% PEG10K, pH 5.5. Top –
Crystals grown at room temperature resulted in amorphous aggregate.
Bottom –  Crystals  grown  at  4°C resulted  in  multiple  square  shaped
crystals approximately 30μm x 30μm in size.
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Figure  54: Example of a phase diagram (Ducruix & Giegé, 1992). The
solubility  curve  divides  the  regions  which  do/do  not  allow
supersaturation. Of the supersaturation regions, the precipitation zone
promotes  amorphous  aggregate  formation.  It  is  the  nucleation  zone
which  is  responsible  for  spontaneous  nuclei  formation  and  crystal
growth whereas the metastable zone promotes growth of stable nuclei
but is unsuitable for initial nuclei formation. In crystallisation it is ideal
for nucleation to occur between the metastable and nucleation regions
as this results in fewer but bigger crystals. 
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 Figure 55: Above – A microscopic view of a crystal suspended in a loop;
the crystal is held in place via surface tension of the solution. Below - A
photograph  of  an  x-ray  machine  from  Diamond  Light  Source,
Oxfordshire. The crystal containing loops are placed on the goniometer
head (red arrow) and subject to a stream of liquid nitrogen to prevent
thawing.
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Figure 56: A cartoon diagram to illustrate vapour diffusion techniques. Left – The sitting drop technique.  Here the protein
containing drop is placed on a pedestal separate from the reservoir well solution. Right – The hanging drop technique.
This involves the suspension of the protein droplet on a siliconised cover slip above the reservoir. Both methods are
carried out in a closed system to allow vapour diffusion to occur and equilibrium to be reached. 
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Bragg’s Law
In order for an object to diffract a wave, the wave must be no bigger than the
object  in  question.  X-rays  are  a  form of  electromagnetic  radiation  with  a
wavelength of 0.1-100Å. The average bond length is 1.5Å so x-rays in the
range  of  0.6-3Å are  appropriate  for  atomic  structure  determination.  Light,
having a wavelength of 600nm, is unable to interact with the electron cloud
surrounding atoms so is useless for this level of structural analysis. 
In  1913  William  Lawrence  Bragg  and  his  father  William  Henry  Bragg
discovered that crystalline solids produced surprising patterns of reflected x-
rays. They found that crystals produced intense peaks of reflected radiation at
certain specific wavelengths and incident angles. They explained this result
by modelling the crystal as a set of parallel lines separated by a constant
perimeter of d as shown in Figure 57. The layers look like rows because the
layers are projected onto two dimensions and the viewer’s eye-line is parallel
to  the  layers.  The  variable d is  the  distance  between  atomic  layers  in  a
crystal,  and  the  variable  lambda  is  the wavelength of  the  incident  X-ray
beam. 
The rays of the incident beam are always in phase and parallel up to the point
at which the top beam strikes the top layer at atom z. The penetrating X-ray
travels down to the internal layer, diffracts, and travels back over the same
distance before returning to the surface. The distance travelled depends on
the separation of the layers and the angle at which the X-ray entered the
material. William Bragg proposed that a diffracted x-ray from the surface of a
substance has travelled less distance than the diffracted x-ray from a plane of
atoms inside the crystal. If the two beams are to continue travelling adjacent
and  parallel  to  one  another,  this  extra  distance  must  be  an  integral  (n)
multiple of  the wavelength ( ) for  the phases of the two beams to be the
same. Bragg expressed this in an equation now known as Bragg's Law: 
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n λ = 2 d sinθ
where n is an integer and θ is the angle between the incident (or diffracted) ray and the
relevant crystal planes
When n is an integer (1, 2, 3 etc.) the reflected waves from different layers
are perfectly in phase with each other – a.k.a. constructive interference - and
produce a dark spot on a diffraction pattern. Otherwise the waves are not in
phase – destructive interference - and will either be missing or faint (Bragg &
Bragg, 1913).  
One of the concluding ideas from Bragg's Law is that diffraction is, in effect,
an  "arranged  event";  three  parameters  need  to  be  harmonised:  the
wavelength of the X-rays, λDE3) encoding for the T7 RNAP under the transcriptional, the crystal orientation as defined by the angle, θ
and the spacing, d, of the crystal planes under consideration. For any given
wavelength and set of planes, one can conspire to arrange for diffraction to
occur by, for example, continuously changing the orientation, i.e. changing
theta, until  a point arrives when Bragg's Law is satisfied. This is precisely
when diffraction occurs. 
Bragg's law confirmed the existence of real particles at the atomic scale, as
well as providing a powerful new tool for studying crystals in the form of X-ray
and  neutron  diffraction.  In  fact,  for  this  William  Lawrence  Bragg  and  his
father, Sir William Henry Bragg, were awarded the Nobel Prize in physics in
1915 for their work in determining crystal structures.
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A diagram to illustrate Braggs Law:
d = distance between atomic planes
θ = angle of incidence/diffraction. 
Figure  57: Braggs Law states that the x-ray wave which is diffracted
from the surface of  a substance travels less distance than the x-ray
which is diffracted from a plane of atoms inside the crystal. The extra
distance travelled by the penetrating wave depends on the separation of
the layers and the angle at which the X-ray entered the material. When
the reflected waves from different  layers  are  perfectly  in  phase with
each a dark spot is observed on the diffraction pattern. When the waves
are not in phase, spots will either be missing or faint.
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X-HelixRay Sources and Detectors
There  are  three  forms  of  x-ray  source:  x-ray  tubes,  rotating  anodes  and
particle storage rings. The tubes and anodes generate x-rays by bombarding
a metallic  target – normally copper – with a beam of electrons. Following
collision,  an  electron  from a  low  lying  orbital  in  the  target  metal  atom is
displaced creating a vacancy in its orbital. This is then filled with an electron
from a higher orbital. As the electron drops, excess energy is released in the
form of an x-ray photon (Drenth, 2013) (Figure 58).
In the case of particle storage rings – a.k.a. synchrotrons - electrons are sped
up to 99% of the speed of light. They are contained in vacuum storage rings,
sustained via magnets and driven in a circular motion by energy from radio
frequency transmitters. The sustaining of the electrons in this circular motion
produces x-ray beams which are deflected from side to side using magnets.
This  creates  a  fan  of  x-rays  which  can  be  used  in  several  workstations
located at regular intervals around the ring. The x-ray beam is optimised prior
to diffraction via monochromators and mirrors. The mirrors focus the beam
onto the crystal whereas the monochromator selects the required wavelength
from  the  spectrum  and  remove  unwanted  radiation  (Whittaker,  1982).
Monochromators  are  made  from crystals  of  silicon,  germanium or  carbon
each of which will select a wavelength upon diffraction (Drenth, 2013).
Partical storage rings (synchrotrons) are the preferred method for creating x-
rays as the resulting beam is more powerful  and intense compared to the
alternative methods thus produces higher quality data at a higher resolution
(Lindley, 1999). They have reduced exposure times from hours to minutes
causing a reduction in crystal  damage, and they also collect  an increased
amount of data. One further advantage of using storage rings is the fact that
the  x-rays  produced are  tuneable.  This  quality  proves useful  in  Multi  and
Single  wavelength  anomalous  diffraction  (MAD/SAD)  where  wavelength
specificity is used to solve the ‘Phase Problem’ – a term used to describe the
loss  of  information  concerning  the  phase of  the  x-ray  wave  during
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measurement  (more  details  to  follow).  By  collecting  data  at  several
wavelengths  one  can  determine  phase  information  by  measuring  the
difference in anomalous scattering (Drenth, 2013).
Although synchrotrons have proved to be the superior method in diffraction,
‘in house’ x-ray sources are still in use today. ‘In house’ sources are much
cheaper and easier to maintain due to the x-ray source being produced by a
rotating  copper  anode  rather  than  vacuumed  electrons.  Unfortunately  the
repetition rate of the ‘in  house’ data collection laser is limited to a few hertz
rather  than the megahertz  repetition rates naturally  arising in  storage ring
emission. This means crystals have to undergo radiation for much longer in
order to produce the same amount of images risking damage to the crystal.
However, ‘in house’ does has the advantage of convenience which is why it is
still used as a screening method today. Diamond Light Source Synchrotron is
one of two synchrotrons in Europe and thus requires travel and shift work in
order to use it (Skarzynski, 2013) (Figure 59). 
Various detectors can be used during x-ray crystallography however the most
common  is  the  charged  coupled  devices  (CCDs).  CCDs  are  essentially
photon counters.  They are covered with phosphorus and emit  visible  light
when  exposed  to  diffracted  x-rays.  When  an  entire  diffraction  pattern  is
collected  the  accumulated  pixels  are  converted  into  a  digital  signal  for
subsequent processing by a computer (Drenth, 2013).
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Figure 58: A diagram to demonstrate x-ray generation in tubes and anodes. Initially there is a collision of copper (Cu2+)
with  a  beam  of  electrons.  This  causes  the  displacement  of  an  electron  from  a  low  lying  copper  orbital.  This  is
subsequently replaced with an electron from a higher orbital causing excess energy to be released in the form of an x-ray
photon.
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Figure 59: Photographs of Diamond Light Source, Oxfordshire. Above –
A cartoon  of  the  interior  structure.  The  accelerator  is  located in  the
centre of the ring and is responsible for accelerating electrons to 99%
the speed of light.  Once accelerated, they are contained in the vacuum
storage  ring  and  sustained  via  magnets  in  a  circular  motion.  The
sustaining of the electrons in this circular motion produces x-ray beams
which  are  used  in  several  workstations  located  at  regular  intervals
around the ring. Below – A digital photograph of the exterior structure.
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Data Processing
When  the  crystal  is  hit  by  x-rays,  the  beams  diffract  at  unique  angles
depending on which atom they make contact with. This generates a spot on
the diffraction pattern with particular co-ordinates. The coordinates of each
spot is measured in relation to the centre so to give it a value; the centre of
the diffraction pattern has the coordinates (h,k,l) = (0,0,0). Data processing is
required in order to turn the raw experimental data into a manageable data set
in  the  form of  an  .mtz  file.  The .mtz  file  contains  the  Miller  indices  (hkl),
intensities (Ihkl) and standard uncertainties (σIIhkl) of all  the reflections in the
diffraction  experiment  that  are  required  for  the  Fourier  transform  formula
below. Through this, the electron density surrounding an average molecule in
the unit cell (ρx,y,z) can be described.
There are three stages in data processing: autoindexing, post-refinement and
integration. During the first stage – autoindexing – the unit cell parameters are
determined alongside the point group and orientation of the crystal in relation
to the x-ray beam. The unit cell  is the most basic repeating structure of a
lattice. It has three lengths (a,b, and c), three angles (  β and ) and can beɑ- ɣ.
divided into asymmetric units. The values of these dimensions describe the
morphology of the unit cell (Figure 61). 
The symmetry of a unit cell is described by its space group. The beginning
letter of a space group represents the lattice type and the numbers represent
the operations defining the symmetry of the cell. (e.g. P212121) There are 5
lattice types: P, C, F, I, and R. P (primitive) is the smallest lattice type and the
most desired as it contains a single lattice point at each corner around which
the asymmetric units are arranged. The other lattice types are said to be face-
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centered or body-centered as they contain (in addition to the lattice points at
the corner of the cell) extra points in the centre of one face (C), all faces (F) or
the centre of the cell (I). The unit cell can adopt one of seven different crystal
systems: triclinic, monoclinic, orthorhombic, trigonal, tetragonal, hexagonal or
cubic.  A  combination  of  these  seven  crystal  systems  plus  the  5  types  of
centering allows the possibility of 14 Bravias lattices  (Ladd & Palmer, 2014)
(Figure 62).
The  post  refinement  stage  follows  autoindexing.  This  process  refines  the
initial estimates of the cell parameters by combining one or two segments of
data, each containing two or three different images. Following this, the final
integration stage merges all  of the collected images and refines the crystal
and detector parameters to generate a full list of hkl and Ihkl. 
Upon further scrutiny one will notice that the actual diffractors of x-ray beams
are  the  clouds  of  electrons  around  the  atom,  not  the  atom  itself.  –  i.e.
diffraction  patterns  represent  electron  distribution/density  surrounding  a
molecule. It is the crystallographers’ job to rearrange the atoms so that they fit
within this electron density map.
The Phase Problem
The  Fourier  transform  above  is  used  to  convert  diffraction  data  into  the
electron density of the unit cell. Most of the parameters needed to construct
this  equation  are  available  from the  diffraction  data.  A  diffraction  wave  is
made  up  of  3  factors;  frequency,  phase  and  amplitude  (Figure  60).  The
frequency is that of the x-ray source and the amplitude is equal to the square
root of the intensity measured for the reflection hkl (Ihkl)1/2. The phase of the
wave, however, is unknown. This loss of phase information is known as the
‘Phase Problem’. 
There are three methods used to overcome the ‘phase problem’ 
 Isomorphous replacement
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 Single/multi-wavelength anomalous dispersion (SAD/MAD)
 Molecular replacement
Isomorphous  replacement  involves  the  insertion  of  a  heavy  atom into  the
structure  either  by  crystal  soaking  or  through  protein  synthesis  with
analogues.  These  heavy  atoms  are  used  to  help  orient  and  position  the
reflections. The advantage of using this method is that the addition of the
heavy atom does not alter the crystal formation or the unit cell in any way; it is
isomorphic  to  the  native  crystal.  The  disadvantage  is  that  at  least  two
isomorphous derivatives must be evaluated -  the native and heavy -  since
using only one will give two possible phases. This is time consuming and can
use large quantities of  protein  sample.  However,  once both data sets  are
collected the Patterson difference map can then identify the location of the
heavy atom in the map determining both amplitude and phase. 
MAD is when diffraction is recorded at multiple wavelengths. The atoms inner
electrons absorb x-rays and reemit them after a delay causing a phase shift in
all of the reflections. This is known as the anomalous dispersion effect. By
analyzing the phase shift rather than just the individual reflections, a solution
for the phases can be provided. Here, the advantage is that the method does
not require multiple crystal structures with heavy and light atoms. The difficulty
with this method is that it requires very specific wavelengths which can only
be obtained using synchrotron radiation.
In the case of SAD, a single dataset is collected at a single wavelength. The
advantage of this method is the reduction of beam exposure to the crystal,
minimising radiation damage during data collection. The disadvantage lies in
the quality of the data produced. The electron density map of the resulting
data must be adjusted at the interstitial regions between protein molecules
occupied by the solvent in a process called ‘solvent flattening’. Only then can
the results be comparable with those derived from MAD experiments. This is a
time consuming process.
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Figure 60: A graph to illustrate the features of an x-ray wave.  Amplitude represents the maximum displacement of a point
in a vibrating wave whereas wavelength is the distance between successive crests in a wave. To explain phase, one must
remember that waves are composed of peaks and valleys with a zero-crossing between them. The phase of a wave is
described as the distance between the first zero-crossing and the point of origin.
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Figure 61: The dimensions of a unit cell.
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Bravias Lattice Parameters Simple (P) Volume
Centered (I)
Base
Centered (C)
Face
Centered (F)
Triclinic ɑ1 ≠ ɑ2 ≠ ɑ3
ɑ12 ≠ ɑ23 ≠ ɑ31
Monoclinic ɑ1 ≠ ɑ2 ≠ ɑ3
ɑ23 = ɑ31 = 90°
ɑ12 ≠ 90°
Orthorhombic ɑ1 ≠  ɑ2 ≠ ɑ3
ɑ12 = ɑ23 = ɑ31 = 90°
Tetragonal ɑ1 = ɑ2 ≠ ɑ3
ɑ12 = ɑ23 = ɑ31 = 90°
Trigonal ɑ1 = ɑ2 = ɑ3
ɑ12 = ɑ23 = ɑ31  < 120°
Cubic ɑ1 = ɑ2 = ɑ3
ɑ12 = ɑ23 = ɑ31 = 90°
Hexagonal ɑ1 =  ɑ2 ≠ ɑ3
ɑ12 = 120°
ɑ23 = ɑ31 = 90°
Figure 62: A table of the 14 Bravias lattices.
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Molecular Replacement
Molecular replacement was the chosen method for this project. This is where
the phases of a similar,  previously solved structure are used to orient the
experimental  molecule  in  the  unit  cell.  The  advantage  of  this  is  that  the
calculated phases can be applied to the experimental molecule in order to
solve the structure. The disadvantage of this method is that it can severely
bias the solution of the experimental structure. In order to use the molecular
replacement method there needs to be homology of at least 25% between the
model and experimental structures. To prevent model bias from occurring the
structures are put through multiple cycles of refinement, map calculation and
model building.
Molecular  replacement  requires  a  six  dimensional  search  which  includes
three translations and three rotations. By splitting this search into two different
stages efficiency is maintained and computing time is minimized. The model
is first rotated whilst ignoring its symmetry until the best agreement with the
observed  data  is  observed.  The  correctly  orientated  structure  is  then
translated within its parameters until best agreement with the diffraction data
is obtained. 
The ‘R factor’  is  used to  evaluate  the  translation  function.  It  monitors the
relationship  between  the  model  structure  amplitudes  (calculated)  and  the
experimental ones (observed).
With each reflection the difference between the observed and actual structure
factors are calculated and the magnitudes of the difference for each reflection
are added together and divided by the sum of Fobs.  If the agreement is close
then the sum of the differences will be smaller than the intensities themselves
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and R is therefore small. A perfect agreement will have an R factor of 0 but
crystallographers consider values between 0.3 and 0.4 to be respectable. The
final value of the R factor never actually becomes zero as its value depends
on the degree of order held within the crystal and the quality of the diffraction
data; neither of which will be perfect.
Although  an  extremely  useful  technique,  molecular  replacement  is  only  a
preliminary method of  structure solving. In  order to  refine the model,  rigid
body refinement must be performed. 
Structure Refinement
Upon  solving  the  ‘Phase  Problem’  using  one  of  the  three  techniques
mentioned above,  the data  must  continue to  be processed with  structural
refinement and modeling techniques. The purpose of refinement is to achieve
the  best  fit  between  the  pre-solved  model  (calculated  data)  and  the
experimental  data  (observed  data).  This  is  done  by  altering  the  atomic
positions x,y and z until  an improved fit  is obtained. Again, the R factor is
used to  measure  the  discrepancies  between the  calculated  and observed
data.  As  agreement  between  the  two  improves,  the  R  factor  falls  down
towards zero. 
The refinement of proteins is much more difficult than the refinement of their
inorganic counterparts. This is due to the large quantities of atoms present in
a  protein  structure.  Each  atom  has  three  parameters  which  need  to  be
included in the refinement process: occupancy, temperature factor (B-factor)
and atomic position. The more atoms there are, the weaker the ratio between
observations and atomic parameters. To resolve this ratio problem, a number
of constraints and restraints are used in the refinement process. 
A constraint is a fixed value for a certain parameter. An example of this is
when the occupancy of a particular atom is set to 0.1 during refinement. A
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restraint allows slightly more flexibility in value but in this case bond lengths
and angles must be within strict range of values. The inclusion of constraints
and restraints in refinement acts as an equivalent to increasing the number of
observations.  It  also  helps  to  maintain  the  correct  stereochemistry  of  the
model.
There is a limit to the amount of constraints and restraints that can be used in
refinement. This is dependent on data quality and resolution. The lower the
resolution – i.e. the lower the amount of reflections – the fewer observations
there  are  ergo  limiting  the  ability  to  refine  all  the  atomic  parameters
individually.  The  observations  available  at  relatively  low resolutions  would
only permit the refinement of the main chain conformational angles (torsion
angles). This generates two variables per amino acid: φ and ψ. In the case of
higher resolution data, side chain conformation angles (χ) can also be refined) can also be refined
but only with the bond angles, bond lengths and planarities tightly restrained
with a single B factor for the whole structure. This circumstance provides four
variables per amino acid. With further improvement of the data two separate
B factors can be calculated for each amino acid (one for the main chains and
another for the side chains) generating three more variables per amino acid.
Resolutions of 2.5 Å or better allow separate B factors to be calculated for
each atom. At 2.0 Å, cartesian angles can be refined for each atom. Upon
reaching 1.5 Å, anisotropic B factors showing density contribution of individual
atoms and the particular direction in which they are free to move, are added
as parameters.
Model Building
As the name suggests, model building is used to rebuild the structure model
into the electron density map wherever necessary. This is done manually by
the crystallographer and can be considered as the final “polishing” step in
structure solving. 
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This method requires the electron density to be calculated, ρ (x,y,z). Normally
two types of electron density map are calculated: a 2Fo-Fc map and a  Fo-Fc
map.  The  Fo-Fc map provides information on the new model. The resulting
Fourier term can be either positive or negative depending on whether Fo or Fc
is larger. A positive Fourier term indicates that the observed intensities (Fo) to
ρ are greater than that of the calculated structure factors (Fc).  This in turn
suggests that the unit cell contains more electron density in this region than
implied by the model (Fc) and requires the movement of atoms towards this
area  in  order  to  increase  the  electron  density.  A  negative  Fourier  term
indicates that the model implies more electron density in the region than the
unit cell actually contains. Atoms must therefore move away from this area
(Figure 63). 
The Fo-Fc map can be difficult to interpret on its own so the more interpretable
2Fo-Fc map is also calculated. By doing so, the influence of Fc is still reduced
but to a lesser extent than the Fo-Fc map. If errors in the model are minimal,
this map is completely positive and depicts a molecular surface covering all
the atoms of the protein.
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Figure 63: An example of a model constructed using an electron density map. The protein chain is represented in yellow
sticks and the blue netting represents the  clouds of electrons surrounding the atoms, not the atoms themselves. The
atoms are manipulated manually so to fit them into the density map in a process called ‘modeling’. 
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Chapter 5
Amyloid Treatment and Structural Studies
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Antibodies against SAP
Chapter Aims
This chapter aims to look at the relationship between SAP and its specific
antibody through use of x-ray crystallographic techniques. The reason for this
refers back to O’Nuallain and Wetzel’s work on SAP knockout mice in 2002.
They made the following conclusion:
 ‘SAP has an anti-opsonin role’ - i.e. the immune system is normally able to
recognise amyloid but SAP provides a protective coat around the fibrils. This
in turn prevents phagocytic  cell  recognition and thus prevents an immune
response in the presence of amyloid deposits.
Chapter  4  briefly  mentioned  GlaxoSmithKline’s  recent  developments  on
antibodies  specific  to  SAP.  These anti-SAP antibodies  have  the  ability  to
detach SAP from amyloid deposits and thus leave the deposits exposed to
the  host’s  immune system.  The  exact  mechanism behind  this  is  not  fully
understood however clinical trials have shown that following the removal of
deposit bound SAP from the body, deposits are dissociated and fibre mass is
reduced. 
Unfortunately, affinity towards the anti-SAP antibody is not specific to deposit
bound SAP alone. Serum SAP also exhibits optimal binding to the antibody.
Due to this, an anti-SAP antibody dosage often exhibits complete saturation
before it has even been able to reach its deposit bound target. In an attempt
to resolve this  problem, the drug R-1-[6-[R-2-carboxy-pyrrolidin-1-yl]-6-oxo-
hexanoyl] pyrrolidine-2-carboxylic acid (CPHPC) has very recently been used
in conjunction with the anti-SAP antibody in clinical trials. 
CPHPC acts as a competitive inhibitor of SAP. CPHPC is a small palindromic
molecule which has the ability to remove 99% of SAP from circulation within a
256
single week of administration. X-ray crystallography has been used to better
understand the  mechanism in  which  it  does this.   The  resulting  structure
shows that five CPHPC molecules dimerise two SAP molecules, B-face-to-B-
face, via cross-linking of lysine 143 in neighboring SAP monomers  (Figure
64).  When  CPHPC  is  administered  in  patients,  the  resulting  decameric
complex is immediately removed from the system via the kidneys and liver
and as of yet, no side effects have been noted. Once treatment has ceased,
serum levels  are restored to  their  original  concentrations after  four  weeks
(Pepys et al. 2002).  It has also been noted that CPHPC has the ability to
detach and remove deposit bound SAP from the system in a fashion similar to
the antibodies.  However, this is done inefficiently which explains why it has
not been used as a lone treatment process until recently.
In order to efficiently dissociate amyloid deposits it is necessary to use both
anti-SAP antibodies and CPHPC in conjunction with one another. Treatment
begins when CPHPC is introduced to the system. The drug readily clears the
circulatory SAP from the system leaving the deposit bound SAP. Following
this, the anti-SAP antibodies are administered.  These antibodies bind to the
remaining SAP - those which re bound to the amyloid deposits - and cause
them to dissociate from the fibres thus leaving them exposed. This stimulates
an  immunological  cascade.  Signals  created  by  the  antibodies  activate  a
compliment  dependent, macrophage-derived, giant cell  attack on the newly
exposed fibres and the deposits are depleted (O’Nuallain and Wetzel 2002). 
The  use  of  this  combined  treatment  against  amyloid  originally  proved
successful in 2010 when Bodin et al attempted this on mice carrying visceral
amyloid deposits  (Bodin et al.  2010). They found that upon addition of the
antibody,  amyloid  deposit  mass  was  rapidly  reduced  with  no  clinical  or
biochemical adverse effects. Currently, anti-SAP antibodies are being used in
conjunction with CPHPC as a clinical treatment for human patients suffering
from amyloidosis at the Royal free Hospital, London. The latest results show
that the treatment appears to be safe, reduces amyloid in almost all subjects
and can even improve organ function.  The depletion of amyloid is not equal
in all patients but the clearance of amyloid is much faster than that with other
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treatments.  The most recent trial  was conducted on  a total  of  16 patients
ranging  between  18  to  70  years  of  age.  Upon  administration  of  CPHPC,
circulating SAP was depleted to less than 0.5 mg per litre in patients with a
small or moderate amyloid load and to less than 2 mg per litre in patients with
a  large  amyloid  load.  Following  treatment  with  anti-SAP  antibodies,  only
transient  low-grade  infusional  side  effects  were  observed.  Three  patients
experienced  brief  episodes  of  headache  and  another  a  brief  episode  of
nausea (Richards et al. 2015). 
Although these results appear promising, more work needs to be carried out
in  order  to  guarantee  safety  and  effectiveness  of  the  treatment.  Thus far
these  trials  have  shown  a  decrease  in  amyloid  but  they  have  yet  to  be
successful  in  complete amyloid  eradication.  It  is  necessary to  remove the
entire  deposit  otherwise  symptoms  may  return  and  surgery  may  still  be
required at a later date. By understanding the location and mechanism behind
SAP:antibody binding it may become apparent how to optimise the treatment
process. 
To this date, extensive structural analysis has not been carried out on the
SAP:antibody complex. It is not known how or where they bind. This limits the
understanding scientists have on the interactions between the two molecules
and how detachment from in vivo fibres actually occurs. In order to add some
clarity towards this, the crystal structure of SAP bound to its specific antibody
has to be made and subject to x-ray diffraction analysis. Attempts to carry out
such a protocol have never been done before, however, it should be possible
if the following steps are carried out: 
- Digest  the SAP specific  antibody so to  remove its flexible hinge
region and thus make it suitable for crystallisation.  
- Combine SAP with an excess of the digested fragments in order to
create a fully saturated SAP:Fab complex. 
- Decipher the optimal  conditions required for crystallisation of the
complex.
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- Submit the complex crystal  to x-ray analysis in order to obtain a
diffraction data set.
- Solve the diffraction data set using the CCP4i programme suite so
to decipher the interaction between the SAP and Fab fragments.
 
By solving the structure of this complex, the mechanism behind SAP:antibody
binding  could  be  distinguished.  This  could  lead  to  later  developments
regarding  this  treatment  thus allowing for  higher  success rates  and lower
fatality numbers.
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Figure 64: Images depicting the interaction of SAP with CPHPC. Above –
A stick diagram showing the point of cross-linking in the SAP sequence.
Below – A structure of the complex in solution.  Two SAP pentamers
(green) are cross-linked, B-face to B-face, by five molecules of CPHPC
via lysine143. The residues involved in binding (138 – 144) are shown in
red and calcium ions  are  represented in  orange.   (PDB code:  4AVT)
(Kolstoe et al. 2009) 
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 An Introduction to Antibodies
The body is continuously exposed to a variety of foreign materials (antigens).
These antigens must each be eliminated quickly and efficiently to prevent any
harm to the body. It  would not be practical for nature to devise a different
molecular solution for each antigen as the genome is not large enough to
contain that amount of information. Instead, nature has created a single way
in which to resolve the antigen problem; the antibody.
An antibody has two functions in the immune system. The first is to recognise
and bind antigens whereas the second is to trigger the elimination of  that
material via effector molecule binding.  The first of the two functions requires a
great deal of diversity as the antibody has to be able to recognise and bind a
divert number of molecular structures. The second function, however, requires
a  certain  level  of  consistency  in  order  to  trigger  the  appropriate  immune
response upon binding.  The conflicting requirements are met by the antibody
structure (Delves et al. 2006). 
The antibody is ‘Y’ shaped and consists of three units. Two of these units are
identical and are involved in antigen binding. These are called the fragment
antigen binding units (Fab). The Fab units contain protein sequence segments
which vary greatly between antibodies and provide binding specificity to a
large number of antigens. The remaining fragment crystalline unit (Fc) has
little variation in its primary protein sequence and is responsible for triggering
the immune system through effector molecule binding (Janeway et al. 2001). 
There is  an extended sequence segment which connects the Fab and Fc
regions referred to as the hinge region. The hinge region adds flexibility to the
Y structure allowing the antibody to bind to molecular structures of different
spacing  on  an antigen  cell  surface  (Figure  65).  Although  this  flexibility  is
useful  for  molecular function,  it  is  an undesirable quality in  terms of  x-ray
crystallography.  Fortunately  the  hinge  region  is  extremely  susceptible  to
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cleavage by proteases which enables non flexible (i.e. uniform) structures to
be produced (Delves et al. 2006).
There are five antibody subclasses found in humans named Immunoglobulin
γ, α, μ, δ and ε (IgG, IgA, IgM, IgD and IgE). Each is responsible for binding a
different  effector  molecule  and thus triggers a different  pathogenic  system
upon antigen binding. All five antibody subclasses are composed of a four-
chain structure which consists of two identical ‘heavy’ and two identical ‘light’
polypeptide chains. The heavy chains span the Fab and Fc units whereas the
light chains are associated purely with the Fab unit. The five subclasses are
mostly identical however they each have variations in their Fc region which is
what determines their unique trigger system. The structural variety of each
subclass  also  determines  the  polymerisation  state  of  the  monomer.  For
example, IgM predominantly exists as a pentameric form where as the other
subclasses are monomeric. The IgA subclass does have the ability to form a
dimer but  only exhibits this when excreted in seromucous secretions (Delves
et al. 2006) (Schroeder Jr. and Cavacini 2010) (Table 7).  
Immunoglobulin G (IgG) Structure and function
IgG is the most abundant immunoglobulin form. It is synthesised and secreted
by plasma B cells and exists up to 75% in serum (Hadley 2007). The heavy
chains in IgG are approximately 50kDa in length while the light chains are half
the size at 25kDa each. This totals to 150kDa per antibody molecule. The
heavy chains are linked together via two inter-peptide disulphide bonds and
each has a  light  chain  attached  via  another  inter-peptide  disulphide  bond
(Schroeder Jr. and Cavacini 2010).  
There are 4 IgG subclasses in humans (IgG1,2,3 and 4) named in order of
abundance  with  1  being  the  most  abundant  (Figure  66).  They  have  a
sequence homology of 95% with differences lying in their hinge region. Of the
four,  IgG1 is the subclass which is most commonly used for  experimental
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work due to its abundance. It consists of twelve domains, four in each heavy
chain and two in each light chain. The heavy chains have three constant and
one variable domain labelled Constant-Heavy domain 1,2 and 3 and Variable-
Heavy domain (CH1, CH2, CH3 and VH). In contrast, the light chains have only
one of each: Constant-Light domain (CL) and Variable-Light domain (VL). Each
domain, whether heavy or light, is between 110- 130 residues long, 12-13kDa
in size and is folded into two twisted stacked beta sheets (Figure 67, Figure
68).  The  sheets  enclose  an  internal  volume  of  hydrophobic  residues  in
something which is referred to as an immunoglobulin fold (Schroeder Jr. and
Cavacini 2010). One of these sheets has four anti-parallel strands whilst the
other  has three.  They are connected via  bends/loops with  little  secondary
structure and stabilised by an internal disulphide bond. The residues involved
in the sheets tend to be conserved whereas the residues in the loops are
more diverse (Harris et al. 1996).
Each domain is bound to its neighbour via Van der Waals interactions. They
all have close lateral sideways association except CH2 which has a conserved
sugar  chain  linked  to  it,  weakening  its  bonds  to  its  neighbours.  CH2  also
contains  the  binding  site  for  several  important  effector  molecules  e.g. Fc
receptors  and  C1q  from  the  complement  system.  These  are  protein
complexes which  bind  to  CH2 of  IgG and actively  induce the  compliment
pathway.
All  of  the  constant  domains  are  completely  identical  whereas the  variable
domains  contain  changeable  antigen  binding  sites.  There  is  an  enormous
range in diversity when it comes to these antigen binding sites, however, the
two  variable  domains  on  each  IgG  molecule  are  identical  making  each
antibody specific to one particular antigen. (Delves et al. 2006).
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Figure  65:  A  simplified  antibody  structure  with  Fab  and  Fc  regions
labelled. The “Y” structure consists of four chains; two light and two
heavy. The heavy chain spans both the Fab and FC region whereas the
light  chain  lies  exclusively  in  the  Fab  region.  The  Fab  regions  are
identical  and  are  responsible  for  antigen  binding  where  as  the
remaining  Fc  unit  is  responsible  for  triggering  the  immune  system
through effector molecule binding (CK-12, 2017)
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The five Immunoglobulin (Ig) subclasses
IgG IgA IgM IgD IgE
Heavy chain type ɣ. ɑ- μ δ ε
Molecular weight 150kDa 385kDa 900kDa 180kDa 200kDa
Number  of  antigen
binding sites
2 4 10 2 2
Secretory
component? 
no yes no no no
J Chain no yes yes no no
Crosses placenta yes no no no no
Fixes complement yes no yes no no
Fc binds to phagocytes Some polymorphonuclear
leukocytes and lymphocytes
B cells Not involved in
compliment
Mast cells and
basophils
Function Main antibody of
secondary immune
responses,
neutralizes toxins
and opsinisation
Secreted into mucus, tears and
saliva
Main antibody of
primary response. Best
at fixing complement
B cell receptor Antibody of allergy
and antiparasitic
activity
Table 6: A table comparing the five antibody subclasses.
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 Figure 66: A comparison of the four IgG subclasses. Each are identical in all
structural aspects expect for their hinge region. IgG2’s hinge region consists
of 4 inter-heavy chain disulphide bonds where as IgG3 consists of 11. Both
IgG1 and IgG4 hinge regions hold two inter-heavy chain disulphide bonds,
however, IgG1 is constructed of 15 amino acids where as IgG4 is constructed
of 12 (Immunoglobulin G Deficiency, 2017).
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Table 7: A table comparing the properties of the four IgG subclasses (Vidarsson, Dekkers, and Rispens 2014).
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 Figure 67: A simplified diagram of an IgG1 antibody. The 12 domains are
divided into  2  light  (L)  chains  and 2  heavy (H)  chains  connected by
intermolecular  disulphide  bridges.  The  constant  (C)  and  variable  (V)
domains are labelled as well as the enzyme cleavage sites of papain and
pepsin (Delves et al., 2006).
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Figure 68: A ribbon diagram of IgG1. The heavy chains are represented
in blue (dark ad light) and the light chains in orange. The yellow spheres
represent the disulphide bonds which connect the chains to form the
typical “Y” structure. The Fab and Fc regions are labelled alongside the
oligosaccharides and immunoglobulin domains (Jefferis 2006). 
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VDJ Recombination
In order for an interaction to occur between antibody and antigen they must
compliment each other in terms of shape and polarity. The antigen binding
region of an antibody, also known as the hypervariable region, is made up of
six Compliment Determining Region (CDR) loops; three from the VH domain
and three from the  CH domain  (Figure  69).  Although made from a  small
genome (30k genes), the antibody is able to create enough variation in these
loops  for  it  to  recognise  millions  of  antigens.  This  is  achieved  through
something  called  somatic  VDJ  recombination.  This  is  where  DNA  is  not
inherited from the germ line cells but instead rearranges itself in somatic – in
the cells of the body. Specifically it  occurs during b-cell development in the
bone marrow and involves the splicing of gene segments; mostly introns and
some exons.
The three loops from the VL domain are named L1,2 and 3 and the three
loops from the VH domain are named H1,2, and 3. The loops L2, H2 L3 and
H3  are  Beta-hairpins.  These  specific  loops  are  responsible  for  linking
successive anti-parallel strands of a single beta sheet whereas L1 and H1
form bridges from a strand in one of the beta sheets to a strand in the other.
Five of the six CDR loops have a conserved suit of residues whose function is
to maintain loop conformation in this hypervariable area. H3 is the loop with
more variability in length, sequence and structure. H3 appears in the centre of
the antigen binding site and makes significant interactions with its surrounding
loops – i.e. its conformation depends on its environment (Lesk 2010) (Wood
2004).
The  variable  light  and  heavy  chain  loci  of  humans  contain  multiple  gene
segments  which are joined through somatic  recombination to  produce the
final variable region exon.  The heavy chain variable region is constructed by
the joining  of  three gene segments  named variable  (V),  diversity  (D)  and
joining  (J).  The  light  chain  gene  is  constructed of  only  V  and J  and has
options for both kappa and lambda variations. Diversity is increased further
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through frequent mutations of the CDRs during B-cell  maturation and from
random pairing of heavy and light chains (Paul 2008).
VH genes are mapped in chromosome 14 although some orphan IgH have
been found in chromosome 15 and 16.  The heavy chain has over  100 V
genes, 27 D genes, 11 C genes and 9J gene giving a possibility of 24,000
conformations. The light chain lambda locus is found on chromosome 22 with
70 functional V genes and 7 functional J genes giving a possibility of 490
conformations.  The  remaining  light  chain  kappa  locus  is  located  on
chromosome  2  with  70V  and  5J  (350  combinations).  The  kappa  locus,
however, contains a large duplication of most the V genes (Liljas, A. 2009).
Diversity is further induced by random combination of heavy and light chains.
This allows a total of 24000  (490 x  350) possible combinations. Additional point
mutations and insertion/deletion of gene segments increases this further and
provides protection against millions of antigens.
 
Light lambda Light kappa Heavy
V 70+ 70+ 100+
J 7 5 9
C 7 1 11
D - - 27
 A table demonstrating the genetic availabilities for VDJ recombination.
VDJ recombination is  a  regulated and ordered event.  In  the  light  chain it
involves the DNA exon being constructed from a single V to J gene segment
join. In the heavy chain, D is first joined to J and then V is combined to the DJ
sequence. The re-arranged DNA is then transcribed, spliced and translated
as normal (Delves et al. 2006) (Figure 70).
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 Figure 69: A ribbon diagram demonstrating the structure and packaging
of  the  constant  and variable  immunoglobulin  domains.  Each domain
consists of two twisted stacked beta sheets (blue and gold) enclosing
an internal volume of hydrophobic residues. The discrepancies between
the two domains are highlighted in red. The variable domain consists of
two extra β-strands and three hypervariable CDR regions at the antigen
binding site to enable higher levels of  diversity.  Regardless of being
variable  or  constant,  all  domains  require  intra-molecular  di-sulphide
bonds for domain stability (labelled –S=S-) (Branden and Tooze 1991). 
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 Figure  70: A ribbon diagram illustrating the CDR loops present at an
antigen binding site of an antibody.  Three loops are provided by the
heavy chain (labelled H1,2 and 3) and three are provided by the light
chain (labelled L1,2,and 3) giving a total of six hypervariable loops per
arm. With each IgG1 molecule having two arms this gives an overall of
12 loops per IgG1 molecule (PDB code: 4NUJ). 
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A diagram illustrating VDJ recombination. In the light chain, the exon is constructed from a single V to J gene segment
join.  In the heavy chain,  D is first joined to J and then V is combined to the DJ sequence. The re-arranged DNA is
transcribed, spliced and translated as normal (Systems Immunology, 2017).
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Antibody Preparations for X-HelixRay Crystallography
The anti-SAP antibody was provided by GlaxoSmithKlein in the form of an
IgG1 molecule.  In  Due to  the  flexible  nature  of  the  IgG molecule,  it  was
important that it be subject to fragmentation before any form of x-ray analysis
could occur. 
Antibody fragmentation can be achieved through the use of any protease; an
enzyme that performs proteolysis by hydrolysing peptide bonds. However, for
the purposes of  this  particular  experiment,  it  necessary to  cleave the IgG
molecule specifically in its hinge region. Cleavage of this region results in rigid
Fab and Fc production which is ideal for crystal growth.
The enzyme papain was chosen for IgG fragmentation.  Papain, also known
as  papaya  proteinase I,  is  a  cysteine  protease  found  in  papaya  whose
cleavage site lies within the flexible hinge region of the IgG antibody. It is 212
residues long and is formed of two domains which are stabilised by three
disulphide bridges. It is the cleft between these two domains which contains
the  active  site.  Like  all  cysteine  proteases,  papain  cleaves  proteins  via
hydrolysis of the peptide bond using a nucleophilic cysteine thiol in a catalytic
triad mechanism (Kamphuis et al. 1986). 
The first step in this reaction is the deprotonation of a cysteine thiol (cysteine
25) in the enzymes active site by the adjacent histidine (histidine 159).  The
deprotonated thiol attacks IgG’s heavy chain between residues 224 and 225
(histidine and threonine respectively) via nucleophilic attack on the carbonyl.
This causes cleavage to occur between histidine 224 and threonine 225 and
as a result of this, a fragment of the substrate peptide is released (threonine
225 – lysine 330).  Subsequently,  histidine 224 becomes the new carboxyl
terminus. It binds  the cysteine thiol from the proteinase creating a thioester
intermediate and causing the enzyme histidine to be restored to its original
deprotonated  state.  Finally,  hydrolysis  occurs  on  the  thioester  creating  a
carboxylic  acid  moiety  on  the  remaining  fragment  and  regenerating  the
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enzyme.  This process is then repeated between residues 233 (glutamic acid)
and 234 (Leucine) (Lowe 1970).  
It should be noted that the catalytic activity of papain can be inhibited in the
presence of metal  ions and certain organic compounds such as Imidazole
(Sathish, Kaul, and Prakash 2000). Studies have shown papain to lose 50%
of  its  activity  in  2x10-4 M of  cadmium ions and 4x10-4 M of  zinc  ions.  At
concentrations 1x10-3 M or higher of either metal or compound papain has
shown to be completely inactivated. The loss in activity can be explained by
the fact that all three have higher affinity for the active site than the substrate.
Binding of these to the papain active site leads to small changes in the beta-
structure content and causes a decrease in the thermal stability of the protein.
A protocol for papain digestion was found in a journal by Andrew and Titus in
2001.  Here they carry out a 1:100 mass digestion for a total of 3 hours in
order to obtain Fab and Fc fragments. These are later separated through the
use of a HiTrap protein-A affinity column.
Protein-A  is  another  molecule  often  used  for  single  step,  affinity
chromatography. Protein-A is a 42kDa recombinant protein made in bacteria
(Staphylococcus aureus).  It  is composed of 5 homologous immunoglobulin
binding sites which fold into a 3 helix bundle. It  has the ability to bind all
human  immunoglobulins  through  their  Fc  region  by  means  of  N-
hydroxysuccinimide (NHS) activation; a process which causes the coupling of
the IgG C-terminus carboxyl group with the amine group of protein-A via ester
intermediates.  This  means  that  when  subject  to  protein-A  columns,  the
digested Fc fragments and the undigested IgG fragments all exhibit column
binding whereas the remaining Fab fragments are eluted. In order to then
remove the bound Fc and IgG fragments from the column, pH 4 buffer can be
used.  This low pH increases the hydrogen concentration in the column and
removes  the  negative  charge  from  protein  A  thus  releasing  the
immunoglobulin carboxyl group.
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Once separated from the other digestion components, the Fab fragments can
be combined with the SAP so the make the complex. It is essential that the
Fab  fragments  be  added  in  excess  to  ensure  full  saturation  of  the  SAP
molecules therefore the molar masses of each component must be take into
account. Fab fragments have a molecular mass of 50kDa where as the SAP
pentamer  has  a  molecular  mass  of  125kDa.  This  means  that  the  Fab
fragments are already in 2.5x molar excess. Therefore a minimum volume
ratio of 2:1 SAP:Fab respectively would be necessary to ensure uniformity. 
Upon forming of the complex, it can be separated from the excess Fab using
High Performance Liquid  Chromatography (HPLC).  This  particular  form of
chromatography separates its constituents via their size.  A pumping system
drives  the  mobile  phase  (the  sample)  through  the  HPLC  column  which
contains a solid phase in the form of a porous resin. This resin allows smaller
particles to pass through its complex network whilst excluding lager particles.
In  the  case  of  these  experiments,  the  larger  SAP:Fab  complex  will  have
difficulty travelling through the central pore system of the column compared to
the smaller excess Fab fragments. This will result in the complex travelling
around the resin beads – a faster route – and being eluted first. Meanwhile,
the excess Fab will be small enough to travel through the central aqueous
system within the beads - a longer route - resulting in a later elution time. 
Once separated and concentrated, the rigid complex will be able to undergo
multiple rounds of crystallisation and optimisation in an attempt to form large,
clear crystals suitable for x-ray analysis.
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Methods
IgG Fragmentation Protocol
IgG Preparation
A  sample  of  103.5mg/ml  anti-SAP  IgG  antibody  was  obtained  from
GlaxoSmithKlein  (GSK).  All  impurities  were  removed  from the  sample  via
overnight dialysis in a cellulose membrane with a molecular weight cut off
point of 100kDa. Dialysis was achieved at a ratio of 1:1000, IgG to sample
buffer respectively (20mM sodium phosphate, pH 7). 
In preparation of IgG fragmentation, an aliquot of dialysed IgG was diluted to
4ml of approximately 12mg/ml concentration using sample buffer containing
EDTA (20mM sodium phosphate,  5mM EDTA,  pH7).  This  was  to  ensure
chelation  of  any  metal  ions  present  in  the  solution  and  thus  prevent
inactivation of papain further on in the protocol. The EDTA was subsequently
removed via overnight dialysis against 500ml of sample buffer at 4°C and the
prepared IgG was concentrated via  centrifugation in an 18cm radius rotor
Beckman  Allegra  X-12R  centrifuge  until  1ml  of  approximately  20mg/ml
sample remained. 
Papain Cleavage (1:100 Mass Digestion)
Immediately  before  digestion,  powdered  bovine  papain  was  dissolved  in
digestion buffer (20mM sodium phosphate, 20mM Cysteine, pH 7) in order to
produce a fresh enzyme stock 1mg/ml in concentration.  An aliquot was taken
and diluted  to  0.2mg/ml  using  more  digestion  buffer.  Of  this,  0.66ml  was
added to the 1ml of prepared IgG to create a 1:100 mass ratio of papain to
IgG respectively. The mixture was diluted to 4ml through further additions of
digestion buffer and the mixture was left  to incubate at 37°C for a total  of
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three hours.  Samples of the digested mixture were subject  to SDS PAGE
analysis periodically on a 12% acrylamide gel so to check the outcome of the
digestion. After completion of the incubation period, 30mM of iodoacetamide
was added so to deactivate the papain and the digested sample was dialysed
overnight  against  sample  buffer  in  order  to  remove  cysteines  from  the
solution.
Papain Cleavage (1:100 Molar Digestion)
Immediately  before  digestion,  powdered  bovine  papain  was  dissolved  in
digestion buffer (20mM sodium phosphate, 20mM Cysteine, pH 7) in order to
produce a fresh enzyme stock 1mg/ml in concentration.  An aliquot of this
was taken and diluted to 0.2mg/ml using digestion buffer. Of this, a total of
0.17ml was added to 1ml of prepared IgG described above and this mixture
was diluted to 4ml through the addition of more digestion buffer. The mixture
was left to incubate at 37°C for a total of three hours. Samples of the digested
mixture  would  be  subject  to  SDS PAGE analysis   periodically  on  a  12%
acrylamide  gel  so  to  check  the  outcome  of  the  digestion.  Following
completion of the incubation period, 30mM of iodoacetamide was added to
the  mixture  so  to  deactivate  the  papain  and  the  sample  was  dialysed
overnight  against  sample  buffer  in  order  to  remove  cysteines  from  the
solution. 
Separation of Digestion Fragments
In order to purify the digested Fab fragments, a 1ml HiTrap protein-A affinity
column  was  used.  Following  initial  equilibration  using  sample  buffer,  the
digested sample was passed through twice to ensure that  all  Fc and IgG
fragments bound to the solid medium whilst the Fab fragments were eluted
and collected. Following this, strength pH4 buffer (0.1M sodium citrate) was
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used to detach and collect the Fc and IgG from the immobilised protein A.
The column was then neutralised through the use of more sample buffer and
stored in 20% ethanol. 
Following  separation,  the  purified  Fab  fragments  were  dialysed  overnight
against  sample  buffer  at  4°C  to  remove  phosphate  from  the  solution  -
phosphate is known to precipitate in the presence of calcium - a component
present in the SAP stocks. Following this, all digestion products were subject
to SDS-PAGE analysis in order to ensure purity of each sample. Once purity
was confirmed,  the Fab samples from each digestion were combined and
concentrated  in an 18cm radius rotor Beckman Allegra X-12R centrifuge at
4°C.
Making the SAP:Fab Complex
At this point, it was unknown how many Fab fragments would bind to SAP but
a maximum of five was designated per pentamer; one for each subunit. In
order to ensure uniform complexes were to be formed, it was essential that
the  Fab fragments  be added in  excess.  Fab fragments  have a  molecular
mass  of  50kDa  where  as  the  SAP  pentamer  has  a  molecular  mass  of
125kDa. This means that the Fab fragments are already in 2.5x molar excess.
Therefore  a minimum volume ratio  of  2:1  SAP:Fab  respectively  would  be
necessary to ensure uniformity.  It was chosen to add Fab in 4x molar excess
as a precautionary measure to ensure full saturation of each SAP pentamer.
Example below:
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Example of making the SAP:Fab complex:
A total of 350μl Fab was collected (27.01mg/ml).
350/1000 x 27.01= 9.45mg of Fab was collected
Therefore, for a 4x molar ratio: 
9.45  /  4  =  2.36mg  of  SAP stock  (9.2mg/ml)  would  be
needed
4.72 / 9.2 x 1000 = 257μl SAP to be added to Fab sample
In  order  to  ensure  the  complex  was  in  the  pentameric  form  –  the  form
representative of amyloid bound SAP - the designated SAP was incubated in
calcium containing TC buffer for half an hour at room temperature before the
Fab fragments were added. Subsequently, the mixture was gently mixed on a
vortex and incubated for a further half an hour at room temperature before
purification methods were carried out.
 The complex was separated from the excess Fab using a  Superdex 200
10/300  GL  GE  Healthcare  Life  Sciences HPLC  column  and  the  eluted
complexes  were  concentrated  via  centrifugation  in  an  18cm  radius  rotor
Beckman Allegra X-12R centrifuge at 4°C.
Crystallisation of the SAP:Fab Complex 
Possible crystallisation “hits” for this new complex were determined using the
robot crystallisation technique via the ‘mosquito’ programme. Crystallisation
was performed using the method of vapour diffusion at room temperature in
1μl  hanging drops at  a  ratio  of  1:1  protein  to  well  solution.  A total  of  96
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different crystallisation solutions were trialled using the MD1-42 selection of
the Molecular Dimensions commercial solutions. 
The screens obtaining hits were replicated manually and optimised through
changes in pH, temperature, precipitant and protein concentration. Crystals
were harvested and flash-cooled in liquid nitrogen using 50% (v/v) glycerol as
a cryoprotectant.  
Data Collection and Processing 
Diffraction patterns were obtained from a crystal grown in 0.2M NaCl, 0.1M
potassium phosphate, 40% PEG 200 at a 1:1 ratio (protein:well solution) at a
temperature  of  4°C. Diffraction  to  approximately  4.4Å was  observed  at
Diamond Light Source, Oxfordshire. A total of 450 Oscillation frames of 0.2°
were measured with an exposure time of 0.08 seconds per frame (Beamsize
50x20μm, λDE3) encoding for the T7 RNAP under the transcriptional = 0.9763 Å). The data was processed automatically at Diamond. 
Molecular Replacement
Matthews Co-Helixefficient
Solvent  calculations  were  performed  using  the  ‘Matthews  -  Cell  Content
Analysis’ aspect of the CCP4i crystallography programme suite.  Here, the
cell parameters, space group and molecular weight of the complex were used
to determine the solvent content. As the composition of the complex was not
known for certain the molecular weight had to be estimated. It was decided to
use the figure 375kDa as this is the total for an SAP molecule bound to a five
Fab fragments. 
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Phaser
Initial  phases were  obtained by  molecular  replacement  using  the  ‘Phaser’
aspect  of  the  CCP4i  programme  suite.  The  search  models  used  in  the
rotation and translation search of the 4.4Å data were a SAP pentamer from
the  refined  structure  of  human  SAP to  2Å  with  the  calcium ions  omitted
(accession  code  1sac;  Emsley  et  al.,  1994)  and  Fab  fragment  refined
structure of the human HIV-1 broadly neutralizing antibody PGT152 to 1.8Å
(accession code 4NUJ; Blattner et al., 2014).
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Results 
IgG Fragmentation 
A sample of 103.5mg/ml anti-SAP IgG antibody was dialysed and digested
using the protein papain at a mass ratio of 1:100 papain to IgG respectively.
The  mixture  was  left  to  incubate  at  37°C for  a  total  of  three  hours.  The
digestion was stopped via the addition of 30mM of iodoacetamide and the
results of the digestion were presented on a 12% SDS acrylamide gel (Figure
71).
The  contents  of  each  lane  are  as  follows:  1)  IgG control  showing  heavy
chains  at  approximately  50kDa  and  light  chains  at  25kDa,  2)  Digestion
sample after 15 minutes, 3) Digestion sample after 30 minutes, 4) Digestion
sample after 45 minutes, 5) Digestion sample after 60 minutes, 6) Digestion
sample after 90 minutes, 7) Digestion sample after 120 minutes, 8) Digestion
sample after 180 minutes, 9) BenchMark Pre-stained Protein Ladder. 
The results of the gel clearly demonstrate that digestion of the heavy chain
into Fab and Fc fragments occurs straight away. Lane 2, which represents the
sample after only 15 minutes of digestion, clearly shows two additional bands
representing  the  Fab  and  Fc  fragments  at  approximately  25  and  30kDa
respectively compared to the IgG sample in lane 1. The band 60kDa in size
representing  in-tact  heavy  chains  disappears  in  lane  5  indicating  that
digestion is complete within one hour. When looking at the bottom area of the
gel an issue becomes apparent. Over digested protein fragments are clearly
visible  in  the  form  of  smears  in  lanes  2-8.  This  suggests  that  over-
fragmentation  of  the  IgG  molecule  has  occurred.  This  is  an  undesirable
outcome as over-digestion can lead to low yields of Fab fragments. Due to
the ‘trial and error’ nature of crystal making, high yields of Fab fragments are
a necessity. They allow the preservation of the IgG stock and also allow for
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more opportunities to attempt crystallisation if optimum conditions are difficult
to find.
In order to resolve this issue of over-fragmentation, it was decided to attempt
digestion using a 1:100  molar ratio instead (papain to IgG respectively).  In
order to perform a 1:100 molar digestion between the two components the
molecular  weights  of  each  had  to  be  taken  into  account.  Papain  has  a
molecular weight of 23kDa where as IgG has a molecular weight of 145kDa.
This means that  papain is already 6 times in molar excess.  Therefore,  in
order to establish this particular molar ratio, the amount of papain had to be
x600 less than that of IgG. 
Upon digestion of IgG with papain at a molar ratio of 1:100 at 37°C for a total
of three hours the following acrylamide gel was produced:  (Figure 72). The
contents of each lane are as follows: 1) IgG control showing heavy chains at
approximately 50kDa and light chains at 25kDa, 2) Digestion sample after 15
minutes, 3) Digestion sample after 30 minutes, 4) Digestion sample after 45
minutes, 5) Digestion sample after 60 minutes, 6) Digestion sample after 90
minutes, 7) Digestion sample after 120 minutes, 8) Digestion sample after
180 minutes, 9) BenchMark Pre-stained Protein Ladder.
Again, this gel clearly demonstrates that digestion occurs immediately. Bands
representing Fab and Fc fragments are clearly seen at approximately 25 and
30kDa after only  15 minutes of  incubation as represented by lane 2.  The
smear marks at the bottom of the gel are no longer present confirming that
over-digestion is eliminated in the molar ratio. However, unlike in the 1:100
mass ratio,  digestion does not  actually  reach completion.  A clear band at
approximately  60KDa  can  still  be  seen  in  lane  8  indicating  in-tact  heavy
chains are still present at the end of the protocol.
Comparing these two gels it becomes apparent that the molar ratio provides a
‘cleaner’ digestion, however, this method does not merit in terms of time or
yield. For a full digestion to occur, an estimated 6 hours of incubation would
be needed. In contrast,  the 1:100 mass digestion, although much quicker,
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produces too much waste in the form of over fragmented IgG molecules. Both
of  these  present  a  problem  with  respect  to  crystallisation.  In  order  for
SAP:Fab crystals to be obtained, multiple digestions need to be carried out in
order to obtain sufficient stocks of Fab. This means the long digestion times
of the molar protocol and the low yields of Fab fragments in the mass protocol
are impractical.  
In an attempt to solve these issues the digestion protocol was adjusted so to
increase yields in a shorted time frame. Papain amounts were reduced to a
third of their original 1:100 mass amounts and digestion time was reduced to
one hour. Although this method would still result in the incomplete digestion of
IgG  and  possibly  the  production  of  some  over-digested  fragments,  these
would not be to the extremes as seen in the previous digestions. Any over-
digested fragments could be removed later during the purification process
and left over IgG could be reused for subsequent digestions. 
Using these newly adjusted digestion conditions, the digestion process was
repeated a total of 9 times so to build up sufficient stocks of the Fab fragment.
Following each digestion, the samples were submitted to SDS PAGE analysis
to  ensure  successful  digestion  had  occurred.  An  example  is  exhibited  in
(Figure 73). The contents of each lane are as follows:  1) IgG control showing
heavy chains at approximately 50kDa and light chains at 25kDa, 2) Digestion
sample after 1 hour showing Fc and Fab fragments along with a faint band
representing undigested heavy chains, 3) Purified Fab, 4) Purified Fc with
faint lines representing undigested heavy chains, 5) BenchMark Pre-stained
Protein Ladder. 
The sample in lane 2 clearly demonstrates successful digestion of the IgG
molecule.  Strong bands at  approximately  25kDa and 30kDa can be seen
representing Fab and Fc respectively. A very faint band representing heavy
chains can still be seen at approximately 60kDa however this is not seen in
lane 3 indicating that the Fab fragments have successfully been separated
from the IgG and Fc fragments through use of the protein-A affinity column.
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The results of all 9 digestions are listed in the table below:
Digestion
number
Initial IgG
amount (mg)
Final Fab
Amount
(mg)
Final Fc
amount (mg)
Yield (%)
1 7.5 3.5 0.7 56
2 20 3.6 3.1 34
3 14 6.1 3.7 70
4 22 9.0 7.3 74
5 23 12.0 5.8 77
6 20 5.5 6.9 62
7 20 9.8 6.2 80
8 18 6.0 6.4 61
9 21 6.7 3.1 46
Table  8:  A  table  of  anti-SAP  IgG1  digestion  yields.  Yields  were
calculated through the combination of final Fab and Fc concentrations
compared to the initial  IgG concentration of that particular digestion.
Component  amounts  were  determined  through  use  of  a  nano  drop
spectrophotometer set at a wavelength of 280nm. Units were converted
using the Beer Lambert Law. 
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Figure  71:  The  Electrophoresis  results  of  a  1:100  Mass  Digestion  -
Papain  to  IgG  respectively.  A  total  of  10μl  was  added  to  each  lane
except in the case of the marker in lane 9 where only 5μl was added for
preservation  purposes.  During  preparation,  samples  were  diluted  to
1mg/ml  using  SDS containing  laemmli  buffer and  boiled  in  order  to
enforce  monomerisation  and  uptake  of  negative  charge.
Electrophoresis was carried out for 1 hour 20 minutes at 25 mA on a
home made 12% acrylamide gel. 
The contents of each lane are as follows: 1 – IgG control showing heavy
chains at approximately 50kDa and light chains at 25kDa, 2 – Digestion
sample after  15 minutes,  3  – Digestion sample after  30 minutes,  4  –
Digestion  sample  after  45  minutes,  5  –  Digestion  sample  after  60
minutes, 6 – Digestion sample after 90 minutes, 7 – Digestion sample
after  120  minutes,  8  –  Digestion  sample  after  180  minutes,  9  -
BenchMark Pre-stained Protein Ladder. 
Digestion of the heavy chain into Fab and Fc fragments occurs straight
away as seen in lane 2 where clear bands representing each fragment
are visible in the 15 minute sample. Also, the band representing in-tact
heavy chain disappears in lane 5 indicating that digestion is complete
within one hour. However, over digested protein fragments are visible at
the bottom of the gel in the form of smears in lanes 2-8. 
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Figure  72:  The  Electrophoresis  results  of  a  1:100  Molar  Digestion  -
Papain to anti-SAP IgG respectively. A total of 10μl was added to each
lane except in the case of the marker where only 5μl  was added for
preservation  purposes.  During  preparation,  samples  were  diluted  to
1mg/ml using laemmli buffer containing  sodium dodecyl sulfate (SDS)
and boiled in order to enforce monomerisation and uptake of negative
charge. Electrophoresis was carried out for 1 hour 20 minutes at 25 mA
on a home made 12% acrylamide gel. 
The contents of each lane are as follows: 1 – IgG control showing heavy
chains at approximately 50kDa and light chains at 25kDa, 2 – Digestion
sample after  15 minutes,  3  – Digestion sample after  30 minutes,  4  –
Digestion  sample  after  45  minutes,  5  -  Digestion  sample  after  60
minutes, 6 – Digestion sample after 90 minutes, 7 – Digestion sample
after  120  minutes,  8  –  Digestion  sample  after  180  minutes,  9  -
BenchMark Pre-stained Protein Ladder (molecular weights of each band
is labelled). 
Digestion of the heavy chain into Fab and Fc fragments did not reach
completion – a band representing heavy chains at approximately 60kDa
is still present in lane 8 after 3 hours of digestion. However, digestion
does occur straight away in lane 2 after only 15 minutes of incubation
with no noticeable smear marks occurring at the bottom of the gel.
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Figure 73: Typical electrophoresis results of an optimised anti-SAP IgG
digestion.  A total of 7.5μl was added to each lane except in the case of
the marker where only 5μl was added for preservation purposes. During
preparation,  samples  were  diluted  to  1mg/ml  using  sodium  dodecyl
sulfate (SDS) and boiled in order to enforce monomerisation and uptake
of negative charge. Electrophoresis was carried out for 1 hour at 25 mA
on a home made 12% acrylamide gel. 
 The contents of each lane is as follows: 1 – IgG control showing heavy
chains at approximately 50kDa and light chains at 25kDa, 2 – Digestion
sample after 1 hour showing Fc and Fab fragments along with a faint
band  representing  undigested  heavy  chains,  3  –  Purified  Fab,  4  –
Purified Fc with faint lines representing undigested heavy chains, 5 -
BenchMark Pre-stained Protein Ladder (molecular weight of each band
is labelled).
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Making the SAP:Fab Complex
The purified samples of Fab fragments were combined and concentrated on
an 18cm radius rotor Beckman Allegra X-12R centrifuge at 4°C until a 350μl
sample 27.1mg/ml Fab was produced. This was gently mixed with 257μl SAP
to ensure the Fab fragments were in x4 molar excess and incubated for half
an hour at room temperature to ensure binding. 
High Performance Liquid Chromatography (HPLC) was used to separate the
complex from the excess Fab fragments.  Two distinct peaks can be seen on
the elution graph. The larger first peak represents the pure SAP:Fab complex
and the second smaller peak represents the excess Fab fragments which did
not bind.  
Crystallisation of the SAP:Fab Complex 
Possible crystallisation “hits” for this new complex were determined using the
robot crystallisation technique via the ‘mosquito’ programme. Crystallisation
was performed using the method of vapour diffusion at room temperature in
1μl  hanging drops at  a  ratio  of  1:1  protein  to  well  solution.  A total  of  96
different crystallisation solutions were tested using the MD1-42 selection of
the Molecular Dimensions commercial solutions. 
Over nucleation of the SAP:Fab complex was experienced in the following
six conditions after 2 weeks of incubation at room temperature: 
A6 - 0.2M Sodium chloride, 0.1M sodium/potassium phosphate, pH
6.5, 25% (w/v) PEG 1000
C2 - 0.1M Sodium citrate, pH 4.5, 20% (w/v) PEG 4000
C7 - 0.1M Sodium citrate, pH 5.6, 20% (w/v) PEG 4000, 20% (v/v) 2-
propanol
D7 - 0.1M Sodium citrate, pH 5.5, 15% (w/v) PEG 6000
E2 - 0.1M Sodium citrate, pH 5.0, 8% (w/v) PEG 8000
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E11 - 0.1M Sodium citrate, pH 5.0, 20% (w/v) PEG 8000
These “hits” were replicated manually using the method of vapour diffusion at
room temperature using 4μl hanging drops at a ratio of 1:1 protein to well
solution respectively.  Each particular  ‘hit’  was repeated exactly  as per  the
commercial solution in a single well of its own individual crystallisation tray.
The remaining 15 wells of each tray, although similar to the ’hit  condition’
were subject to slight alterations in pH, precipitant concentration and protein
concentration as a way to decipher preferred growth conditions. 
Vast amounts of over-nucleation were noticed in these manual trays after two
weeks of incubation. The pattern of nucleation was observed and from this,
preferred well conditions were estimated and created on new crystallisation
trays. Due to the large amounts of over nucleation, it was decided to submit
the trays to colder temperatures of 4°C so to encourage slower growth and
thus encourage crystal formation.
Following  eight  rounds  of  optimisation  and  more  than  a  year  of  trial  and
testing, crystals were finally produced in two of the six crystal screens. Those
from Crystal screen #1 were produced via the hanging drop method at 4°C at
pH’s of 4.5 and 5.5 , 0.1 sodium citrate, 13-14% PEG 3000 at ratios of 1:1
and 2:3  protein  to  well  solution  respectively.  The crystals  were  of  needle
morphology and initially  formed following 3 weeks of  incubation.  A further
month was needed in order to allow crystal growth (Figure 74, ). Those from
Crystal screen #2 were produced via the hanging drop method at 4°C at pH’s
of 6 and 8, 0.2M sodium chloride, 0.1M potassium phosphate, 30-45% PEG
200 at ratios of 1:1 and 2:3 protein to well solution respectively. The crystals
were  of  cube  morphology  however  they  contained  cracks  and  were  very
sensitive to changes in temperature and environment. They formed following
4 weeks of incubation (Figure 75, ).
Although crystals were produced in both trays,  the crystals from screen 1
were deemed too thin for x-ray analysis so were not flash frozen. In order to
provide  safe  freezing  conditions  for  the  remaining  cube  crystals,  various
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cryoprotectants from the Molecular Dimensions CryoProtX™MD1-61 kit were
trialled. The majority of these, unfortunately, resulted in extreme cracking of
the crystals and many were destroyed. Ultimately  a simple solution of 50%
glycerol was found to be the best suited for this crystal  type. It  should be
noted, however,  that  upon transferring the crystals to this  solution,  further
cracking could still be exhibited in the lattices if the change of environmental
conditions occurred too fast.  
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Crystal screen #1
Protein: SAP:Fab complex
Conditions: 0.1M Na Citrate, PEG 3K
Ligand: Calcium, PE
Figure 74: A representation of a manually prepared crystal screen. This
particular screen illustrates the optimised conditions for the SAP:Fab
complex grown in sodium citrate and PEG3000 over a pH range of 4.5-
5.5. (o/n = over nucleation, *HIT = crystal(s)).
Crystal Screen #2
Protein: SAP:Fab complex
Conditions: 0.2M NaCl, 0.1M Potassium phosphate, PEG 200
Ligand: Calcium, PE
Figure 75: A representation of a manually prepared crystal screen. This
particular screen illustrates the optimised conditions for the SAP:Fab
complex grown in sodium chloride, potassium phosphate and PEG 200
over a pH range of 6-8. (o/n = over nucleation, *HIT = crystal(s)).
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pH 4.5 pH 5.5
1 2 3 4 5 6 PEG 3K
A 12%
B o/n *HIT 13%
C *HIT o/n o/n o/n *HIT o/n 14%
D 15%
Drop ratio
Protein: well
2:2 2:3 2:4 2:2 2:3 2:4
pH 6 pH 7 pH 8
1 2 3 4 5 6 PEG 20K
A *HIT 30%
B o/n *HIT 35%
C o/n *HIT 40%
D o/n 45%
Drop ratio
Protein: well
2:2 2:3 2:2 2:3 2:2 2:3
Figure  76:  Comparisons  of  SAP:Fab  crystals  grown in  different  well
solutions.   Above  –  Example  of  crystals  grown  in  0.2M  NaCl,  0.1M
potassium phosphate, 40% PEG 200 at a 1:1 ratio (protein:well solution).
Well ‘C5’ from Crystal Screen 3 produced large square and rectangular
crystals  approximately  150  x  150µm  in  size.   Below  –  Example  of
crystals  grown  in  0.1M  Na  Citrate,  14%  PEG  3K  at  a  ratio  of  2:3
(protein:well solution).  Well ‘C5’ from Crystal Screen 1 produced long,
needle-like crystals approximately 5 x 750µm in size.
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Data Collection and Processing 
Of the14 cube shaped crystals from screen 2, only two survived the flash
freezing  process and  were  taken to  Diamond Light  Source  for  diffraction.
These crystals were both approximately 150 x 150µm in size and grown in a
solution containing 0.2M sodium chloride, 0.1M Potassium phosphate, 35%
PEG 200. 
Upon arrival to Diamond it was discovered that one of the crystals had not
survived transportation, however,  diffraction patterns were obtained for the
remaining crystal. Diffraction data was collected to 4.4Å (Beamsize 50x20μm,
λDE3) encoding for the T7 RNAP under the transcriptional = 0.9763 Å). Oscillation frames of 0.2° were measured with an exposure
time of 0.08 seconds per frame to produce a total of 450 diffraction images.
The  data  was  auto-processed  by  Diamond  and  the  following  unit  cell
dimensions were proposed: a = 176.22, b = 217.09, c = 259.93,  = 90.00, βɑ-
=  90.00,   =  90.00.  This  suggests  that  the  crystal  belonged  to  theɣ.
Orthorhombic space group P21 (P 21 21 21).
Parameter Value
Space group P21
Unit cell a = 176.22, b = 217.09, c = 259.93, ɑ-
= 90.00, β = 90.00,  = 90.00ɣ.
Resolution (Å) 4.4
Measured reflections 450
Multiplicity 3.4
Completeness (%) 99.7
Mean (I)/sd(I) (outer resolution shell) 9.6
Solvent Content (%) 39.43
Data processing statistics for the SAP:Fab crystal
Molecular Replacement
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Solvent calculations were performed using the ‘Matthews coefficient – Cell
Content  Analysis’  function  of  the  CCP4i  programme suite.  Here,  the  cell
parameters, space group and molecular weight of the complex were used to
determine the solvent content. As the composition of the complex was not
known for certain an estimated molecular weight was inputted. A molecular
weight of 375kDa was chosen as this is the mass of a fully saturated SAP
molecule, i.e. an SAP molecule with five Fab fragments bound. 
The results of the Matthew’s coefficient for an estimated molecular weight of
375kDa were as follows: 
Nmol/asym Matthews Coeff %solvent P(4.41) P(tot)
1 6.63 81.46 0.00 0.00
2 3.31 62.91 0.24 0.16
3 2.21 44.37 0.75 0.83
4 1.66 25.83 0.00 0.00
5 1.33 7.29 0.00 0.00
A table showing the results of the Matthew’s coefficient calculation of
the SAP:Fab dataset.
On average protein crystals should have a solvent content of around 43%,
which equates to a Matthews coefficient of between 1.7 and 3.5 cubic A/Da.
According  to  the  table  above,  the  closest  solution  obtained  was  one  of
44.37%. This solution has 3 molecules in an asymmetric unit and exhibits a
Matthew’s coefficient of 2.21. 
Initial  phases were  obtained by  molecular  replacement  using  the  ‘Phaser’
aspect  of  the  CCP4i  programme  suite.  The  search  models  used  in  the
rotation and translation search of the 4.4Å data were an SAP pentamer from
the  refined  structure  of  human  SAP to  2Å  with  the  calcium ions  omitted
(accession  code  1sac;  Emsley  et  al.,  1994)  and  Fab  fragment  refined
structure of the human HIV-1 broadly neutralizing antibody PGT152 to 1.8Å
(accession code 4NUJ; Blattner et al., 2014)
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After  24  hours  of  calculating,  Phaser  confirmed that  there  were  indeed 3
molecules in the asymmetric unit. The results of the rotation function showed
that 25 solutions had been found:
Number LLG z-score
1 90.83 5.11
2 83.07 4.83
3 79.89 4.72
4 78.97 4.69
5 75.67 4.58
6 73.30 4.49
7 68.93 4.34
8 68.71 4.33
9 66.53 4.26
10 59.30 4.00
11 52.26 3.76
12 50.83 3.71
13 42.40 3.41
14 41.67 3.39
15 41.34 3.38
16 38.42 3.27
17 37.86 3.25
18 36.82 3.22
19 36.53 3.21
20 35.83 3.18
21 34.28 3.13
22 34.04 3.12
23 33.42 3.10
24 32.85 3.08
25 32.71 3.07
 A table showing the 25 possible rotation solutions as calculated by the
Phaser programme.
The strength of each solution is represented by the Log Likelihood Gain (LLG)
and the ‘z-score’. The LLG is an indication of how much "better" the solution
is compared to a random solution where as the z-score shows you how many
deviations  the  solution  is  above  the  mean.  In  both  cases  a  higher  value
indicates a good solution. An LLG of 0 or less means that your solution is no
better or even worse than a random selection of atoms where as a z-score of
less than 5 indicates that a solution may not be possible. The best rotation
solution as presented by Phaser had an LLG of 90.83 and a z-score of 5.11.
This suggests that the solution may be solvable but this is not guaranteed. 
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The program took the top rotation function (SET 1)  and found 9 possible
translation solutions. The results are as follows:
Number LLG z-score
1 50.09 4.17
2 43.11 3.83
3 36.68 2.64
4 35.36 1.06
5 33.73 1.85
6 30.15 1.53
7 27.20 1.78
8 22.67 1.47
9 20.93 1.10
A table showing the 9 possible translation solutions as calculated by
the Phaser programme.
Again the strength of each solution was represented by the Log Likelihood
Gain (LLG) and the ‘z-score’. The best solution as presented by Phaser had
an LLG of 50.09 and a z-score of 4.17. This suggests that this particular data
set  is  no  better  than  a  random solution  of  atoms and  cannot  be  solved.
Attempts  to  model  the  structure  using  the  ‘coot’  function  from the  CCP4i
programme suit were carried out in spite of this, however, it became clear
very early on that refinement would indeed not be possible. The fit  of  the
density  angles  into  the  proposed  map demonstrated  almost  no  validation
whatsoever.
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Discussion
The aims of this chapter were as follows: 
- To undergo multiple rounds of anti-SAP antibody digestion so to
obtain a stock of Fab fragments
- To Combine SAP with excess Fab fragments in order to create a
fully saturated SAP:Fab complex 
- Find optimal conditions to allow for crystal growth of said complex
- Submit the complex crystal  to x-ray analysis in order to obtain a
diffraction data set
- Solve the diffraction data set using the CCP4i programme suite so
to decipher the interaction between the SAP and Fab fragments.
Of  these  five  steps,  four  were  successfully  carried  out  and  executed.
Optimum conditions for SAP:Fab formation were deduced and a crystal was
subsequently  submitted  to  x-ray  diffraction.  Issues  arose  with  regards  to
solving the structure, however, due to the low LLG and z-scores calculated
from the translation function of the Phaser programme. 
Building and refining a protein model is not an exact science. Rather, it is a
subjective  process,  governed  by  experience,  prejudices,  expectations  and
local practices. This means that errors in this process are almost unavoidable,
but it is the crystallographer's task to remove as many of these as possible. It
is a difficult process due to the limited resolutions and imperfect phases often
presented by the diffraction data.
With  high  resolution  data  and  good  phases,  the  resulting  model  is
approximately 95% a consequence of the data; however, once the resolution
becomes worse than 2 Å, this balance shifts and protein models can often be
a  result  of  the  crystallographer’s  imagination.  In  general,  the  clarity  and
interpretability  of  electron  density  maps  depends  on  the  resolution  of  the
diffraction data even when based on accurate phases. This is because the
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relative  error  of  diffraction  intensities  in  the  resolution  shell  of  4.5-4.0  for
crystals diffracting to 4 Å is much larger than for crystals diffracting to 1.5 or
even 2 Å. 
Resolution is defined as the minimum spacing (d) of crystal lattice planes that
still  provide  measurable  diffraction  of  x-rays.  It  measures  the  minimum
distance between structural features that can be distinguished on an electron
density map and thus defines the level of detail  that can be obtained. The
smaller the spacing the more reflections available to define the structure and
thus the higher the resolution of the data. In general, data to a resolution of
1.99Å or higher is considered good. Those between 2 and 3 Å are generally
considered medium whereas anything beyond 3 Å is typically classed as low
resolution data (Wlodawer et al. 2008).
The data achieved from the SAP:Fab complex exhibited a resolution of 4.4Å.
Although this is considered low in terms of model building, crystals of lower
data have previously been solved. The most famous of these is the myoglobin
structure which was presented at a resolution of approximately 6 Å in 1958 by
Kendrew et al. This was the very first crystal structure to ever be solved. Due
to its low resolution, much of the atomic detail known today about myoglobin
was missing from this data however a very rough idea on its structure was
presented. 
Similar ideas can be presented with regards to the SAP:Fab structure. The
estimated images  as  presented in  ‘coot’  give  an  idea as  to  how the  two
molecules interact. It would appear that SAP binds to a single Fab fragment
rather than the 5 previously guessed. Of which, the Fab fragment binds to the
edge of the SAP structure with a slight propensity towards the calcium binding
B-face.  The  most  plausible  reasoning  behind  this  low  number  of  Fab
fragments interactions can be explained by allosteric conformation changes.
This is the process where upon binding of a Fab fragment to one of the SAP
monomeric  units,  conformational  changes  occur  on  the  rest  of  the  SAP
structure.  These  alterations  in  structure  prevent  any  further  interactions
between  SAP  and  Fab  fragments.  The  precise  residues  involved  in  Fab
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binding  and  the  structural  changes  which  occur,  unfortunately,  cannot  be
determined using this information (Figure 77). 
The downfall of the SAP:Fab structure determination is thought to lie within
the experimental aspect of this chapter. One must remember that in order for
successful  diffraction  to  occur  several  stages  need  to  be  executed  and
optimised.  The  right  environmental  conditions  must  be  fond  to  encourage
large, clear crystal growth. Once grown, the crystals must be flash frozen with
liquid nitrogen in order to resist radical damage from the x-ray beam. This
must be done with a cryoprotectant which does not cause any damage to the
crystal itself. If any one of these stages experience an issue then it is likely
the  finishing  data  will  be  compromised.  The  SAP:Fab  crystal  had
demonstrated  a  cracked  morphology  within  its  tray  conditions;  a  property
which  was  only  enhanced  through  the  transference  to  a  cryoprotectant
medium. This is clearly the root of the data inadequacy.
The most obvious solution for this problem would be to optimise the crystal
screens further and thus produce more crystals. These could be subject to
further trial  and error in an attempt to find alternate cryoprotectants which
provide a safer environment for flash freezing and hopefully allow for better
diffraction. 
This solution was attempted. When replicated and subject to another round of
optimisation,  cube  shaped  crystals  were,  again,  produced  in  solutions
containing 0.2M sodium chloride, 0.1M Potassium phosphate and PEG 200.
Unfortunately,  these screens were knocked over and destroyed by a third
party before freezing. Stock solutions, at this point had been depleted and
another tray could not be produced in time.  
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Figure 77: Images of the estimated SAP:Fab binding as demonstrated in
the  ‘coot’  function  of  the  CCP4i  programme  suite.  It  is  clearly
demonstrated that a single Fab fragment binds to the pentameric SAP
structure. (Above) The structure from a flat perspective of the B-face of
SAP. (Below) The structure from a side perspective. Here you can see
that the binding of the Fab fragment leans towards the B-face of the
SAP molecule. 
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Final Remarks
The purpose of this thesis was to determine whether SAP exhibits both pro-
fibrillogenic  and  anti-fibrillogenic  activities  as  argued  by  Hamazaki  and
Janciauskiene. Using insulin fibres made at neutral pH this was proven to be
true.  ThT,  Congo  red,  CD  and  TEM  analysis  all  confirmed  this.  SAP
pentamers enhance fibre growth whereas the decamers prohibit it. As of yet,
this dual role has not been confirmed with any other amyloid prone protein
due to the difficulties faced when trying to produce said proteins ‘in house’.
However, with a few more trials it would almost certainly be proven true. The
morphologies  of  these  new  fibres  would  likely  differ  from  that  of  insulin
possibly causing SAP to have either a bigger or smaller impact on them.
By acting as a reducer of amyloid fibre mass, the possibility of using SAP
decamers as a treatment for amyloid can be taken into consideration. Thus
far, however, SAP has only demonstrated its enhancing capabilities  in vivo
and not its molecular chaperone behaviour. This fact, one could argue, makes
the insulin results irrelevant. If SAP behaviour cannot be replicated in vivo this
reducing role can be considered immaterial. That being said, if it could be
proven that SAP has the  potential  to behave as a chaperone  in vivo,  then
attempts could be made to facilitate this and thus a treatment against amyloid
related disease could be developed. Not only is SAP universal to all forms of
amyloid - therefore has the capability to act against every form of amyloid- , it
is  also a component  already present  in  the human body so is  unlikely  to
impose further damage to the host. 
By using the decamers to reduce fibre mass one would regain tissue function
and reduce symptoms of the patient. It may be true that the decamer abilities
are limited to reducing amyloid fibres and not eradicating them, nevertheless,
the  lowering  of  deposit  masses  is  enough  to  prolong  the  lives  of  these
patients and reverse their symptoms. Remember, amyloid is not cytotoxic and
in  low  concentrations  amyloid  is  not  life  threatening.  For  that  reason,
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prolonged administration  of  an  SAP treatment  could be used until  correct
diagnosis has occurred and the relevant treatment obtained. 
Of course there are factors which would need to be taken into consideration
before such a treatment could be concocted. Firstly, if SAP decamers were
able to form in the serum would they not already be present? Serum has a
physiological pH of 7.35-7.45 with a low calcium concentration of 8.5-10.2mg/
dL of which only 4.8-5.7mg/dL exists as free ionised ion in serum. This is not
sufficient to saturate the SAP when their diverse molecular masses are taken
into  consideration  and  therefore  one  should  expect  SAP  to  exist  as  a
decamer but it does not - Why? Is it simply a matter of pentamer binding with
alternate serum proteins which prevent decamer formations or is it due some
other  unknown  reason?   Secondly,  if  SAP  decamers  were  successfully
administered into a patient, what would prevent them from reverting back to
the pentamer formation and thus increase stability and growth rates of the
existing fibres? 
Although amyloid diseases are considered rare, they are likely more common
than  previously  thought.  The  wide  range  of  symptoms  associated  with
amyloid  disease  often  leads  to  misdiagnosis  and  thus  there  is  a  lack  of
literature  regarding  this  category  of  diseases.  The  field  has  been  grossly
under researched as a result of this. So far 36 proteins have been associated
with  amyloid  diseases  and  this  number  is  continually  increasing.  Each  of
these  diseases  requires  unique  treatment  to  combat  its  unique  set  of
symptoms  and  any  delay  can  easily  result  in  irreversible  if  not  fatal
consequences. Not enough is known about amyloid in general let alone each
specific type to allow for effective, individual treatment plans. Because of this,
the idea of having a general SAP treatment plan is extremely appealing.
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